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µCT Micro-computed tomography 
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DMEM Dulbecco's Modified Eagle Medium 
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ER+ Estrogen receptor-positive 
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HER-2 Human epidermal growth factor receptor 2 
hMSC Human mesenchymal stem cell 
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RANKL Receptor activator of nuclear factor kappa-B ligand 
rh Recombinant human 
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RT Room temperature 
SB SB202190 
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TMA Tissue microarray 
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1  Introduction 
1.1 Malignant bone disease  
1.1.1 Trends of bone metastasis in breast and prostate cancer 
Breast and prostate cancer are the leading causes of cancer-related death in women and 
men respectively, second only to lung cancer (Howlader et al., 2011). Due to early diagnosis 
and continued development of targeted therapies, the survival rates of patients affected with 
prostate and breast cancer have significantly improved over the last decades (Askoxylakis et 
al., 2010; Siegel et al., 2012). However, among these survivors the number of patients living 
with metastatic bone disease has increased (Weilbaecher et al., 2011). In breast cancer the 
manifestation and detection of bone metastases is normally delayed, taking place many 
years after a primary diagnosis and initial treatment (Dillekås et al., 2014). Equally, following 
successful resection of localized prostate cancer, 20-40% patients will relapse within 10 
years (Roehl et al., 2004; Antonarakis et al., 2012). In both cases, surviving patients cannot 
consider themselves as being cured until decades after initial treatment which has a huge 
impact on their psychological health, triggering depression and anxiety disorders 
(Andrykowski et al., 2008; MJ et al., 2014). 
In Europe, the management of skeletal complications arising from bone metastases is 
associated with substantial costs, burdening the health systems of many countries (Pereira 
et al., 2016). In breast cancer, nearly 80% of patients will present with bone metastases at 
advanced disease stages, 85% of these will have lesions classified as osteolytic and over 
50% will experience a major skeletal-related event (SRE) during disease progression. SREs 
include bone pain, hypercalcemia, pathological fractures and spinal cord compression, which 
considerably reduce a patient’s quality of life and continued survival (Weinfurt et al., 2005; 
Coleman, 2006; Saad et al., 2007). Breast cancer bone metastases are incurable with a 
median survival rate of 20 months from the first detection of disease relapse in the bone 
(Coleman and Rubens, 1987; Coleman et al., 1998; Domchek et al., 2000). In the case of 
prostate cancer, the survival rate for local and regional stages at diagnosis is close to 100% 
after five years; however, this falls to less than 30% in the case of advanced disease 
progression at diagnosis where the cancer has spread to the bones or other organs 
(American cancer society, 2017). Ninety percent of prostate cancer patients with metastatic 
disease will present with evidence of bone metastases (Bubendorf et al., 2000).  
Breast cancer cells primarily induce osteolytic bone metastases that are characterized by an 
increased bone resorption, whereas prostate cancer metastases can present a more diverse 
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phenotype, of typically osteosclerotic or mixed lesions (Hofbauer et al., 2014). Despite this, 
evidence now suggests that osteolytic activity is required to precondition bone during the 
development of prostate cancer bone metastasis (Keller and Brown, 2004; Roato et al., 
2008) and cases of progressive osteolytic prostate cancer metastases have been reported 
(Rajendiran et al. 2011; Segamwenge et al. 2012). In both breast and prostate cancer 
metastases, the development of combined tumor and bone-targeted therapies has become a 
priority, giving rise to the clinical research field of osteo-oncology (Ibrahim et al., 2013). 
1.1.2 The vicious cycle of osteolytic bone metastasis 
Metastasis is a hallmark of cancer of which breast and prostate cancer have the highest 
incidence of bone-specific metastasis (Hanahan and Weinberg, 2011). Although the 
prognosis for patients with bone metastases arising from these two cancer types is better 
than other bone metastatic cancer types such as advanced lung cancer, with survival 
measured in years rather than months, eventually skeletal morbidity and SREs conclude with 
patient morbidity and mortality (Coleman, 2006). It is accepted that many molecular and 
epigenetic adaptations are required in order for an individual cancer cell to escape from the 
primary tumor, avoid immune surveillance and survive in the physically stressful conditions of 
the systemic circulation before finally invading a distant organ or tissue type (Valastyan and 
Weinberg, 2011). Following successful circumnavigation of these barriers, many features of 
the bone microenvironment make it an attractive site for metastasizing cancer cells to 
colonize. Stromal cell expression of adhesion markers such as VCAM-1 (Chen and 
Massagué, 2012), chemo-attractive gradients including CXCR4/CXCL12 signaling (Shi et al., 
2014), the anatomy of bone vascularization (Raymaekers et al., 2015), the presence of stem 
cell niches in the bone which can be hijacked (Schuettpelz and Link, 2011; Dhawan et al., 
2016) and a close proximity to a biological hoard of growth factors stored within the bone 
matrix (Suva et al., 2009), all associate to gild the bone as an attractive destination.  
Having progressed through multifaceted steps of the metastatic cascade and upon reaching 
the ‘soil’ of the bone microenvironment, the cancerous ‘seed’ (Paget, 1889) may then 
undergo a period of dormancy, perhaps gathering further mutations required for adaptation to 
a supportive niche, insufficient vascularization or immune cell pressures (Croucher et al., 
2016). Initiation of overt metastasis may occur months or years after this initial seeding in 
response to as yet not well studied molecular triggers. Conceivably, stromal cell-derived 
growth factors may play an important role in this process of metastatic outgrowth (Massagué 
and Obenauf, 2016). For metastases to become successfully established and reach a stage 
of malignancy secondary to the primary tumor, the ability to elicit tumor promoting responses 
from the neighboring stromal cells is mandatory (Valastyan and Weinberg, 2011). In the 
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context of bone metastases, access to tumor promoting factors in the mineralized matrix and 
capacity for expansion requires perversion of the mechanism required for normal bone 
turnover.  
Under the coordination of mechanosensing osteocytes, synchronized cellular units, 
consisting of bone-forming osteoblasts coupled with bone-resorbing osteoclasts, are 
responsible for the homeostatic turnover of bone in response to mechanical and metabolic 
needs. Imbalances in the function of these cell types result in impaired bone quality (Fig. 1) 
(Eastell et al., 2016). Both osteoblasts and osteoclasts can promote the secretion of 
adhesion, angiogenic and growth factors important for vascularization of the bone and 
maintenance of the hematopoietic stem cell niches (Tamma and Ribatti, 2017). 
Unfortunately, these factors are also attractive to the biology of the metastasizing cancer 
cells, supporting and promoting their proliferation in the bone microenvironment (Croucher et 
al., 2016). Interaction with cancer cells can further upregulate these factors, launching the 
vicious cycle of osteolytic bone metastasis and bone destruction (Chirgwin and Guise, 2000).  
As micrometastases become more established in the bone, their actions become more 
insidious, regulating the differentiation and function of both cell types and leading to bone 
lesions with characteristic phenotypes (Suva et al., 2011). In general, tumor-driven bone 
destruction occurs as a spectrum of ‘lytic’, ‘sclerotic’ or ‘mixed’ lesions, which can be 
detected radiologically or with magnetic resonance imaging (MRI) and often result in 
Figure 1: Bone turnover is regulated by the coupling of osteoblasts and osteoclasts. For 
healthy bone tissue, bone formation by osteoblasts and resorption by osteoclasts needs to be balanced. In 
several diseases such as osteoporosis and osteopetrosis, this equilibrium is out of balance and bone quality is 
affected. Here, increasing numbers of cells are used to represent the increasing functionality and activity of each 
cell type. In osteoporosis increased activity of osteoclasts leads to bone destruction whereas in osteopetrosis 
increased activity of osteoblasts leads to increased bone formation. In both cases bone is fragility is increased 
as are the risk of skeletal related events (SREs). 
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fractures (Fig. 2) (Coleman, 1997). In osteolytic lesions, factors secreted by the cancer cells 
promote and inhibit osteoclast and osteoblast biology respectively (Chen et al., 2010). 
Factors which stimulate osteoclastogenesis and activity include interleukins (IL) -6, 8 and 11, 
matrix metalloproteinases (MMPs), parathyroid-hormone related protein (PTHrP) and tumor-
necrosis factor alpha (TNF-α). Their actions can be either direct or indirect, disrupting the 
osteoblast-regulated receptor activator of nuclear factor kappa-B ligand/osteoprotegerin 
(RANKL-OPG) axis in favor of increased RANKL expression which binds to the osteoclast 
expressed receptor activator of nuclear factor kappa-B (RANK) to promote 
osteoclastogenesis (Weilbaecher et al., 2011). Metastases-secreted DKK-1 is a prime 
example of a breast cancer-derived factor that when elevated in the bone microenvironment, 
directly inhibits osteoblast function, decreasing the expression of OPG and indirectly allowing 
uninhibited RANKL to stimulate osteoclastogenesis and bone resorption to proceed in an 
unchecked fashion (Mundy, 2002; Voorzanger-Rousselot et al., 2007; Pinzone et al., 2009). 
Mineralized bone matrix is also a reservoir of inactive growth factors including ions such as 
Figure 2: Visualizing bone metastases arising from breast and prostate cancer. A-B) Time-
lapsed X-rays of the hip in a patient diagnosed with breast cancer. A) Metastasis-free hip 12 months prior to 
detection of B) an osteolytic breast cancer metastasis in the neck of the femur. C) Multiple sclerotic lesions 
seen at the pelvic bones arising from prostate cancer metastases. D) Magnetic resonance imaging (MRI) of a 
pathological fracture at the left neck of the femur resulting from increased bone destruction mediated by 
osteolytic breast cancer metastases. E) MRI of an osteolytic lesion in the left iliac bone arising from prostate 
cancer. F) MRI of mixed sclerotic and lytic breast cancer metastases throughout the spine. Arrow color key: 
red; osteolytic metastasis, blue; osteosclerotic metastasis, yellow; pathologic fracture, green; compression 
fracture. Image acknowledgements: A + B; Dr Chris O'Donnell, Radiopaedia.org, rID: 16667, C; Dr Nafisa 
Shakir Batta, Radiopaedia.org, rID: 38894, D; Dr Domenico Nicoletti, Radiopaedia.org, rID: 42973, E; R 
Govarthanan et al. 2011 International Journal of Case Reports and Images, F; A.Prof Frank Gaillard, 
Radiopaedia.org, rID: 46907. 
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calcium (Ca2+), insulin growth factors (IGFs) and transforming growth factor-β (TGF-β). As 
dysregulated bone remodeling and resorption progresses, the release and subsequent 
activation of these factors is increased, further enhancing tumor proliferation and tumor-
mediated dysregulation of bone-forming activities (Fig. 3) (Voorzanger-Rousselot et al., 
2007; Weilbaecher et al., 2011; Hofbauer et al., 2014). With this constant progression in 
malignancy and regression in bone quality in mind, it is easy to appreciate how SREs are 
prevalent and a pre-destined consequence of secondary cancer in the bone.  
 
1.1.3 The poisoned apple: cancer treatments inducing bone resorption 
Independently of bone destruction induced by cancer-secreted factors, a reduction in bone 
quality can occur much earlier in the course of tumor progression, being exacerbated by 
treatments targeting the primary tumor. For example, in hormone dependent tumors of 
prostate and breast cancer, estrogen and androgen suppression are the principal bastions 
Figure 3: The ‘vicious cycle’ of osteolytic bone metastasis. Disseminated tumor cells home to the 
bone microenvironment where they may remain dormant for many years before stromal cell-derived signals 
trigger their expansion. Expanding micrometastases secrete DKK-1 and other factors that inhibit the 
differentiation of osteoblast progenitors, imbalancing the osteoblast-regulated ratio of osteoprotegrin (OPG) and 
receptor activator of nuclear factor κB ligand (RANKL). The increased production and activity of RANKL 
stimulates the differentiation and activation of mature osteoclasts from osteoclast progenitors, leading to 
resorption of the bone matrix. As the bone is resorbed, growth factors including calcium (Ca2+), transforming 
growth factor β (TGF- β), and insulin-like growth factors (IGFs) are released from the resorbed matrix. These 
factors supplement cancer cell growth, completing and augmenting the vicious cycle of metastatic cancer 
growth and bone osteolysis. 
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for treating these diseases at early and advanced stages (Sharifi et al., 2005; Lumachi et al., 
2013).  
In breast cancer patients, the maintenance of bone health is also a significant clinical 
challenge, with most treatment options exerting negative effects on bone (Chen et al., 2010; 
Hadji, 2015). Hormone ablative treatment approaches, such as aromatase inhibition in the 
cases of estrogen receptor-positive (ER+) cancers, rapidly induce bone resorption by 
promoting osteoclastogenesis and suppressing osteoblastogenesis (Brufsky, 2006; Chien 
and Goss, 2006; Brufsky, 2007). Despite an inevitable loss of bone integrity and an 
increased risk and rate of fractures, compromised bone quality is an accepted side-effect of 
therapies which significantly improve breast cancer patient survival. Rather alarmingly, 
compromised bone quality and increased bone remodeling may in fact encourage the growth 
of latent or dormant cancer cells in the bone (Zheng et al., 2013; Penelope D Ottewell et al., 
2014a; Wang et al., 2015; Wright et al., 2017). Once cancer has successfully established 
metastases in the bone, the deterioration in bone health and SREs come to pass much 
earlier.  
Androgens maintain trabecular bone mass and cortical bone growth, promoting osteoblast 
biology and protecting against osteoporosis directly and indirectly following aromatization of 
testosterone to estradiol (Vanderschueren et al. 2008; Clarke & Khosla 2009). Standard of 
care (SOC) dictates the use of androgen-deprivation therapy (ADT) as a treatment for 
advanced prostate cancer (Recine & Sternberg 2015). Despite being an effective therapy in 
targeting tumor biology, deleterious consequences become apparent in bone biology; with 
decreases in bone mineral density (BMD) leading to increased risks of fractures (Bienz & 
Saad 2015). Patients with prostate cancer are surviving longer and deteriorating bone-health 
quickly becomes a major concern for continued mobility and mortality (Polascik 2008). 
1.1.4 The need for new therapeutics targeting osteolytic bone metastases 
Undeniably, novel anti-tumor agents are warranted that target the bone microenvironment 
and support bone health in the context of malignant bone disease (Mundy 2002; Irelli et al. 
2016). Current therapies aiming to preserve the bone are founded on those used for 
osteoporosis (Rachner et al., 2012). Fifteen years ago, bisphosphonates (BPs) were the only 
established pharmacological agent available for preventing bone loss associated with 
hormone ablation therapies routinely used against hormone receptor-positive cancer and 
simultaneously impeding disease progression in the bone (Hortobagyi et al., 1996; Boissier 
et al., 2000; Lipton, 2004; Saad et al., 2008). Mechanistically, BPs inhibit bone resorption by 
inducing osteoclast apoptosis (Drake et al., 2008), however, it has been shown that even 
when patients with metastatic bone disease were receiving classic antiresorptive treatment 
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with BPs, levels of the bone resorption maker N-telopeptide continued to demonstrate a 
positive correlation with the number of SREs and death (Brown et al., 2003; Brown et al., 
2005). Antiresorptive BPs can demonstrate adverse, albeit rare effects for the patients 
relying on their bone-protective effects; influencing tolerability and drug continuance. These 
include adverse effects in the upper gastro-intestinal tract, acute phase reaction, 
musculoskeletal pain and hypocalcaemia which are classified as short-term. Examples of 
long-term adverse effects include osteonecrosis of the jaw, atypical femur fracture and 
controversially, atrial fibrillation. The main problem with this class of drug is that due to the 
mechanism of action suppressing bone turnover, severe and prolonged suppression can 
eventually lead to increased skeletal fragility (Kennel and Drake, 2009). In addition, BPs 
cannot be used in the case of renal insufficiency, which is a common complication of 
malignancy and chemotherapy, occurring in up to 50% of cases (Darmon et al., 2006).  
With increased understanding of the molecular pathways involved in both bone homeostasis 
and tumorigenesis, new therapeutic targets are being identified and successfully developed 
for use in the clinic. One prime example is that of the RANK/RANKL/OPG signaling system 
and the approval of denosumab for osteoporosis, CIBL and metastatic bone disease (Boyce 
and Xing, 2008; Tsourdi et al., 2011). Denosumab is a monoclonal antibody targeting 
osteoblast surface-bound RANKL, preventing its binding and activation of osteoclast surface-
bound RANK. This results in an inhibition of osteoclast differentiation and activation, reducing 
bone resorption and which has demonstrated proven pro-bone effects clinically (Bone et al., 
2011; Hanley et al., 2012). Denosumab has been assessed positively as a bone-protective 
agent in both metastatic breast and prostate cancer (Stopeck. et al., 2016) and has been 
shown to improve rates of metastasis-free survival in prostate cancer (Smith et al., 2013). 
The role for RANKL/RANK signaling has also been defined as directly promoting 
tumorigenesis and metastasis in breast cancer (Hofbauer et al., 2011; Azim and Azim, 2013). 
With this collective knowledge regarding the role of RANKL in tumor and bone biology, 
denosumab represents a specific bone-targeted therapy in the context of bone metastasis, 
and is an illustration of how promising agents can both prevent bone loss and inhibit tumor 
growth. Despite this, it also displays a profile of adverse effects similar to the BP zoledronic 
acid which affect its continuance and prolonged therapy (Stopeck et al., 2016).  
The clinical evidence in support of using BPs and denosumab for the treatment of bone 
metastases are summarized in Table 1. 
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Table 1: Bone-targeted therapies currently approved for bone metastases 
Drug Class  
(example) Clinical trial (study name) Supporting evidence 
Bisphosphonates 
(BPs) 
(zoledronic acid) 
Long-term efficacy of zoledronic 
acid for the prevention of skeletal 
complications in patients with 
metastatic hormone-refractory 
prostate cancer (Saad et al., 2004). 
Patients in the zoledronic acid group had a 
lower incidence of SREs than patients in the 
placebo group (-11%, p = 0 .028). 
Adjuvant bisphosphonate treatment 
in early breast cancer meta-analyses 
of individual patient data from 
randomized trials (Bergh et al., 2015). 
Adjuvant BPs reduced the rate of breast 
cancer recurrence in the bone (Hazard ratio 
(HR) 0·72, confidence intervals (CI) 0.60–
0.86; 2 p = 0.0002) and improved breast 
cancer survival in postmenopausal patients. 
Adjuvant zoledronic acid in patients 
with early breast cancer: 
Final efficacy analysis of the AZURE 
(BIG 01/04) randomized open-label 
phase 3 trial (Coleman et al., 2014). 
Zoledronic acid reduced the development of 
bone metastases, both as a first event (HR 
0.78, 95% CI 0.63–0.96; p=0.020) and at any 
time during follow-up (HR 0.81, 95% CI 
0.68–0.97; p = 0.022). 
RANKL 
monoclonal 
antibodies 
(denosumab) 
Denosumab compared with 
zoledronic acid for the treatment of 
bone metastases in patients with 
advanced breast cancer:  
A randomized, double-blind study 
(Stopeck et al., 2010). 
Denosumab was superior to zoledronic acid 
in delaying or preventing SREs in patients 
with breast cancer metastatic to bone (HR, 
0.82; 95% CI, 0.71 to 0.95; p = 0.01 for 
superiority) and bone turnover markers were 
reduced. 
Denosumab versus zoledronic acid 
for treatment of bone metastases in 
men with castration-resistant 
prostate cancer:  
A randomized, double-blind study 
(Fizazi et al., 2011). 
The median time to first on-study SRE was 
increased by 17.4% with denosumab 
compared to zoledronic acid (HR 0.82, 95% 
CI 0.71-0.95; p = 0.0002 for non-inferiority; p 
= 0.008 for superiority) 
Adjuvant denosumab in breast 
cancer (ABCSG-18):  
A multicenter, randomized, double-
blind, placebo-controlled trial (Gnant 
et al., 2015). 
Lower number of fractures in the denosumab 
cohort (HR 0·44 [95% CI 0·31–0·64], p < 
0·0001), however bone-metastasis free 
survival data has not yet been presented. 
 
1.1.5 Prospective bone-targeted therapies for osteolytic bone metastases 
In the case of bone metastatic cancer and treatment-induced bone loss (TIBL), the answer to 
the question of how to combine patient comfort with effective and long-lasting treatments is 
of paramount importance. In this case, novel agents promoting osteoblast-driven bone 
anabolism and antiresorptive agents which uncouple the activity of osteoblasts with 
osteoclasts in an osteoblast-friendly manner, are of greatest appeal and prospective benefit 
(Rachner et al., 2012). 
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Tumor cell growth and survival relies critically on the action of proteasomes degrading 
impaired proteins, which would otherwise increase metabolic stress of the cancer cells. 
Therefore, the inhibition of proteasome function in cancer has been developed 
therapeutically (Crawford et al., 2011). In multiple myeloma (MM), two protease inhibitors, 
bortezomib and carfilzomib, have been shown to reduce markers of bone resorption and 
increase markers of bone anabolism, the potential mechanism also involving a reduction of 
DKK-1 levels (Heider et al., 2006; Terpos et al., 2006; Terpos et al., 2008). Bortezomib has 
been shown to promote osteoblast differentiation and activity while concurrently inhibiting 
osteoclast differentiation and activity in vitro and in vivo (Giuliani et al., 2007; von Metzler et 
al., 2007), and was also effective at suppressing the growth of MDA-MB-231 breast cancer 
cells and reducing osteolysis following intratibial injection (Jones et al., 2010).  
As another example, members of the TGF-β superfamily of ligands are well studied for their 
active roles in cancer and bone (Chen et al., 2012; Wakefield and Hill, 2013). Activin A is a 
cytokine of the TGF-β superfamily that plays a role in promoting osteoclast activity while 
simultaneously inhibiting osteoblast activity. Activin A has been shown to be elevated in 
osteolytic bone disease secondary to MM (Vallet et al., 2010), breast and prostate cancer 
(Leto et al., 2006) and activin A inhibition by targeting the activin type IIA receptor (ActRIIA) 
with monoclonal antibodies, has progressed through clinical trials evaluating its potential in 
attenuating bone loss in MM (Abdulkadyrov et al., 2014). Evidence suggests that directly 
inhibiting the action of TGF-β with neutralizing antibodies or using small-molecule inhibitors 
of the TGF-β type I receptor is effective in murine models of breast cancer bone metastases, 
with a strong bone-targeted element of increased bone anabolism and suppression of 
resorption by osteoblasts (Mohammad et al., 2009; Buijs et al., 2012).  
It is known that suppression of bone anabolism and the sequential, indirect promotion of 
bone resorption is a major mechanism in the pathological state of bone metastasis. In this 
context, a potent bone-targeted, bone anabolic drug would be useful to prevent the 
progression of metastases in the bone. Acknowledgment of Wnt signaling as a key pathway 
promoting bone formation implies that it could be harnessed to balance dysregulated bone-
turnover. By promoting osteoblast activity, Wnt signaling has direct pro-bone effects and 
additionally regulates RANK/RANKL/OPG signaling, resulting in indirect inhibitory effects on 
osteoclastogenesis (Baron and Rawadi, 2007). The most effective way to promote Wnt 
signaling is to target its inhibitors and to date sclerostin and DKK-1 antibodies have 
progressed furthest down the development pipeline. Sclerostin antibodies have been 
successfully tested in various animal models of osteoporosis (Li et al., 2009) and are 
successful in the clinic, with the monoclonal sclerostin antibody romosozumab improving 
BMD and reducing the risk of fracture in postmenopausal women with osteoporosis 
1  Introduction 
 
 
13 
(McClung et al., 2014; Cosman et al., 2016). DKK-1 antibodies have also shown promise in 
preclinical models of bone loss induced by MM (Fulciniti et al., 2009) and in fracture models 
(Jin et al., 2015), progressing to a phase IB trail for patients for MM where DKK-1 inhibition 
with an antibody (BHQ880) showed clinical activity in combination with zoledronic acid and 
anti-myeloma therapy (Iyer et al., 2014). Finally, treatment with a bispecific antibody which 
concurrently neutralizes DKK-1 and sclerostin, resulted in increases in BMD and promoted 
fracture repair in preclinical models of bone loss and fracture (Florio et al., 2016). The role of 
DKK-1 in bone and cancer will come into focus in the next chapter. 
MTOR inhibition has also been investigated in the context of preventing the progression of 
endocrine therapy-resistant breast cancer in the bone (Gnant et al., 2013). A surprising bone 
protective profile was reported and this will also be discussed in more detail within the 
following sections. 
1.2 Novel targets linking bone and cancer cell biology 
1.2.1 The canonical Wnt inhibitor: Dickkopf-1 and breast cancer 
The existence of the Wnt signaling pathway was first revealed in the early 1980s with the 
discovery of int-1 as a proto-oncogene promoting mammary gland tumorigenesis in mice 
following locus integration by the mouse mammary tumor virus (MMTV) (Nusse and Varmus, 
1982). Towards the end of the 1980s, researchers had sequenced the wingless protein in 
Drosophila, showing that it was in fact the homolog of int-1 in mammals and that this gene 
and its associated pathway were evolutionarily conserved (Rijsewijk et al., 1987). 
Progressive research has since shown that Wnt signaling reaches the highest levels of 
complexity in mammals, regulating many fundamental features of cell biology; cell 
differentiation, cell fate determination, cell proliferation and cell polarity and underlining the 
importance of Wnt signaling in diverse roles of development, physiology and pathology 
(Logan and Nusse, 2004; Prunier et al., 2004). This complexity of Wnt signaling momentarily 
resulted in the classification of four distinct pathways; the canonical or Wnt/β-catenin 
dependent pathway, the non-canonical or β-catenin-independent pathways sub-divided into 
the Planar Cell Polarity and the Wnt/Ca2+ pathways (Komiya and Habas, 2008) and a lesser 
studied, fourth Wnt signaling pathway involving Protein Kinase A (PKA) (Chen et al., 2005).  
Gong et al. provided the first link between canonical Wnt signaling and bone biology by 
showing that individuals with the autosomal recessive disorder osteoporosis-pseudoglioma 
syndrome (OPPG) have mutations in the low-density lipoprotein receptor-related protein 
(LRP) 5, a canonical Wnt-ligand receptor (Gong et al., 2001). These LRP5 mutations 
corresponded to a reduced bone mass in OPPG sufferers when compared with age- and 
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gender-matched controls. In the same study, the expression of LRP5 by osteoblasts in 
different stages of mouse skeletal development localized the cellular mechanism behind this 
observation. Successive links were made by identifying further Wnt-related mutations in 
genetic disorders of the bone (Zheng et al., 2012; Styrkarsdottir et al., 2013). Most recently, 
recessive inactivating mutations in Wnt1 which have been shown to be responsible for the 
genetic disorder osteogenesis imperfecta (OI) type IV (Fahiminiya et al., 2013), the hallmark 
of this group of OI disorders being increased bone fragility and deformity (Rauch and 
Glorieux, 2004). Early onset osteoporosis has also been associated with mutations in Wnt1 
and presents alongside OI (Laine et al., 2013). From another perspective, investigating 
mutations in Wnt signaling inhibitors have also highlighted the role of canonical Wnt 
activation in the bone.  In one breakthrough study, two independent mutations in the Wnt 
signaling inhibitor sclerostin were shown to be responsible for sclerosteosis, an autosomal 
recessive sclerosing bone dysplasia, mediated by unrestricted Wnt signaling (Brunkow et al., 
2001). In parallel, targeting Wnt signaling genes in genetic studies of mice confirmed the 
importance of Wnt signaling in bone homeostasis. For example, artificially generating 
mutations in LRP5 resulted in LRP5 deficient mice which developed a low bone mass 
phenotype (Kato et al., 2002). Similar observations of reduced bone mass and quality were 
apparent in Wnt10b-/- mice which demonstrated increased bone mass and strength 
compared to wild type littermates (Bennett et al., 2005).  
In both human and murine contexts it is apparent that the activation of canonical Wnt 
signaling pathway plays the leading role in regulating and promoting bone formation by 
controlling osteoblast differentiation, whereas the non-canonical Wnt pathways are involved 
in crosstalk and surrogate signaling within the bone microenvironment, having been shown to 
promote the opposing aspect of bone anabolism in bone homeostasis; osteoclastogenesis 
and bone resorption (Baron et al., 2012; Maeda et al., 2012; Baron and Kneissel, 2013). 
Canonical Wnt signaling is required for the successful differentiation of mesenchymal stem 
cells into mature osteoblasts by stimulating the transcription of the bone-related transcription 
factor RUNX2 (Day et al., 2005; Gaur et al., 2005). Osteoblasts are unique bone-forming 
cells, secreting osteoid which mineralizes upon complex molecular and physical cues. 
Therefore, increased osteoblastogenesis results in bone anabolism and this is the primary 
mechanism whereby Wnt signaling regulates bone mass (Krishnan et al., 2006; Long, 2011).  
Comparable to many signaling pathways, canonical Wnt signaling is tightly regulated through 
interactions between its ligands, agonists, antagonists and receptors (MacDonald et al., 
2009). Activation of Wnt signaling at the cell membrane requires members of the LRP 
receptor family 5 and 6 to form a Wnt-ligand-induced complex with members of the frizzled 
receptor family (Cong et al., 2004). Resulting downstream signals within the cytoplasm inhibit 
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the β-catenin destruction complex leading to its accumulation and nuclear translocation (Fig. 
4). Nuclear β-catenin then associates with and activates the T-cell factor/lymphoid enhancer 
factor transcription factor inducing the expression of known target genes (Niehrs, 2012). 
DKK-1 is an inhibitor of canonical Wnt signaling (Fedi et al., 1999) and its prominent 
mechanism of action as a ligand/antagonist of LRP5/6 is obstructing this complex formation 
with frizzleds and hence inhibiting the transduction of the Wnt signal and nuclear 
translocation of β-catenin (Bafico et al., 2001; Mao et al., 2001; Semënov et al., 2001). 
Dickkopf (DKK) is a distinct family of canonical Wnt inhibitors of which DKK-1 has been 
studied in greatest detail and is the most specific inhibitor of canonical Wnt signaling (Niehrs, 
2006). DKK-1 was first identified in early vertebrate embryonic patterning mediated by 
canonical Wnt signaling in Xenopus, were injections of DKK-1 mRNA into blastomeres of the 
4-cell stage embryo induced the development of an extra head (Niehrs et al., 1998). In 
mammals, DKK-1-null mutant mice are embryonic-lethal, lacking head induction and 
regulation of distal limb patterning (Mukhopadhyay et al., 2001). However, when only a single 
allele of DKK-1 is deleted, embryonic lethality is avoided and there is a clear bone phenotype 
of increased bone mass which correlates with increased numbers and function of osteoblasts 
(Morvan et al., 2006). Both widespread and osteoblast-specific overexpression of DKK-1 
resulted in osteopenia caused by a significant reduction in osteoblast numbers, further 
confirming the inhibitory effects of DKK-1 on osteoblastogenesis and osteoblast function (Li 
et al., 2006). Importantly, targeting DKK-1 in vivo using anti-DKK-1 antibodies further 
emphasized the role of DKK-1 in bone biology. Anti-DKK-1 antibodies had pro-bone effects 
with a similar efficacy of intermittent parathyroid hormone treatment in naïve female mice 
(Glantschnig et al., 2010) and when fractures were created in the tibiae of CD1 mice, 
treatment with an anti-DKK-1 antibody optimized the fracture healing process with increased 
canonical Wnt signaling and differentiation in mesenchymal progenitor cells identified as the 
mechanism responsible (Jin et al., 2015). 
When examining the role of Wnt signaling in normal cellular processes, it is easy to 
appreciate how the dysregulation of Wnt signaling can be involved in many developmental 
defects and disease pathologies (Clevers and Nusse, 2012). In fact, when researchers first 
conceived the idea of a conserved signaling pathway, Wnt signaling components had already 
been shown to be involved in both carcinogenesis and embryogenesis (Peifer and Polakis, 
2000). To date, aberrant Wnt signaling has been shown to govern many aspects of 
carcinogenesis including the maintenance of cancer stem cells, tumor angiogenesis, cancer 
immunology and metastasis (Zhan et al., 2017). DKK-1 has been identified as a target gene 
of the β-catenin/TCF transcription complex, implying that this Wnt inhibitor is involved in a 
novel Wnt signaling feedback loop (Niida et al., 2004). For this reason, it is also logical to  
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Figure 4: The signaling pathways linking bone and cancer cell biology. Canonical Wnt: 
canonical Wnt ligands bind to the Frizzled/LRP5/6 complex (1), transducing a signal cascade which results in 
the inactivation of the β-catenin destruction complex and its sequestration to the plasma membrane (2). β-
catenin accumulates in the cytosol and subsequently translocates to the nucleus, binding to transcription 
factors and activating target genes (3). DKK-1 inhibits this series of events by binding to LRP5/6, preventing 
the formation of the Frizzled complex and Wnt ligand binding (4). This results in the maintenance of the 
destruction complex which leads to the phosphorylation, ubiquitination and proteosomal degradation of β-
catenin (5). Therefore, β-Catenin is unable to accumulate, translocate and mediate gene transcription in the 
presence of DKK-1. mTOR: Growth factors such as cytokines or hormones bind tyrosine kinase receptors in 
the plasma membrane (6) and transduce a signaling cascade through the PI3K/AKT axis to phosphorylate 
and activate mTORC1 (7). Downstream, activated mTORC1 phosphorylates and activates S6K1 and 4EBP 
(8). S6K1increases protein synthesis by ribosomes and 4EBP enhances the specific translation of CCND1 
(cyclin D1) and c-Myc mRNAs. Cyclin D1 and c-Myc accumulate in the cytosol and translocate to the nucleus 
were they mediate the transcription of target genes by binding to transcription factors or DNA directly (9). 
Everolimus forms a drug-receptor complex with FKPB12 which specifically binds to and efficiently blocks 
downstream mTOR activity (10). P38 MAPK: Stress signals (11) activate small GTPases, initiating a core 
triple kinase cascade to activate p38 MAPK (12). P38 MAPK can elicit many downstream signals in the 
cytoplasm but can also translocate to the nucleus were it can bind to various transcription factors and 
mediate target gene transcription (13). All 3 pathways have been shown to be linked by GSK3β (14). Both 
AKT and p38 MAPK can phosphorylate GSK3β when activated – resulting in the inhibition of canonical Wnt 
signaling by deactivation of the β-catenin destruction complex. 
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suspect that dysregulated DKK-1 expression can play an important role in tumor initiation 
and progression. In reality a vast body of research supports this suspicion, nevertheless, 
diverse and conflicting roles of DKK-1 continue to be described in a comprehensive variety of 
tumor etiologies and types (Menezes et al., 2012). 
DKK-1 as a candidate biomarker and its usefulness in the diagnosis of cancer has been 
investigated in many different cancer types, with the dysregulation of its expression being a 
predictor of poor prognosis providing non-invasive, diagnostic power. The type of 
dysregulation (upregulation or downregulation) is context specific and varies depending on 
the cancer type and stage, correlating with clinicopathological traits such as disease 
progression and tumor grade. MM was the first cancer entity were DKK-1 levels were 
investigated in the serum of affected patients (Tian et al., 2003; Politou et al., 2006). DKK-1 
was first identified as a possible secreted factor of MM cells due to the impaired 
osteoblastogenesis and osteolytic bone disease which occurs as MM progresses. In these 
studies, DKK-1 serum levels were significantly increased both in respect to monoclonal 
gammopathy of undetermined significance (MGUS) and control patients. Elevated DKK-1 
serum levels have also been documented in osteosarcoma (Lee et al., 2007), bladder (Sun 
et al., 2015), hepatocellular (Sun et al., 2015), pancreatic (Han et al., 2015), esophageal 
(Begenik et al., 2014), cervical (Jiang et al., 2013), endometrial (Jiang et al., 2009), prostate 
(Rachner et al, 2014a) and non-small cell lung cancer (Dong et al., 2014) with an overall 
tendency to correlate with lymph-node and distant metastasis.  
Significantly, DKK-1 has been shown to be elevated in the serum of breast cancer sufferers 
with reports of elevated levels in both early and late stages of the disease (Voorzanger-
Rousselot et al., 2009), correlating with a poor prognosis of reduced overall survival and 
increased rate of disease relapse.(Zhou et al., 2014) Controversially, DKK-1 has been shown 
to be silenced in breast cancers due to increased methylation of its promoter (Acar et al., 
2014). Despite this finding, another group reports that DKK-1 is less frequently silenced in 
both cell lines and tumors (Suzuki et al., 2008). DKK-1 expression in association with that of 
β-catenin has been shown to correlate with a worse prognosis for triple-negative ((ER, 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2)) breast 
cancer (TNBC) patients (Xu et al., 2012). But once again, further work would similarly 
propose a role for DKK-1 as tumor-suppressor. Increased proliferation has been observed in 
a variant of the ER+ cell-line MCF-7 (Zhou et al., 2010). The authors report that an enhanced 
downregulation of DKK-1 is responsible for this observation, with uninhibited Wnt signaling 
as the mechanism driving this increased proliferation. A further study supports the role of 
DKK-1 as a suppressor of tumor formation in a number of cell lines investigated in vitro 
(Cowling et al., 2007). Employing the use of mathematical models has also been explored to 
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determine the role of DKK-1 in breast cancer (Agur et al., 2011). These lines of inquiry would 
support a dose dependent effect of DKK-1 regulating the differentiation of cancer stem cells 
(CSCs). High DKK-1 increases the terminal differentiation of CSCs eventually leading to their 
loss from the tumor cell population and low levels of DKK-1 may promote the proliferation of 
CSCs without the loss in their capacity for future differentiation which is considered as one of 
the driving forces in tumorigenesis (Charafe-Jauffret et al., 2009). Similar observations and 
studies of DKK-1 expression in prostate cancer will also be discussed in later sections.  
Thus far, the relevance of DKK-1 expression in breast cancer tumorigenesis remains 
ambiguous. Considering its actions in the context of bone biology, if DKK-1 does play the 
role of a tumor promoter in breast cancer, it could be an interesting therapeutic target in this 
cancer type which commonly forms osteolytic bone metastases in later disease stages. This, 
coupled with increasing reports of involvement in the process of metastasis, make DKK-1 a 
prime target for investigation.  
1.2.3 The nutrient sensor: mechanistic target of rapamycin and breast cancer  
The macrolide compound rapamycin (also known as sirolimus) was first isolated as an 
antifungal agent from the bacterial species Streptomyces hygroscopicus in 1974 (Sehgal et 
al., 1975). Its function has since evolved for use in immune suppression, first achieving Food 
and Drug Administration (FDA) approval in 1999 to prevent renal graft rejection (WHO 
Pharmaceuticals Newsletter, 1999), and it has continued to flaunt its versatility into the last 
decades being recognized as an established tumor suppressor and chemotherapeutic agent 
of aggressive cancer types (Seto, 2012; Vignot et al., 2005). Rapamycin was the key 
required to identify the target protein which it inhibits, and the study of the  multifaceted 
mechanistic target of rapamycin (mTOR) signaling pathway was begun (Heitman et al., 
1991). There are two mTOR complexes (mTORC), mTORC1 and mTORC2. MTORC2 is 
insensitive to the inhibitory effect of rapamycin whereas the inhibition of mTORC1 by 
rapamycin is unambiguous (Jacinto et al., 2004). Rapamycin forms a drug-receptor complex 
with the FK506 binding protein (FKPB12) which specifically binds to and efficiently blocks 
mTOR activity stemming from mTORC1 (Abraham, 2002; Guertin and Sabatini, 2007). With 
this in mind, the majority of knowledge that we have regarding the mTOR pathway has been 
gained by studying the activity of mTORC1, and so it will remain in the focus of this work.  
The activity of mTOR and hence mTORC1, is integral to the function of the mTOR signaling 
pathway and its regulation of cell growth and metabolism. MTORC1 regulates many cellular 
process including; protein synthesis (Wang and Proud, 2006), lipid synthesis (Laplante and 
Sabatini, 2009), mitochondrial energy production (Morita et al., 2013) and autophagy (Ganley 
et al., 2009). It does so in response to both environmental and intracellular cues including; 
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nutrients, various growth factors, insulin and even stress; endoplasmic reticulum stress, 
oxidative stress and hypoxia (Ma and Blenis, 2009; Heberle et al., 2015). This diverse range 
of stimulants and reactions required for the maintenance of the homeostatic cell, make it 
easy to appreciate how dysregulation of the mTOR pathway has been identified as a 
significant component in many disease processes including cancer (Pópulo et al., 2012). In 
the most recognized sequence of effects, mTOR-mediated survival signaling is regulated 
upstream by factors activating the PI3K/Akt pathway (Wullschleger et al., 2006) leading to 
downstream phosphorylation of p70S6 Kinase (also known as S6K1) and 4EBP1.(Nojima et 
al., 2003) Activation of these targets results in a combination of increased ribosomal 
synthesis, mRNA translation and protein synthesis. Specific mRNAs targeted for increased 
translation by 4EBP1 include CCND1 (cyclin D1) and c-Myc, which accumulate in the 
cytoplasm and translocate to the nucleus, directly binding DNA and other transcription 
factors in order to regulate cell cycling and proliferation (Fig. 4) (Vignot et al., 2005). In many 
cancer types, mTOR signaling is upregulated due the hyperactivation of its upstream 
regulators, including AKT and PI3K which are oncogenes in their own right (Zoncu et al., 
2011). Furthermore, hyperactivated signaling can be a direct result of gain-of-function 
mutations in mTOR, reinforcing the role for mTOR as a therapeutic target in oncology 
(Grabiner et al., 2014). 
Rapamycin, while demonstrating pharmacological benefits in organ transplantation, required 
improved bioavailability and oral pharmacokinetics. For this reason, everolimus (a rapamycin 
derivative/analog) was developed by Novartis Pharma Corp and was proven to be as 
effective as rapamycin in vivo, having identical inhibition profiles of targets downstream of 
mTOR signaling (Schuler et al., 1997; Neuhaus et al., 2001). Currently, everolimus has FDA 
approval as an individual agent or in combination with other drugs, being prescribed for 
patients with the following tumor types; giant cell astrocytomas, neuroendocrine tumors of 
pancreatic origin, advanced renal cell carcinoma and advanced hormone receptor-positive, 
HER-2-negative breast cancer (FDA website, 2016). Of interest to this work is the 
therapeutic role of everolimus in breast cancer. 
MTOR signaling has been identified as a facilitator of endocrine resistance (Fig. 5) which 
unfavorably complicates the treatment of advancing breast cancer, correlating with an 
increased incidence of metastasis and decrease in patient survival (Beeram et al., 2007; 
Miller et al., 2010; Tokunaga et al., 2014; Lui et al., 2016). Epidermal growth factors (Wilks, 
2015), the signaling of ERs (Shtivelband, 2013) and the loss of the tumor suppressor PTEN 
(Nagata et al., 2004), have all been shown to be responsible for increasing the activity of 
mTOR in this context. Therapeutically, mTOR inhibition using everolimus in preclinical 
models of ER-positive breast cancer, synergistically inhibited proliferation and induced 
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apoptosis when combined with aromatase inhibitors (AIs) (Boulay et al., 2005). Clinically, 
mTOR inhibition has been evaluated for its ability to overcome endocrine resistance in the 
pivotal phase III BOLERO-2 trial (Baselga et al., 2012). Here, the mTOR-inhibitor everolimus 
was combined with the nonsteroidal AI exemestane and used to treat postmenopausal 
women with ER-positive, HER-2-negative, advanced breast cancer who were refractory to 
letrozole or anastrozole, two AIs. The response from everolimus treatment prolonged the 
median progression free survival of patients by 6.9 months compared to only 2.8 months with 
exemestane alone. This encourages the consideration of mTOR inhibition as a valuable 
therapeutic addition for the treatment of endocrine resistance in breast cancer.  
Further exploratory analyses in the BOLERO-2 trial have yielded interesting observations 
with regard to mTOR inhibition and its role in the progression of bone metastases (Gnant et 
al., 2013). In the exemestane cohort, bone turnover markers were increased when measured 
at 6 and 12 weeks. This is expected in the case of aromatase inhibition as estrogen is a key 
regulator in the physiologic remodelling of bone, suppressing osteoclast-mediated bone 
resorption (Perez and Weilbaecher, 2006). However, the same bone turnover markers were 
significantly lower when evaluating the combined exemestane/everolimus cohort. 
Additionally, the rate of disease progression in the bone was also lower in the combination 
group.  
Figure 5: Treatment evasion of the estrogen receptor in metastatic estrogen receptor-positive 
breast cancer. Estrogen receptor-positive (ER+) breast cancer relies on the binding of the hormone estrogen 
to the nuclear receptor, mediating growth positive gene transcription. ER+ breast cancer is initially sensitive to 
endocrine therapies, however over time become resistant to said therapies, allowing the disease to progress 
commonly in the form of bone metastases. MTOR signaling has been associated with endocrine resistance and 
has been targeted therapeutically in the clinic, with the aim to inhibit disease progression and prolong survival 
in these patients. Image adapted from Dr. Nikhil Wagle (slideshare.net, 2015) 
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Of interest, a role for mTOR signaling has been previously attributed to different aspects of 
bone biology (Hadji et al., 2013). The activity of bone resorbing osteoclasts depends on the 
mTOR pathway as the osteoclast differentiation factor RANKL signals through the mTOR/S6 
kinase (Glantschnig et al., 2003). In osteoblasts, an increase of bone protective OPG has 
been observed following mTOR inhibition by rapamycin (Mogi and Kondo, 2009) and in a rat 
ovariectomy (OVX) model, everolimus was shown to decrease osteoclast mediated bone 
resorption and inhibit the in vitro production of cathepsin K, an osteoclast-secreted protease 
that breaks down bone matrix proteins.(Kneissel et al., 2004)  
In preclinical investigations, everolimus shows promise in dictating anti-tumor responses in 
different cancer types. However, in the majority of clinical studies, everolimus has only been 
investigated in combination with other established bone-protective drugs. Therefore, the use 
of everolimus as an individual preventative agent or bone-targeted agent in the context of 
bone metastases is still not clear. On the foundation of the BOLERO-2 trail, a section of this 
thesis work has sought to illuminate how the actions of everolimus at the cellular level may 
lead to reduced bone turnover, and the consequences this may have for disease progression 
in the bone. Often associated with osteolytic malignant bone disease, the actions of 
everolimus in a hormone-deprived environment will also remain in the focus of this 
investigation.  
1.2.4 The stress-responders: p38 mitogen-activated protein kinases and prostate 
cancer 
Signaling by p38 mitogen-activated protein kinases (MAPK) have also been implicated in the 
progression of osteotropic cancer types (Yin et al., 2005). P38 MAPK are key signal 
transduction enzymes, responsible for transducing signals from the cell membrane to the 
nucleus. They are activated by a variety of environmental insults, inflammatory cytokines and 
growth factors, controlling numerous cell functions, including cell cycle, apoptosis and 
proliferation (ZHANG and LIU, 2002).  P38 MAPK comprises four unique isoforms 
(p38β/MAPK11, p38γ/MAPK12, p38δ/MAPK13 and p38α/MAPK14) sharing varied degrees 
of sequence homology and activity. MAPK14 and MAPK11 are the two most discussed in 
cancer research to date, being the closest related in structure, activity and sensitivity to 
inhibitors (Cuenda and Rousseau, 2007). Their activation and activity are mediated by 
various mechanisms. One such mechanism is by the activation of small GTPases which 
initiate a core triple kinase cascade with sequential phosphorylations of MAP kinase kinases 
(MAP3K), MAP kinase kinases (MKK) and p38 MAPK to elicit signal transduction, nuclear 
translocation of p38 MAPK and binding of transcription factors (Fig. 4) (Seger and Krebs, 
1995; Lewis et al., 1998). 
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P38 MAPK activity is dysregulated in prostate cancer, with reports controversially describing 
tumorigenic and mainly proapoptotic, tumor suppressor roles (Rodríguez-Berriguete et al., 
2012). With the focus of this work remaining on the pro-tumor effects of p38 MAPK, it has 
been described that upstream and downstream components of the p38 MAPK signaling 
pathway are upregulated in prostate cancer compared to benign prostate hyperplasia (Ricote 
et al., 2006a). Mechanistically, it was suggested that inhibition of p38 MAPK could be a 
potential therapy for prostate cancer by decreasing IL-1-induced cell proliferation and 
increasing TNF-α-induced cell death. The same group went on to validate this hypothesis, 
demonstrating that inhibition of p38 MAPK promotes TNF-α-induced apoptosis in androgen-
dependent prostatic cancer LNCaP prostatic cancer cells (Ricote et al., 2006b). A decisive 
proliferative role, rather than a proapoptotic role for p38 MAPK has also been associated with 
the initiation of prostate cancer in a transgenic mouse model (Uzgare et al., 2003). 
The acquirement of androgen-resistance in cancer is a common occurrence in advanced 
prostate cancer leading to metastasis (Feldman and Feldman, 2001). IL-1 6 has also been 
proposed as a co-activator of the AR, supporting castration-resistant prostate cancer (Ueda 
et al., 2002; Feng et al., 2009).  With this in context, it has been shown that p38 MAPK is a 
regulator of IL-6-induced AR activity in prostate cancer cells (Lin et al., 2001a) Additionally, 
another mechanism of increased androgen-independent AR activation in LNCaP cells 
resulting from hypoxia-reoxygenation, is also dependent on p38 MAPK (Khandrika et al., 
2009). Not only is p38 MAPK implicated in androgen independence but also in gaining a 
metastatic phenotype, another hallmark of advanced prostate cancer. By different 
mechanisms, p38 MAPK has been shown to activate MMP and integrin expression, 
enhancing the invasion and migration abilities of prostate cancer cell lines (Huang et al., 
2005; Tang and Lu, 2009; Shen et al., 2010), highlighting its role in prostate cancer 
metastasis.  
Signaling pathways do not always act in an exclusive manner and crosstalk is common. 
Crosstalk is influenced by the cell context and is an integral component of cellular regulation 
(Cuadrado and Nebreda, 2010). The inactivation of GSK3β establishes a link between the 
p38 MAPK and the canonical Wnt pathways. Active Wnt binding suppresses GSK3β activity 
by inhibiting its phosphorylation. This in turn inhibits the β-catenin destruction complex, which 
allows β-catenin to accumulate and translocate to the nucleus where it is responsible for the 
activation of canonical Wnt-target gene transcription (Wu and Pan, 2010). Interestingly, 
phosphorylation of GSK3β’s C-terminal residue Ser389 by p38 MAPK, can also result in the 
accumulation of β-Catenin and the transcription of Wnt-target genes (Thornton et al., 2008). 
In a novel Wnt feedback loop, DKK-1 has been shown to be a target gene of β-Catenin/TCF-
regulated transcription (Niida et al., 2004). Of relevance, high DKK-1 serum levels correlate 
1  Introduction 
 
 
23 
with poor survival of prostate cancer patients and preclinical studies have shown that the 
molecular behavior of tumor-derived DKK-1 can promote an osteolytic phenotype in 
osteotropic prostate cancers by inhibiting osteoblastogenesis (Hall et al., 2008; Rachner et 
al., 2014).  
Studies of bone destruction associated with rheumatoid arthritis have led us further in the 
direction of how p38 MAPK and DKK-1 could be linked. TNF-α has been identified as key 
inducer of DKK-1 in murine and human models of rheumatoid arthritis, where inhibition of 
DKK-1 in the murine model was able to suppress associated bone destruction (Diarra et al., 
2007). Turning the spotlight to the role of p38 MAPK activity in bone biology it would also 
appear that p38 MAPK is also an important downstream target of TNF-α which has been 
shown to be a stimulator of osteoclastogenesis in inflammatory conditions (Lam et al., 2000). 
Later studies have gone on to directly link p38 MAPK regulation and DKK-1 expression in the 
biology of osteolytic bone metastases. Increased secretion of DKK-1 by bone metastatic 
breast cancer cells, suppresses osteoblastogenesis (Bu et al., 2008) and in MM, p38 MAPK 
has been shown to regulate DKK-1 and MCP-1 expression and secretion, disrupting the 
coupling of osteoblast and osteoclast differentiation and recruitment, enabling the 
progression of osteolytic lesions (He et al., 2012). Here, intrinsic activation of p38 MAPK in 
myeloma cells upregulated DKK-1 expression and secretion in vitro and in myeloma-bearing 
mice, whereas knockdown or inhibition of p38 MAPK activity using shRNA and siRNAs or 
small-molecule inhibitors respectively, significantly downregulated DKK-1 secretion. 
Interestingly, inhibition of p38 MAPK using the small-molecule inhibitor SB20358 resulted in 
potentiation of osteoblast function when murine myoblastic C2C12 cells were differentiated 
with BMP-2 (Viñals et al. 2002). 
Thus far, the suggestion that p38 MAPK regulates DKK-1 in osteotropic prostate cancer 
remains to be proven. The ensuing work was carried out in order to determine if DKK-1 is 
regulated by p38 MAPK in prostate cancer and to assess if targeting p38 MAPK could 
potentially have positive effects against pro-metastatic processes in the bone, such as 
restoring DKK-1-suppressed osteoblastogenesis. 
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2  Objective 
The past 20 years of scientific research have made many developments in the diagnosis and 
treatment of breast and prostate cancer. Patient survival rates have unquestionably 
improved, however in parallel; the incidence of secondary, metastatic bone disease has been 
amplified. Current therapies aim to prevent the spread of detected bone metastases by 
protecting the bone and targeting the tumor entities. Despite these therapies, bone 
metastases continue to progress, causing pain, debilitation and eventually death. Bone 
metastases are neither preventable nor curable, and more potent therapies are required.  
Anti-DKK-1 therapies will soon be realized in the clinic, with trials in MM leading the way in 
drug development. The translational potential of anti-DKK-1 therapy for use in other cancer 
types such as breast cancer is also an attractive concept. To date, many conflicting reports 
have proposed both tumor suppressor and tumor promoter roles for DKK-1. Therefore, 
further research will decide if anti-DKK-1 therapy can be considered for breast cancer in the 
future. The role of DKK-1 in osteolytic bone metastases has also been recognized, however 
the molecular mechanisms that regulate the expression and activity of DKK-1 also require 
further elucidation. In the context of DKK-1 regulation, one signaling pathway of interest is 
p38 MAPK signaling. MTOR signaling is also proving to be a key player in the colonization of 
bone by cancer cells. The BOLERO-2 trial has validated mTOR inhibition in combination with 
aromatase inhibition, as an effective therapy to prevent the progression of hormone receptor-
positive breast cancer in the bone. Still, questions have arisen as to how the effects are 
mediated, i.e. could mTOR inhibition have desirable effects on bone as well as cancer cells?  
The main objective of this study was to investigate the therapeutic potential that DKK-1 
neutralization, mTOR inhibition and p38 MAPK-mediated regulation of DKK-1 may present in 
suppressing the progression of osteotropic cancers. 
In summary, three major questions were addressed: 
1. Is DKK-1 a tumor promoter of osteotropic breast cancer? 
2. How does mTOR inhibition contribute to a reduced progression of metastatic bone 
disease? 
3. Does p38 MAPK regulate DKK-1 in osteotropic prostate cancer cells and can the 
inhibition of p38 MAPK signaling rescue suppressed osteoblastogenesis? 
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3  Materials and methods 
3.1  Materials 
3.1.1 Reagents 
   Reagent Company, City, Country 
   4′,6-Diamidin-2-phenylindol (DAPI) Sigma-Aldrich, Munich, Germany 
   5 x First Strand Buffer Invitrogen, Karlsruhe, Germany 
   Agarose SERVA, Heidelberg, Germany 
   Alizarin Red S Sigma-Aldrich, Munich, Germany 
   Alpha medium Biochrom, Berlin, Germany 
   Ampicillin Sigma-Aldrich, Darmstadt, Germany 
   Anisomycin Enzo Life Sciences, Farmingdale, NY, USA 
   Aquatex® Merck Millipore, Darmstadt, Germany 
   Ascorbate phosphate Sigma-Aldrich, Darmstadt, Germany 
   Bovine serum albumin (BSA); fraction V Carl Roth, Karlsruhe, Germany 
   Calcein Sigma-Aldrich, Dharmstadt, Germany 
   Caspase 3/7 Glo® assay Promega, Hamburg, Germany 
   CellTiterBlue® Promega, Hamburg, Germany 
   Citric acid monohydrate Merck Millipore, Darmstadt, Germany 
   cOmpleteTM  
   (Prostease inhibitor cocktail) 
Roche, Mannheim, Germany 
   Crystal violet Sigma-Aldrich, Munich, Germany 
   Cuvettes (Plastic) Kartell LABWARE, Milan, Italy 
   CYBR® Green PCR Master Mix Thermo Fisher Scientific, Schwerte, Germany 
   DAB chromogen and substrate buffer DAKO, Hamburg, Germany 
   Deoxyribonucleotide triphosphates 
   (dNTP  Mix) 
Fermentas, St. Leon-Rot, Germany 
   Dexamethasone Sigma-Aldrich, Darmstadt, Germany 
   DharmaFECT™ GE Healthcare, Munich, Germany 
   Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich, Germany 
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   Dithiothreitol (DTT)  Invitrogen, Karlsruhe, Germany 
   DKK-1 ELISA, human Biomedica, Vienna, Austria 
   D-luciferin  PerkinElmer, Rodgau, Germany 
   Doramapimod Medichem Express, NJ, USA 
   Dual-Luciferase Wnt Reporter Assay Promega, Hamburg, Germany 
   Dulbecco's Modified Eagle Medium:  
   DMEM   (1X) 
Gibco Life Technologies, Darmstadt, Germany 
   Dulbecco's Modified Eagle Medium:  
   Nutrient Mixture F-12 (DMEM/F12) 
Gibco Life Technologies, Darmstadt, Germany 
   ECL Plus Western Blotting substrate Thermo Fisher Scientific, Schwerte, Germany 
   Entellan Merck Millipore, Darmstadt, Germany 
   Eosin Carl Roth, Karlsruhe, Germany 
   Ethanol, absolute  VWR, Darmstadt, Germany 
   Ethylenediaminetetraacetic acid (EDTA) Serva, Heidelberg, Germany 
   Fetal calf serum (FCS) Biochrom, Berlin, Germany 
   Fluorescent Mounting Medium  Dako North America Inc., Carpinteria, CA, USA 
   Formaldehyde (37%) Merck Millipore, Darmstadt, Germany 
   FuGENE® HD Transfection Reagent Promega, Hamburg, Germany 
   Glutamine Biochrom, Berlin, Germany 
   Hank’s balanced salt solution (HBSS) Gibco Life Technologies, Darmstadt, Germany 
   Hematoxylin Clin-Tech, Guilford, UK 
   High Pure RNA Isolation Kit Roche, Mannheim, Germany 
   Hydrochloric acid (HCl) Merck Millipore, Darmstadt, Germany 
   Hydrogen peroxide 35% Merck Millipore, Darmstadt, Germany 
   Hygromycin B Thermo Fisher Scientific, Schwerte, Germany 
   Isopropyl alcohol Merck Millipore, Darmstadt, Germany 
   Ketamine  Bela-pharm, Vechta, Germany 
   LB Broth (DifcoTM) BD Biosciences, Heidelberg, Germany 
   LB-Agar  Carl Roth, Karlsruhe, Germany 
   LY2228820 Selleck Chemicals, Munich, Germany 
   Matrigel® basement membrane matrix Corning, Wiesbaden, Germany 
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   Mayer’s Hemalum Solution Merck Millipore, Darmstadt, Germany 
   Methanol Merck Millipore, Darmstadt, Germany 
   Mini trans-blot filter paper Whatman, Dassel, Germany 
   N,N,3,5-Tetramethylaniline  
   (Technovit 9100 NEW kit) 
Heraeus Kulzer GmbH, Hanau, Germany 
   Nitrocellulose blotting membrane  GE Healthcare, Munich, Germany 
   Non-fat dry milk Carl Roth, Karlsruhe, Germany 
   Opti-MEM® I + GlutaMAX™ - I Gibco Life Technologies, Darmstadt, Germany 
   Osteosoft® Merck Millipore, Darmstadt, Germany 
   PageRuler Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
   Paraformaldehyde (PFA); 37% Merck Millipore, Darmstadt, Germany 
   Penicillin/streptomycin  Gibco Life Technologies, Darmstadt, Germany 
   peqGOLD TriFast™ Peqlab, Erlangen, Germany 
   Phosphate buffered saline (PBS) Biochrom AG, Berlin, Germany 
   PhosSTOPTM 
   Phosphatase inhibitor cocktail 
Roche, Mannheim, Germany 
   Pierce™ BCA protein assay kit Thermo Fisher Scientific, Schwerte, Germany 
   Plasmid Maxi Kit  Qiagen, Hilden, Germany 
   Power SYBR Green PCR Master Mix Applied Biosystems, Darmstadt, Germany 
   Primers Sigma-Aldrich, Munich, Germany 
   Propidium iodide BD Biosciences, Heidelberg, Germany 
   Protease inhibitor cocktail Roche, Mannheim, Germany 
   Puromycin Gibco Life Technologies, Darmstadt, Germany 
   QIAamp® DNA Mini Kit  Qiagen, Hilden, Germany 
   RAD001 (Everolimus)  Selleck Chemicals, Munich, Germany 
   Recombinant human BMP-2  Peprotech, Rocky Hill, NJ, USA 
   Recombinant human BMP-4  Peprotech, Rocky Hill, NJ, USA 
   Recombinant human DKK-1 R&D systems, Minneapolis, MN, USA 
   Recombinant human Wnt3a R&D systems, Minneapolis, MN, USA 
   Recombinant murine M-CSF  R&D systems, Minneapolis, MN, USA 
   Recombinant murine RANKL  R&D systems, Minneapolis, MN, USA 
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   Reducing reagent, 20x Fermentas, St. Leon-Rot, Germany 
   Ribonuclease A Sigma-Aldrich, Munich, Germany 
   RNase AWAY Molecular BioProducts (ThermoScientific), Bonn, Germany 
   RNaseOUT™ Recombinant Ribo-nuclease    
   Inhibitor 
Invitrogen, Karlsruhe, Germany 
   Roti-histofix (4% PFA) Carl Roth, Karlsruhe, Germany 
   RPMI 1640 Medium Gibco Life Technologies, Darmstadt, Germany 
   RT2 Human Extracellular Matrix and     
   Adhesion Molecules (PAHS-013C) 
Qiagen, Hilden, Germany 
   RT2 Human Wnt Signaling Pathway 
   (PAHS-   043ZC) 
Qiagen, Hilden, Germany 
   S.O.C. Medium Invitrogen, Karlsruhe, Germany 
   SB202190 Selleck Chemicals, Munich, Germany 
   Sodium chloride  Merck, Darmstadt, Germany 
   Sodium dodecyl sulfate (SDS) ultra-pure Carl Roth, Karlsruhe, Germany 
   SuperScript II reverse transcriptase Invitrogen, Karlsruhe, Germany 
   Tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
   Tris Carl Roth, Karlsruhe, Germany 
   Triton X-100 Serva, Heidelberg, Germany 
   Trypan blue solution Sigma-Aldrich, Munich, Germany 
   Trypsin-EDTA (0.05%) Gibco Life Technologies, Darmstadt, Germany 
   Tween-20 Serva, Heidelberg, Germany 
   VECTASTAIN Elite ABC Kits  VECTOR Laboratories, Peterborough, UK 
   Xylazine  Pharma Partner, Hamburg, Germany 
   Xylene VWR Chemicals, Dresden, Germany 
   β-glycerol phosphate Sigma-Aldrich, Darmstadt, Germany 
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3.1.2 Equipment 
Instrument Company, city, country 
7500 Fast Real-Time PCR System Applied Biosystems, Carlsbad, CA, USA 
   Autoclip® applier BD Biosciences, Heidelberg, Germany 
BD LSR II Flow Cytometer  BD Biosciences, Heidelberg, Germany 
Bench Hera Safe Heraeus (Thermo Scientific), Bonn, Germany 
Blot chambers BioRad, Munich, Germany 
Canon PowerShot G9 digital camera Canon, Krefeld, Germany 
Centrifuges 
   Biofuge PrimoR 
   Biofuge fresco 
   Centrifuge 5415D & 5810R 
   Labofuge 400 
   Micro centrifuge Galaxy-Ministar 
   SIGMA 3K30  
   Table centrifuge Galaxy Mini 
   Universal 320 
 
Heraeus (Thermo Scientific), Bonn, Germany 
Heraeus (Thermo Scientific), Bonn, Germany 
Eppendorf, Hamburg, Germany 
Heraeus (Thermo Scientific), Bonn, Germany 
VWR, Darmstadt, Germany 
Sigma-Aldrich, Munich, Germany  
VWR, Darmstadt, Germany 
Hettrich, Tuttlingen, Germany 
Counting chamber Laboroptik Ltd, Lancing, UK 
Electrophoresis chamber Mini-Protean & Mini 
Trans-Blot 
BioRad, Munich, Germany 
Elmasonic S30  Elma Schmidbauer GmbH, Singen, Germany 
FLUOstar® Omega microplate reader  BMG Labtech, Offenburg, Germany 
Fridges 
   Liebherr Premium (+4°C)  
   Liebherr glassline (+4°C)  
   Liebherr comfort (+4°C)  
   Liebherr profi-line (-20°C)  
Panasonic ultra-low temperature freezer (-80 °C)  
 
Liebherr, Bulle, France 
Liebherr, Bulle, France 
Liebherr, Bulle, France 
Liebherr, Bulle, France 
Ewald Innovationstechnik GmbH, Bad Nenndorf, 
Germany 
Hood MC6 Waldner, Wangen, Germany 
Hot plate shaker PHMP Grant-bio, Grants Pass, Oregon, USA 
Ice machine Ziegra, Isernhagen, Germany 
Incubator Hera Cell Heraeus (Thermo Scientific), Bonn, Germany 
IVIS 200 in vivo imaging system  (Xenogen, Alameda, CA, USA) 
Leica TP 1020 (Tissue processor) Leica Biosystems, Nussloch, Germany 
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Magnetic stirrer MR Hei-Tec Heidolph, Schwabach, Germany 
MF ChemieBIS 3.2 Bio-Imaging Systems, Wolferstadt, Germany 
Microscope Axio Imager M1 Carl Zeiss Jena, Jena, Germany 
Microscope Axiovert 40C Carl Zeiss Jena, Jena, Germany 
Microtome RM2265 Leica Biosystems, Nussloch, Germany 
Mouse incubator Uniprotect Bioscape, Emmendingen, Germany 
Mr. Frosty Brand Products, Fulda, Germany 
Multichannel pipette Eppendorf, Hamburg, Germany 
Nano Drop ND-1000 Thermo Scientific/ PEQLAB, Erlangen, Germany 
OLYMPUS FE-4040 digital camera Olympus, Hamburg, Germany 
pH meter 766 Knick, Berlin, Germany 
Pipetus-akku Hirschmann, Eberstadt, Germany 
Professional Standard Thermo Cycler Analytikjena, Göttingen, Germany 
PureLab Ultra ELGA Labwater, Celle, Germany 
Scales 
  BL 310 
  Discovery 
 
Sartorius, Göttingen, Germany  
OHAUS, Giessen, Germany 
Shaker Janke&Kunkel, Staufen, Germany; 
ES Edmund Bühler GmbH, Hechingen, Germany 
Steam sterilization Varioklav Typ 400 Variomag (Thermo Scientific), Bonn, Germany 
Steamer Braun MultiGourmet B. Braun, Melsungen, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
UVsolo TS Imaging System Biometra, Göttingen, Germany 
VivaCT40 (µCT) ScancoMedical, Brüttisellen, CH 
Vortex genie 2 Scientific Industries, USA 
Water bath GFL, Leipzig, Germany 
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3.1.3 Consumables 
Consumable Company, city, country 
14 ml polystyrene tubes Greiner BioOne, Frickenhausen, Germany 
15 and 50 ml Falcon tubes Greiner BioOne, Frickenhausen, Germany 
96 Fast PCR plate Sarstedt, Nümbrecht, Germany 
Assay plates, 12 & 96 well Corning Inc., Corning, NY, USA 
Autoclip® wound clips (9 mm) BD Biosciences, Heidelberg, Germany 
Beakers, glassware Schott Duran, Mitterteich, Germany 
Cell culture plates and flasks Greiner BioOne, Frickenhausen, Germany 
Cell scraper  TPP, Trasadingen, Switzerland 
Cover slips Menzel-Gläser, Braunschweig, Germany 
Cryo tubes Brand Products, Fulda, Germany 
Eppendorf tubes (2, 1.5, 0.6, 0.2 ml) Eppendorf, Hamburg, Germany 
Filter tips (1, 0.1, 0.01 ml) Biozym Scientific GmbH, Hessisch Oldendorf, Germany 
Filtropur S 0.2 Sarstedt, Nümbrecht, Germany 
Forceps FST Medizintechnik, Bad Oyenhausen, Germany 
Glass/microscope slides Thermo Scientific/ PEQLAB, Erlangen, Germany 
Microlance 3 0.3 x 13 mm BD Biosciences, Heidelberg, Germany 
Needles (24G; 27G) B. Braun, Melsungen, Germany 
Paraffin (Leica Suripath Paraplast) Leica Biosystems, Nussloch, Germany 
Pipette tips (1, 0.2, 0.01 ml) Greiner, Solingen/ Sarstedt, Nümbrecht, Germany 
Pipettes (5, 10, 25 ml) Eppendorf, Hamburg, Germany 
Rat-mouse-diet food pellets (V1534-300) Ssniff®, Soest, Germany 
Scissors FST Medizintechnik, Bad Oyenhausen, GER 
Sealing tape Sarstedt, Nümbrecht, Germany 
Sutures (6/0 0.7 45 cm) B. Braun, Melsungen, Germany 
Syringe Omnifix-F (1, 10 ml) B. Braun, Melsungen, Germany 
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3.1.4 Software 
Software Company (or homepage), city, country 
Axio Vision 3.1 Carl Zeiss, Jena, Germany 
BD FACSDiva v8.0.1 BD Biosciences, San Jose, CA, USA 
Benchling https://benchling.com/ 
BLAST® https://blast.ncbi.nlm.nih.gov/Blast.cgi 
Corel Draw X6 Corel Corporation, Ottawa, CA 
FlowJo® FlowJo, LLC, Ashland, Oregon, USA 
Genome Browser http://genome.ucsc.edu/ 
GraphPad Version 6.03 GraphPad Software Inc., La Jolla, USA 
Grubb’s Test http://graphpad.com/quickcalcs/Grubbs1.cfm 
ImageJ 1.44 http://imagej.nih.gov/ij/ 
Living Image® Software Xenogen, Alameda, CA, USA 
MARS Data Analysis Software BMG Labtech, Offenburg, Germany 
Mutation taster http://www.mutationtaster.org/ 
OligoAnalyzer 3.0 http://eu.idtdna.com/calc/analyzer 
Osteomeasure OsteoMetrics, Decatur, GA, USA 
Primer 3 http://bioinfo.ut.ee/primer3-0.4.0/ 
RT² Profiler PCR Array Data Analysis 
version 3.5 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php 
SCANCO evaluation software  SCANCO Medical, Brüttisellen, Switzerland. 
UVsolo TS image acquisition software Biometra, Göttingen, Germany 
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3.1.5 Cells 
  Cell line Description Source Medium 
   B16-F10 Murine melanoma ATCC, Manassas, VA, USA DMEM (1X) 
   C2C12 Murine myoblasts ATCC, Manassas, VA, USA DMEM/F-12 
   DU145 Human prostate cancer ATCC, Manassas, VA, USA RPMI 1640 
   L-cells (control    
   transfected) 
Murine fibroblasts Dr. Michael Stock (University of Erlangen, Germany) DMEM/F-12 
   L-cells (Wnt3a-   
   transfected) 
Murine fibroblasts Dr. Michael Stock (University of Erlangen, Germany) DMEM/F-12 
   MCF-7/Neu Human breast Dr. Sanjay Tiwari (University Schleswig-Holstein, Kiel) DMEM/F-12 
   MDA-MB-231 Human breast cancer ATCC, Manassas, VA, USA DMEM/F-12 
   MDA-MB-231-   
   LucA12 
Human breast cancer – 
transduced with firefly 
luciferase gene 
Dr. Sanjay Tiwari (University of 
Kiel, Germany) DMEM/F-12 
   MDA-MB-435s Human melanoma ATCC, Manassas, VA, USA DMEM/F-12 
   MDA-PCa-2b Human prostate cancer ATCC, Manassas, VA, USA RPMI 1640 
   One Shot® TOP10 E. coli Invitrogen LB Broth  
   PC3 Human prostate cancer ATCC, Manassas, VA, USA RPMI 1640 
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3.1.6 Primers 
All the listed primers below were purchased from Sigma-Aldrich, suspended in TE buffer (10 mM Tris; 1 mM 
EDTA; pH 8.0) to a final concentration of 100 µM and stored at -20 °C. Primers were created using Primer3 v. 
0.4.0) (http://bioinfo.ut.ee/primer3-0.4.0/primer3/), eligibility for polymerase chain reaction (PCR) checked using 
OligoAnalyzer 3.0 (http://eu.idtdna.com/calc/analyzer) and gene specificity by BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi)  
   Target gene sense primer sequence (5’→ 3’) antisense primer sequence (5’→ 3’) 
human ACTB CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG 
human ALP CAACCCTGGGGAGGAGAC GCATTGGTGTTGTACGTCTTG 
human DKK-1 AGCACCTTGGATGGGTATTC CACACTTGACCTTCTTTCAGGAC 
human MAPK11 GCACGTTCAATTCCTGGTTTAC TCACAGTCCTCGTTCACAGC 
human MAPK12 CAGGCAAGACGCTGTTCAAG TGGTCAGGATAGAGGCAAAATC 
human MAPK14 CGACTTGCTGGAGAAGATGC GGCACAAAGCTGATGACTTC; 
human MMP1 ATTCTCTTGGACTCTCCCATTCTAC GCTGAACATCACCACTGAAGG 
human MMP10 TGACACTCTGGAGGTGATGC CCAGGAAAGGAGCTGAAGTG 
human MMP13 GCAGTCTTTCTTCGGCTTAGAG ATTCACCCACATCAGGAACC 
human OCN TGAGAGCCCTCACACTCCTC ACCTTTGCTGGACTCTGCAC 
human OPG GAACCCCAGAGCGAAATACAG TAGCAGGAGACCAAAGACACTG 
human RUNX2 CAGATGGGACTGTGGTTACTG TGGGGAGGATTTGTGAAGAC 
murine Actb GATCTGGCACCACACCTTCT GGGGTGTTGAAGGTCTCAAA 
murine Alp CTACTTGTGTGGCGTGAAGG CTGGTGGCATCTCGTTATCC 
murine Ctsk AAGTGGTTCAGAAGATGACGGGAC TCTTCAGAGTCAATGCCTCCGTTC 
murine Oa AAT GGG TCT GGC ACC TAC TG GGC TTG TAC GCC TTG TGT TT 
murine Ocn GCGCTCTGTCTCTCTGACCT ACCTTATTGCCCTCCTGCTT 
murine Opg CCTTGCCCTGACCACTCTTA ACACTGGGCTGCAATACACA 
murine Rankl CACTGAGGAGACCACCCAAG GAGATGAAGAGGAGCAGAACG 
murine Runx2 CCCAGCCACCTTTACCTACA TATGGAGTGCTGCTGGTCTG 
murine Trap ACTTGCGACCATTGTTAGCC AGAGGGATCCATGAAGTTGC 
 
ACTB/Actb – β-actin; ALP/Alp – alkaline phospatase; DKK-1 – Dickkopf-1; MAPK – mitogen-activated protein 
kinase; MMP - Matrix metalloproteinase; OCN/Ocn – osteocalcin; OPG/Opg – osteoprotegerin; RUNX2/Runx2 - 
Runt-related transcription factor 2; Ctsk – Cathepsin K; Oa – Osteoactivin; Rankl - Receptor activator of nuclear 
factor kappa-B ligand; Trap - Tartrate-resistant acid phosphatase 
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3.1.7 Short interfering RNAs for knockdown experiments 
Lyophilized short interfering RNAs (siRNAs) were resuspended in nuclease-free water and stored at -
20 °C at a final concentration of 20 µM. The final concentration for knockdown experiments was 50 
nM.  
  Target Catalogue numbers Source 
   human DKK-1 s22721, s22723 
Ambion, 
Life Technologies, 
Darmstadt, 
Germany 
   human LRP5 s8293 
   human LRP6 s8291 
   human MAPK11 HSS183382, HSS183383, HSS183384 
   human MAPK12 HSS109466, HSS109467, HSS184505 
   human MAPK14 s3585, s3586, s3587 
   Silencer® Select Negative 
   Control No. 1 siRNA 
4390843 
 
 
3.1.8 Short guide RNAs and sequencing primers for CRISPR/Cas9 plasmid design 
   Target sense primer sequence (5’→ 3’) antisense primer sequence (5’→ 3’) 
   human DKK-1 
   sgRNA #1 (exon 1) 
caccgCTTTGTCGCGATGGTAGCGG aaacCCGCTACCATCGCGACAAAGc 
   human DKK-1 
   sgRNA #3 (exon 1) 
caccgGTCTTTGTCGCGATGGTAG aaacCTACCATCGCGACAAAGACc 
   human DKK-1 
   sgRNA #4 (exon 4) 
caccgTCTAGCACAACACAATCCTG aaacCAGGATTGTGTTGTGCTAGAc 
   human DKK-1 
   sgRNA #5 (exon 4) 
caccgCTTCTCCACAGTAACAACGC aaacGCGTTGTTACTGTGGAGAAGc 
   human DKK-1 exon 1 
   sequencing primers 
ATCCCGGCTTTGTTGTCTC TACCAAATGCTCCCTGAACC 
   human DKK-1 exon 4 
   sequencing primers 
GGCATAACAGACTGCCACTG CTCCAGGTTTTTGGAAGGTG 
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3.1.9 Vectors for overexpression and knockdown experiments 
   Target Action Vector Catalogue No. Source 
   human DKK-1 Overexpression pCMV-ORF-Myc HG10170-M-M Sino Biological Inc., 
Beijing, China 
   human DKK-1 Knockout pSpCas9(BB)-2A-
Puro (PX459) V2.0 
Plasmid # 62988 addgene.org, Feng 
Zhang Lab  
3.1.10 Antibodies  
   Target protein Catalog No. Host Company 
   Alexa Fluor 594 A11080 goat Invitrogen, Karlsruhe, Germany 
   BHQ880 N/A human Norvatis Pharmaceutical Corp. 
   CD31 (PECAM-1) 77699 rabbit Cell Signaling, Danvers, MA, USA 
   DKK-1 AF1096 goat R&D Systems, Wiesbaden-Nordenstadt, Germany 
   GAPDH 5G4 mouse HyTest Ltd., Intelligate, Turku, Finland 
   Goat IgG Control AB-108-C goat R&D Systems, Wiesbaden-Nordenstadt, Germany 
   Goat IgG; HRP-conjugated HAF109 donkey R&D Systems, Wiesbaden-Nordenstadt, Germany 
   HSP27 2402 mouse Cell Signaling, Danvers, MA, USA 
   Mouse IgG; HRP-conjugated HAF007 goat R&D Systems, Wiesbaden-Nordenstadt, Germany 
   mTOR 2983 rabbit Cell Signaling, Danvers, MA, USA 
   p38 9212 rabbit Cell Signaling, Danvers, MA, USA 
   p38α AF8691 rabbit R&D Systems, Wiesbaden-Nordenstadt, Germany 
   p38β 2339 rabbit Cell Signaling, Danvers, MA, USA 
   p38γ AF1347 rabbit R&D Systems, Wiesbaden-Nordenstadt, Germany 
   PECAM-1 77699 rabbit Cell Signaling, Danvers, MA, USA 
   Phalloidin-AF488  
   (Anti F-Actin) 
A12379 fungus Thermo Fisher Scientific, Schwerte, Germany 
   Phospho-HSP27 
   Ser78 
2405 rabbit Cell Signaling, Danvers, MA, USA 
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   Phospho-mTOR 
   Ser2448 
5536 rabbit Cell Signaling, Danvers, MA, USA 
   Phospho-p38 
   Thr180/Tyr182 
9211 rabbit Cell Signaling, Danvers, MA, USA 
   Rabbit IgG; HRP-conjugated HAF008 goat R&D Systems, Wiesbaden-Nordenstadt, Germany 
   β-Tubulin 2146 rabbit Cell Signaling, Danvers, MA, USA 
3.1.11 Animals 
   Mouse Strain Nomenclature  Source Models 
   C57BL/6 C57BL/6 Janvier Labs, France Subcutaneous allograft tumor and OVX models 
   NMRI-nu NMRI-Foxn1nu /Foxn1nu CRTD, Dresden, Germany 
Subcutaneous xenograft 
tumor/ intracardiac 
metastasis models 
 
3.2.12 Ethical Approvals 
Animals were housed under institutional guidelines and the institutional animal care 
committees of the Technical University Dresden and the Landesdirektion Dresden approved 
all animal procedures. Animal experimentation applications were applied and approved for by 
the same authorities. Approval numbers for each project are as follows: DKK-1 in breast 
cancer; DD24-5131/394/6 and mTOR inhibition in osteotropic breast cancer; DD24-
5131/338/63. The TMA was obtained following ethical approval by the institutional ethics 
committee of the University Hospital of Schleswig-Holstein (file number: B 327/10) and the 
Genetic Engineering Act was complied with (project number 55-8811.72183) for gene editing 
techniques. 
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3.2 Methods 
3.2.1 Cell culture 
All cell lines were tested for genetic authenticity using short tandem repeat profiling, a service 
provided by the DSMZ (German Collection of Microorganisms and Cell Cultures). Normal 
culture conditions included medium supplementation with 10% fetal calf serum (FCS) and 
1% penicillin/streptomycin (P/S) in a humidified atmosphere at 37°C and 5% CO2 in 75 cm2 
plastic cell culture flasks. When cells reached approximately 80% confluency they were split 
by trypsinization and viable cells were counted using trypan blue in a Neubauer chamber. 
Cells were seeded in 6-well plates (for RNA, protein isolation and supernatant collection), 24-
well plates (Tartrate-resistant acid phosphatase (TRAP) staining, Alizarin S Red staining and 
CellTiter-Blue®), 48-well plates (Dual-luciferase reporter assay) or 96-well plates (for 
assessment of cell vitality, caspase activation and crystal violet staining). Depending on the 
respective treatments, optimized cell numbers for each format were seeded.  
3.2.2 Transfections 
siRNA 
Sub-confluent breast and prostate cancer cells in 6-well dishes were transfected with gene-
specific siRNAs using DharmaFECT™ (GE Healthcare, Munich, Germany) diluted in Opti-
MEM® reduced-serum medium (Gibco Life Technologies, Darmstadt, Germany). 100 nM 
siRNAs were diluted in 50 μl of Opti-MEM and 2 μl of DharmaFECTTM in 100 μl of OPTI-
MEM. SiRNA and DharmaFECTTM dilutions were consequently incubated at room 
temperature (RT) for 5 minutes before combining at a ratio of 2:1 respectively, and 
incubating at RT for a further 20 min. Cells were then washed twice with Hank's Balanced 
Salt Solution (HBSS) (Gibco Life Technologies, Darmstadt, Germany)  and 850 μl of Opti-
MEM supplemented with 10% FCS was added. 150 μl of the prepared siRNA and 
DharmaFECTTM mixture was then added drop-wise to the cells. After 5 h, the 
DharmaFECTTM mixture was replaced with normal culture medium containing both FCS and 
P/S. Following this medium change, cells were cultured for a further 24 h before supernatant 
was collected and cells lysed for either protein or RNA analysis. For supernatant collection, 
medium was refreshed 24 h after the transfections and collected 48 h later, before removing 
detached and dead cells by centrifugation and immediate freezing at -20°C for long-term 
storage. 
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CRISPR/Cas9 
Short-guide RNAs (sgRNAs) targeting sequences in exons 1 and 4 of the human DKK-1 
gene were designed using the benchling.com platform. sgRNA primer pairs where 
phosphorylated and annealed before performing Golden Gate cloning (Engler and 
Marillonnet, 2014) into the vector px469 V2.0 which codes for the CRISPR/Cas9 construct 
(Ran et al., 2013). This cloning product was then transformed in E.coli under the selection of 
ampicillin 100 µg/ml (Sigma-Aldrich, Darmstadt, Germany) in LB-Agar (Carl Roth, Karlsruhe, 
Germany) and resulting colonies were sequenced for successful and correct incorporation of 
the sgRNAs by Sanger sequencing (Eurofins, Ebersberg, Germany). Clones with correct 
sequencing were expanded under the selection of ampicillin in LB Broth (DifcoTM, BD 
Biosciences, Heidelberg, Germany) and plasmids were isolated using the Plasmid Maxi Kit 
(Qiagen, Hilden, Germany) 4 plasmids in total, targeting different sequences of DKK-1 in the 
regions of exon 1 and 4 were transfected into MDA-MB-231 breast cancer cells. 0.5 µg of a 
combined sgRNA-plasmid mix or control vector was incubated in 100 µl of Opti-MEM with 6 
µl of the FuGENE® HD Transfection Reagent (Promega, Madison, WI, USA) for 20 min. 
Meanwhile, sub-confluent cells prepared in 6-wells, were washed twice with HBSS and 900 
μl of Opti-MEM supplemented with 10% FCS was added. 100 μl of the prepared plasmid and 
FuGENE® mixture was then added drop-wise to the cells. After 5 h, the plasmid/FuGENE® 
mixture was replaced with normal culture medium containing both FCS and P/S. Following 
this medium change, cells were cultured for a further 24 h before selection of successful 
transfectants commenced using puromycin at a concentration of 5 µg/ml (Gibco Life 
Technologies, Darmstadt, Germany) Cells were selected for 48 h before a culturing for a 
recovery period of 7 days allowing for expansion. Control cells transfected with the initial 
vector where frozen at this point whereas cell transfected with the vectors containing DKK-1 
sgRNAs were split at a ratio of 0.5 cells per 96-well in order to select for individual clones. 
Once individual clones had been successfully expanded, successful DKK-1 knockout by 
CRISPR/Cas9 was detected at the levels mRNA expression by quantitative reverse 
transcription PCR (qRT-PCR) and protein levels by Western Blot (Fig. 6). DNA was isolated 
using the QIAamp® DNA Mini Kit (Qiagen, Hilden Germany), and a PCR was performed for 
DKK-1.  The nature of the mutation event was confirmed by Sanger sequencing (Eurofins). 
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Overexpression 
0.5 µg of a commercially designed DKK-1 overexpression plasmid or control vector (Sino 
Biological Inc.) was incubated in 100 µl of Opti-MEM with 6 µl of the FuGENE® HD 
Transfection Reagent for 20 min. Meanwhile, sub-confluent cells prepared in 6-wells, were 
washed twice with HBSS and 900 μl of Opti-MEM supplemented with 10% FCS was added. 
100 μl of the prepared plasmid and FuGENE® mixture was then added drop-wise to the 
cells. After 5 h, the FuGENE® mixture was replaced with normal culture medium containing 
both FCS and P/S. Following this medium change, cells were cultured for a further 24 h 
before selection of successful transfectants commenced using Hygromycin B (Thermo Fisher 
Scientific, Schwerte, Germany) at a concentration of 500µg/ml Cells were selected for 48 h 
before expansion and assessment of DKK-1 overexpression by qRT-PCR and Western blot. 
 
 
Figure 6: Confirmation of DKK-1 knockout using the CRISPR/Cas9 method in MDA-MB-231 
cells. The knockout of DKK-1 was confirmed at the mRNA and protein levels by qRT-PCR and Western Blot 
respectively in clones DKK-1 (I) and (II) (A). GAPDH is shown as the housekeeping control. DKK-1 expression 
was additionally compared between control cells and clone DKK-1 (I) by IHC of cells prepared in an agar cell 
block and immunofluorescence of cells in vitro (B + C) (green – F-actin (cytoskeleton); blue – DAPI (nucleus); 
red – DKK-1).  
Control DKK-1 (I) 
A B 
C 
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3.2.3 Human DKK-1 enzyme-linked immunosorbent assay (ELISA) 
A commercially available human DKK-1 ELISA (Biomedica, Vienna, Austria) was employed 
to analyze secreted DKK-1 in the supernatants of breast cancer and prostate cancer cells 
The ELISA was performed according to the manufacturer’s protocol. Briefly, cancer cell 
supernatants were pre-diluted in assay buffer at a ratio of 1:200 as determined by pretesting 
and added to human DKK-1 antibody pre-coated microtiter strips. A biotinylated DKK-1 
antibody was also added before an incubation step of 2 h at RT. Strips were then washed 5 
times with a supplied wash buffer. The plates were then incubated with HRP-conjugated 
streptavidin for 1 h at RT. After a further washing step, tetramethylbenzidine solution was 
added for 30 min at RT. After 30 min a stop solution was added and the absorbance 
measured immediately at 450 nm with 630 nm as the reference wavelength using the 
FLUOstar® Omega microplate reader (BMG Labtech, Offenburg, Germany). 
3.2.4 RNA isolation, reverse transcription, and quantitative reverse transcription PCR  
According to the manufacturers’ protocols, the High Pure RNA isolation kit (Roche, 
Mannheim, Germany) or peqGOLD TriFast™ (Peqlab, Erlangen, Germany) were used to 
isolate RNA from in vitro cell cultures or isolated tissues from in vivo experiments 
respectively. The Nano Drop ND-1000 was used to measure RNA concentrations before 
freezing at -80°C or proceeding directly to reverse transcription. 500 ng of purified RNA was 
annealed with a random primer mix following incubation for 3 min at 72 °C.  This mix was 
then added to a mastermix of dithiothreitol (DTT), deoxyribonucleotide triphosphates 
(dNTPs), First Strand Buffer, RNaseOUT™ Recombinant Ribo-nuclease Inhibitor and 
SuperScript II reverse transcriptase. Reverse transcription was completed using an 
incubation step for 1 h at 42°C followed by a denaturation step at 95 °C for 1 min.  
The resulting complementary DNA (cDNA) underwent SYBR green-based real-time 
polymerase chain reaction using a standard protocol in a 96-well-plate format (Applied 
Biosystems, Carlsbad, CA, USA). Sense and antisense primers (final concentration 0.75 µM) 
and SYPR® Green PCR Master Mix (Thermo Fisher Scientific, Schwerte, Germany) were 
prepared as 8 µl per 96-well to which 2 µl of the cDNA was added. Internal controls and 
cDNA samples were pipetted and analyzed in duplicate for each gene assessment. Primer 
sequences are listed in 3.1.6. PCR cycling program ran at 50 °C for 2 min and 95 °C for 
10 min followed by 40 cycles with 95 °C for 15 s and 60 °C for 1 min. The melting curve was 
assessed at 95 °C for 15 s, 60 °C for 1 min and 95 °C for 30 s. The ΔΔCt (cycle threshold) 
method was used to calculate the results, which are presented as the x-fold increase relative 
to the housekeeping gene (human β-actin or murine β-actin) or as a percentage of the 
control. 
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3.2.5 Human profiler PCR array 
The RT2 human profiler arrays (PAHS-043ZC and PAHS-013C, Qiagen, Hilden, Germany) 
were used to analyze the expression of 84 key genes of the Wnt signaling pathway and 
extracellular matrix and adhesion molecules. The assay was performed according to the 
manufacturer’s protocol. Briefly, MDA-MB-231 control and DKK-1 knockout cells were 
cultured in serum-deprived medium for 72 h. RNA was isolated as described and reverse 
transcribed using the supplied R3 Reverse Transcriptase Mix kit (Qiagen, Hilden, Germany). 
The cDNA was mixed with the supplied SYBR Green containing PCR buffer at a pre-
calculated concentration and 25 µl was transferred per well into respective PCR plate 
cavities containing lyophilized gene primers. The PCR conditions were 50°C for 2 min and 
95°C for 10 min followed by 40 cycles with 95°C for 15 seconds and 1 min at 60°C. Fold 
changes in CT values were assessed using the RT2 Profiler PCR Array Data Analysis 
version 3.5, an online program administered by Qiagen. The ΔΔCT method was used to 
calculate the results, which are presented as the x-fold regulation relative to a selection of 
analysis-defined housekeeping genes. 
3.2.6 Human prostate cancer cDNA array 
The Prostate Cancer cDNA array III was sourced from Origene (Rockville, MD, USA) and the 
supplier’s protocol was followed to assess the expression of DKK-1 and p38MAPK isoforms 
in cDNA samples when normalized to β-actin. The array contained 48 samples in total; 9 
samples of normal prostate tissue and 39 samples of prostate cancer with a selection of 
pathological grades from II to IV and an average patient age of 60 years. 
3.2.7 Western Blot 
Following in vitro treatments, cancer cells were washed twice in phosphate-buffered saline 
(PBS) before being lysed in a SDS-based lysis buffer (20 mM Tris/HCl pH 7.4; 1% SDS; 
prostease (x 7) and phosphatase (x 10) inhibitor cocktails (Roche, Mannheim, Germany)) 
and frozen at -80°C. Before quantification, lysates were processed through a 24-gauge 
needle to reduce sample viscosity and centrifuged to remove cell debris. The quantification 
of protein levels were completed using the Pierce™ BCA protein assay kit and measuring 
absorbance in the FLUOstar® Omega microplate reader. Protein samples of 20 µg were 
denatured at 98 °C for 5 min in protein-loading buffer, loaded to a 10-12% SDS-PAGE and 
separated by electrophoresis at 120 V. The separated proteins were then transferred onto a 
0.2 µm nitrocellulose membrane. Blotting was carried out at 0.35 A for 1 h. Blocking of 
unspecific binding sites was performed in either 5% non-fat dry milk or 5% bovine serum 
albumin (BSA) in Tris-buffered saline with 1% Tween-20 (TBS-T) for 1 h. Membranes were 
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then washed 3 times in TBS-T and incubated overnight in 5% non-fat dry milk or BSA in 
TBS-T containing the primary antibody. Use of milk or BSA depended on the instructions of 
the antibody supplier. Membranes were then washed again with TBS-T before incubation for 
1.5 h with the horseradish peroxidase-conjugated secondary antibody in 1% non-fat dry milk 
or 1% BSA in TBS-T. After another washing step, the membranes were developed and 
protein bands of interest were visualized using Super Signal substrate (Pierce, Bonn, 
Germany) and the UV-fluorescence-chemiluminescence-system MF ChemieBIS 3.2 (Bio-
Imaging Systems, Germany). GAPDH or β-tubulin were used as housekeeping proteins. 
3.2.8 Cell viability assay 
To determine the cell viability, CellTiter-Blue® Reagent (Promega, Mannheim, Germany) 
containing resazurin (dark blue) was added to cell culture medium at a ratio of 1:5. Viable cell 
mitochondria reduce the substrate resazurin into the fluorescent resorufin (pink). After an 
incubation of 1.5 h at 37°C, cell culture supernatant was transferred into a black 96-well plate 
and fluorescence was measured within the wavelengths of 605 nm and 573 nm using the 
FLUOstar® Omega microplate reader. The resulting values correlated to cell viability. MDA-
MB-231 cells were seeded at a density of 20,000 cells per 96-well. Cells were allowed to 
adhere before normal medium was removed 4.5 h later and replaced with serum-deprived 
medium. Readings of cell viability were recorded at 6, 24, 48 and 72 h after the initial seeding 
event. All conditions were performed in triplicates and each experimental set-up was 
repeated 3 times. 
3.2.9 Apoptosis assay 
20,000 MDA-MB-231 cells were seeded in 96-well layouts. 5 h later, medium was replaced 
without FBS serum. 72 h following this medium change the cells were assessed for 
apoptosis. Using the caspase 3/7 Glo® assay (Promega, Mannheim, Germany), Z-DEVD-
aminoluciferin was added to the cell culture medium at a ratio of 1:1. In the presence of 
activated caspases 3 and 7, this agent is cleaved into the functional aminoluciferin that 
serves as a substrate for the luciferase in the reagent mix. Following gentle shaking at RT 
temperature for 1 h, the luminescence was detected using the FLUOstar® Omega microplate 
reader according to the manufacturer’s protocol. Luminescent values were normalized to 
crystal violet readings, adjusting for the number of cells. 
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3.2.10 Cell number assay 
In order to assess cell number, cellular proteins and DNA were stained with crystal violet 
(CV) (Sigma-Aldrich, Munich, Germany). Cells were seeded and treated in 96-well plates, in 
parallel treatment conditions to cell viability and apoptosis assays. Cells were washed once 
in PBS before fixing in 10% paraformaldehyde (PFA) (Merck, Darmstadt, Germany) for 15 
min. PFA was removed and cells were washed once with double distilled water (ddH2O) and 
crystal violet working solution (0.02% in 2% EtOH) was added for 20 min. Staining solution 
was removed and 2 washing steps in ddH2O followed. Plates were then dried in a 37°C dry 
incubator overnight. CV was eluted in 10% sodiumdodecylsulfate (SDS) and absorbance 
was measured with the FLUOstar® Omega microplate reader at a detection wavelength of 
595 nm. 
3.2.11 Cell cycle analysis 
MDA-MB-231 control and DKK-1 knockout cells were seeded at a density of 4 x 106 in 75 
cm2 cell culture flasks in normal culture medium. 24 h late, medium was removed and 
replaced with serum-deprived culture medium. Cells were then cultured for a further 72 h 
before trypsinization, centrifugation, washing in PBS and resuspending in 200 µl PBS. Next 
cells were fixed in ice-cold 100% ethanol (EtOH) and 2% FCS. Cells were incubated for a 
minimum of 15 min at 4˚C. EtOH was removed and cells were washed in PBS/ 2%FCS 
before resuspending in 500 µl of freshly prepared propidium iodide (PI)/ribonuclease A 
suspension (40 µg/ml PI and 250 µg/ml ribonuclease A in PBS). Cells were incubated for 30 
min at 37˚C in darkness before a final wash in PBS/2% FCS and storage at 4˚C protected 
from light. Cell cycle analysis was then analyzed by flow cytometry using BD LSR II Flow 
Cytometer (BD Biosciences, San Jose, CA, USA) at an excitation wavelength of 488 nm. The 
doublets were gated-out, the final population was gated for sub-G1, G0/G1, S and G2/M 
phases and the number of events were counted for 10,000 events. Raw data was further 
analyzed using the FlowJo®, an analysis platform for single-cell flow cytometry analysis. 
3.2.12 Wnt signaling assay 
In 48-well plates, C2C12 or MDA-MB-231 breast cancer cells were seeded at a 
concentration of 1.5 x 104 or 3 x 104 cells per well respectively, and transfected with the 
Cignal TCF/LEF Reporter Assay kit (CCS-018L) (Qiagen, Hilden, Germany) to assess the 
activation of the TCF/LCF Wnt promoter. Briefly, 123 ng/cm² of the promoter construct was 
transfected using the FuGENE® HD Transfection Reagent according to the manufacturers’ 
protocols in Opti-MEM® supplemented with 10% FCS. After 5 h transfection/Opti-MEM® mix 
was removed and replaced with normal culture medium. After 24 h, cells were treated with 
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conditioned L-cell control or Wnt3a-containing L-cell medium and prostate cancer cell 
supernatants as indicated. Luciferase activity was assayed 24 h post-treatment using the 
Dual Luciferase Reporter Assay kit (Promega, Hamburg, Germany) as instructed by the 
manufacturer. 
3.2.13 Alkaline phosphatase enzymatic activity assay 
In the presence of Wnt3a, the murine myoblast cell line, C2C12, differentiate along the 
osteoblast lineage and are therefore a commonly used model to assess osteoblastogenesis. 
C2C12 cells were cultured for 72 h in the following supernatant combination: 50% medium 
from transfected L-cells over-expressing Wnt3a (control L-Cell supernatant serving as the 
control), 25% unconditioned medium (5% FCS) and 15% untreated PC3 or pre-conditioned 
PC3 supernatants. Recombinant BMP-2 was also added at a concentration of 200 ng/ml to 
potentiate the induction of alkaline phosphatase (ALP) and allow detection of enzymatic-
activity. Pre-conditioned PC3 supernatant was collected after siRNA knockdown or treatment 
with the p38 MAPK inhibitor LY2228820 (LY). Pre-treating PC3 cells with LY was performed 
to minimize direct effects of the inhibitors on the C2C12. This was achieved by culturing the 
PC3 cells with the inhibitor at a concentration of 10 µM for 6, performing a fresh medium 
change and then collecting the supernatant after 18 h. Supernatant from PC3 cells 
transfected with siRNA was collected after 72 h. C2C12 RNA was then isolated and 
assessed for ALP expression by qRT-PCR. For detection of ALP activity, cells were washed 
in phosphate-buffered saline (PBS) and lysed in 90 µl of 10 mM Tris-HCl pH 8.0, 1 mM 
MgCl2, and 0.5% Triton X-100. After scraping, cell lysates were then transferred to 1.5 ml 
Eppendorf tubes, vortexed for 30 s and allowed to rest on ice for 20 min. The cell lysate was 
then centrifuged at 20,000 × g for 20 min at 4˚C. Supernatant was removed and 10 µl 
aliquots were incubated with 90 µl ALP substrate buffer (100 mM diethanolamine, 150 mM 
NaCl, 2 mM MgCl2, and 2.5 g/ml p-nitrophenylphosphate) for 30 min at 37˚C. The 
absorbance was measured at 410 nm with the FLUOstar® Omega microplate reader. The 
obtained results were normalized to total protein concentrations that were measured using 
the Pierce™ BCA Protein Assay Kit. 
3.2.14 Osteoclast differentiation and TRAP staining 
Osteoclast differentiation was conducted in murine bone marrow-derived mononuclear cells 
(mBMDMCs). Following aspiration of bone marrow, mBMDMCs were selected in flasks with 
25 ng/ml murine M-CSF (R&D systems, Minneapolis, MN, USA) for 2 days before seeding at 
a density of 1 x 104/cm2, continuing with 25 ng/ml rm M-CSF and commencing 50 ng/ml rm 
RANKL. In experimental conditions, increasing concentrations of everolimus (1, 10 and 100 
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nM) were all added to culture conditions at the time of seeding. Parallel differentiation and 
everolimus treatment lasted duration of 5 days with replacement of culture medium, rm M-
CSF, rm RANKL and everolimus taking place every 48 h. On day 5, cells were washed and 
fixed in acetone/citrate buffer. TRAP-positive cells were stained with the leukocyte acid 
phosphatase TRAP Kit (Sigma-Aldrich, Vienna, Austria) as recommended by the supplier. 
Differentiated osteoclasts were defined as cells that were positive for TRAP staining and 
showed 3 or more nuclei. Osteoclasts were counted and representative photographs were 
taken for each everolimus treatment condition.  
3.2.15 Osteoblast differentiation and mineralization assay 
Bone marrow was aspirated from the long bones of female C57BL/6 mice. Cells were 
counted and seeded at a density of 50 x106/75 cm2 and murine mesenchymal stem cells 
(mMSCs) were cultured in DMEM (1X) for a week with medium changes every 2 days. 
Resulting adherent cells were then seeded at a density of 2 x 106/cm2 for treatments, 6-wells 
or 24-well culture plates for RNA assessment and mineralization assays respectively. Cells 
were then maintained in normal medium (containing 10% FCS and 1% P/S) until cells 
reached confluency. On day 1, cells were treated with osteogenic differentiation medium 
(DMEM medium, containing 10% FCS  and 1% P/S supplemented with 100 µM 
dexamethasone,10 mM β-glycerol phosphate, 100 µM ascorbate phosphate (Sigma-Aldrich, 
Darmstadt, Germany) and 100 ng/ml of rh BMP-2 and rh BMP-4 (Peprotech, Rocky Hill, NJ, 
USA)) with increasing concentrations of everolimus. This osteoblastic differentiation medium 
cocktail was replaced every 3 days. For RNA isolation cells culture was stopped on day 7. 
Cells were cultured for 21 days to assess mineralization. On day 21, cells were washed twice 
with PBS and fixed with 10% PFA for 15 minutes at RT. Following fixation, cells were 
washed twice with ddH2O and incubated in a 40 mM Alizarin Red S solution, pH 4.2 (Sigma-
Aldrich, Munich, Germany) for 20 min at RT. Stained cells were subsequently washed with 
ddH2O until the excess dye had been completely removed. Plates were dried at RT overnight 
before imaging. In order to quantify mineralization, the Alizarin Red S bound to the 
mineralized calcium was eluted in 0.1M HCl/0.5% sodiumdodecylsulphate (SDS) solution 30 
min at RT. The resulting eluent was measured with the FLUOstar® Omega microplate 
reader.at a detection wavelength of 540 nm.  
3.2.16 In vivo models 
All mice used in in vivo experiments were kept under the institutional guidelines in a specific 
pathogen free environment, 10 animals per cage, fed ad libitum with a rat-mouse-diet 
(ssniff®, Soest, Germany), had free access to drinking water and welfare was assessed 
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daily. Animals were randomly allocated for all experimental set-ups and investigators were 
blinded for allocation and endpoint measurements but not for animal handling. For surgical 
procedures, in vivo imaging and sacrifice, mice were anesthetized using a mixture of 
ketamine (90 mg/kg) and xylazine (10 mg/kg) in physiologic salt solution. In all subcutaneous 
tumor models, cancer cells were prepared in 50 µl of a 1:1 Matrigel® basement membrane 
matrix (Corning, Wiesbaden, Germany) dilution with PBS per injection site. The site of 
subcutaneous inoculation was dorsally, between the positions of the last rib and the hind 
limb, x 2 injection sites per mouse, left and right. In the BHQ experiment, on one injection site 
only was performed. At sacrifice serum was collected by intracardiac puncture under 
anesthetic and tumor tissue sections were first weighed to assess tumor burden and then 
either fixed in Roti-histofix (4% PFA) (Carl Roth, Karlsruhe, Germany) for 
immunohistochemistry (IHC) or frozen in peqGOLD TriFast™ (Peqlab, Erlangen, Germany) 
at -80°C for future RNA isolation and qRT-PCR. 
DKK-1 subcutaneous tumor models 
The role of DKK-1 expression in tumorigenesis was assessed using a number of different 
subcutaneous tumor models. The first model assessed the effect of neutralizing DKK-1 on 
the tumor growth of MDA-MB-231 and MDA-MB-435 cells. On day 1, 6-week-old female 
NMRI-nu and mice were inoculated subcutaneously with 1.5 x 106 MDA-MB-231 or 1.5 x 106. 
Mice were divided into control (ddH2O) and BHQ880 (BHQ) treatment groups as follows: 
MDA-MB-231; 7 control and 8 BHQ-treated mice, MDA-MB-435; 5 control and 6 BHQ-treated 
mice. BHQ was prepared at a dose of 200 µg in 100 µl ddH2O which was injected 
intraperitoneally 3 times a week for 5 weeks, commencing on day 1. Mice were sacrificed 
after 5 weeks and tumor burden was assessed. To assess in more detail the role of tumor-
derived DKK-1 in ER+ breast cancer, the in vivo growth of MCF-7/Neu cells with an 
overexpression of DKK-1 (DKK-1 OE) was assessed (control, n = 5; DKK-1 OE, n = 5). 6-
week-old female NMRI-nu and mice were inoculated subcutaneously with 2 x 106 cells of 
each line per injection site. Tumors were allowed to grow for 5 weeks before sacrifice and 
assessment of tumor burden. Finally, to assess the role of tumor-derived DKK-1 in ER- 
breast cancer, 1.5 x 106 MDA-MB-231 cells (per injection site) bearing a CRISPR/Cas9 
mediated knockdown or control cells, were subcutaneously-inoculated into 6-week-old 
female NMRI-nu mice. Tumors were allowed to grow for 5 weeks before sacrifice and 
assessment of differences in tumor growth.  
Everolimus subcutaneous tumor models 
On day 1, female NMRI-nu and C57BL/6 mice were inoculated subcutaneously at 6 weeks of 
age with 1.5 x 106 MDA-MB-231 and 1 x 104 B16-F10 cells per injection site respectively. 
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100µl intraperitoneal injections of 1 mg/kg/daily everolimus or control DMSO commenced on 
day 1 for 4 weeks in the case of the MDA-MB-231 model and 2 weeks in the case of the 
B16-F10 model, before sacrifice to assess tumor burden. 10 mice were allocated to each 
treatment group.  
Ovariectomy  
Female C57BL/6 mice underwent OVX at the age of 9 weeks. Mice were divided into sham 
operated (SHAM) or OVX groups. Following anesthetic, hair was clipped from the mid-dorsal 
thoracolumbar region which was then prepped for aseptic surgery. Using surgical scissors, a 
single incision of 5 mm was made in the skin in a caudal-rostral direction, bilateral to the 
spine. Next, a second incision of no more than 5mm was made in the dorsolateral 
musculature of abdominal wall, allowing entrance to the peritoneal cavity. The periovarian fat 
pad was then located using forceps, exteriorized and the ovary identified and immobilized. 
Using a suture, the fallopian tube was ligated and the ovary subsequently excised in one cut 
using scissors. The fat pad was replaced in the abdomen and the wounds were closed with 
staples. The same process was then repeated for the contralateral side and ovary. Effective 
OVX was confirmed by assessing uterus size, which was reduced in OVX mice compared to 
placebo SHAM operated mice. Four weeks later mice were subdivided into everolimus or 
control treatment groups. When assessing the role of everolimus in bone loss induced by a 
hormone-deprived microenvironment, OVX and SHAM mice were treated with 1 mg/kg of 
everolimus or control daily for 4 weeks. Calcein (15 mg/kg) (Sigma-Aldrich, Dharmstadt, 
Germany) labelling was performed 5 and 2 days before sacrifice (inter-label time of 3 days). 
At sacrifice, structural analyses and histomorphometry of the femur bone were assessed.  
Intracardiac bone metastasis model 
Intracardiac injection was performed as a model mimicking bone metastasis. 1 × 105 MDA-
MB-231-LucA12 cells were injected into the left ventricle of the heart of NMRI-nu mice under 
ultrasound guidance. Successful intracardiac injection was determined immediately after 
intracardiac inoculation, by injecting mice with 100 µl of 3 mg/ml D-luciferin (PerkinElmer, 
Rodgau, Germany) in PBS intraperitoneally,  and verifying a global circulation of cancer cells 
with the Xenogen IVIS 200 in vivo imaging system (Xenogen, Alameda, CA, USA). It was 
important to ensure that signals were not confined to the lungs, indicating false injection. 
Intraperitoneal injections of 100µl, 1 mg/kg/daily everolimus or control DMSO commenced on 
the day of tumor cell inoculation. Metastatic burden was monitored through weekly 
bioluminescence imaging until sacrifice 5 weeks post injection. 10 mice per group were 
initially included; however, 1 mouse from each group died following anesthetic administration 
at the first imaging session and were therefore excluded from this experiment.  
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Bioluminescent imaging was used to quantify tumor growth by correlating the tumor burden 
to the luminescence signal measured with a Xenogen IVIS 200 in vivo imaging system. 
Imaging for the assessment of tumor growth commenced 2 weeks post inoculation and 
continuous assessment was performed once a week until sacrifice at the end of week 5. The 
Living Image® software (Xenogen) was utilized to obtain and quantify the bioluminescence 
data. Mice were anesthetized and 5 minutes prior to imaging each mouse was injected 
intraperitoneally with 100 µl of 3 mg/ml D-luciferin. Mice were imaged individually for an 
exposure period of 2 minutes. Resulting bioluminescent images were analyzed by measuring 
the signal within a set area grid with final measurement units in photons/s/cm²/sr.  
3.2.17 Histology, histomorphometry, and immunohistochemistry 
Bone histomorphometry and TRAP staining were performed for femur and tibia sections 
respectively and IHC was performed for primary and xenograft tumor sections as well as 
MDA-MB-231 cell blocks. All tissue types were fixed in 4% PFA and dehydrated with 50% 
EtOH for 24 h before further histological processing. Representative images of interest were 
processed with the Axioimager M1 microscope and AxioVision 3.1 program (Carl Zeiss Jena, 
Jena, Germany). 
Methyl methacrylate histology of the femur for histomorphometric analysis 
In order to analyze calcein labels, femurs required embedding in methyl methacrylate. PFA-
fixed femurs were dehydrated in a tissue processor (Leica TP 1020, Leica Biosystems, 
Nussloch, Germany) with ascending EtOH series  (80% EtOH, 4 h > 96% EtOH, 4 h >  
isopropanol, 4 h). Dehydrated femurs underwent pre-infiltration (4°C, 1 day) and infiltration 
(4°C, 5 days) before being embedded in methyl methacrylate (Technovit 9100 NEW, 
Heraeus, Wehrheim, Germany). 7 µm sections were cut using the microtome RM2265 (Leica 
Biosystems, Nussloch, Germany). Bone sections were placed on chrome alum gelatine 
coated glass slides and deplastinated with methoxyethyl acetate (3 x 5 min). After treatment 
in xylene (VWR Chemicals, Dresden, Germany) for 5 min, sections were mounted with 
coverslips in entellan (Merck Millipore, Darmstadt, Germany). Using the Osteomeasure 
software (OsteoMetrics. Decatur, GA, USA), bone formation rate per bone surface (BFR/BS) 
was validated in unstained sections, in a standardized area of trabecular bone located 4 µm 
below the growth plate of the femur. This was completed using the international standards 
agreed by the Nomenclature Committee of the American Society of Bone and Mineral 
Research.(Parfitt et al., 2009) 
 
 
3  Materials and methods 
 
 
50 
Dehydration and paraffinization of tibiae and tumor tissues 
Dehydration was achieved by processing tissues in an ascending EtOH series (65% EtOH, 1 
h > 80% EtOH, 1 h > 80% EtOH, 1 h > 96% EtOH, 1 h > 96% EtOH 1 h> isopropanol, 1 h > 
isopropanol, 1.5 h > xylene, 1.0 h > xylene 1.5 h > paraffin 1.5 > paraffin 2 h) before finally 
embedding in paraffin (Leica Surigpath Paraplast, Leica Biosystems, Nussloch, Germany). 2 
µm sections were cut and mounted on coated glass slides before rehydration using an 
isopropanol and alcohol gradient (isopropanol, 5 min > 96% - 80% - 70% - 50% EtOH, 2 min 
each) before rinsing with ddH2O for 2 min prior to further preparation for staining.  
TRAP staining of the tibia 
Prior to dehydration, the tibia was decalcified using Osteosoft® (Merck Millipore, Darmstadt, 
Germany). TRAP staining was then performed to analyze the number of osteoclasts 
adherent to the bone surface; osteoclast surface per bone surface (Oc.S./BS). First, sections 
were washed in TRAP buffer (pH 5.0) for 10 min before incubating with hexonium 
pararosanilin and naphthol-AS-BI-phosphate in acetate buffer (TRAP staining solution, pH 
5.6) for 2-4 h at 37°C in a dry oven. Then sections were rinsed again in ddH2O, re-fixed in 
4% formalin for 30 min, counter-stained with Mayer’s hemalum solution (Merck Millipore, 
Darmstadt, Germany) for 1 min and dipped in 1.2% hydrogen chloride (HCl) for for 3 min to 
eliminate redundant hemalum. Sections were finally rinsed in lukewarm tap water for 10 min 
to stabilize the color saturation before mounting in Aquatex® (Merck Millipore, Darmstadt, 
Germany). 
Cell block 
Specificity of the DKK-1-antibody for use in IHC was validated in cell block sections of control 
MDA-MB-231 and the DKK-1 knockout clone DKK-1 (I). 5 x 106 cells were trypsinized, 
washed in PBS and resuspended in 200 µl of culture medium and transferred to an inverted 
1.5 ml Eppendorf tube were the conical bottom had been removed with a scalpel. Meanwhile 
1% agarose (SERVA, Heidelberg, Germany) was dissolved in PBS by boiling in a 
microwave. The agar was then cooled to 50°C before quickly adding to and mixing with the 
prepared cell suspension avoiding the creation of bubbles. The resulting agar cell block was 
cooled at 4°C before fixing in 4% PFA. Histological processing could then proceed as 
described earlier, treating the block as a tissue. 
Immunohistochemistry of tumor and cell block sections 
Primary breast cancer tissue, xenograft tumors from in vivo tumor models and MDA-MB-231 
cell blocks were assessed by IHC. Paraffin-embedded sections were deparaffinized in 
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Xylene and rehydrated as earlier described. Following a rinse in ddH2O, antigen retrieval was 
performed by placing sections in a cuvette filled with citrate buffer (2.1 g/l citric acid-
monohydrate in PBS) and placing in a pre-heated steamer for 20 min. Citrate buffer was then 
allowed to cool to RT for approximately 30 min before continuing. Endogenous peroxidase 
activity was blocked using 0.3% H2O2/PBS for 10 min at RT. Sections were washed for 5 min 
in PBS x 2. This PBS wash step was repeated between all subsequent steps. Two 
VECTASTAIN Elite ABC Kits (VECTOR Laboratories, Peterborough, UK) were used to 
detect proteins of interest; DKK-1 was stained using the anti-goat PK-6105 kit and PECAM-1 
using the anti-rabbit PK-6101 kit. Non-specific binding sites were blocked using blocking 
serum for 45 min at RT (rabbit serum for DKK-1 and goat serum for PECAM-1). Afterwards, 
sections were incubated in primary antibodies (DKK-1 (R&D Systems, Wiesbaden-
Nordenstadt, Germany) or PECAM-1 (Cell Signaling, Danvers, MA, USA)) overnight at 4°C. 
Sections were washed in PBS and treated with secondary anti-goat or anti-rabbit antibody 
conjugated to biotin and incubated for 1 h at RT. Sections were once again washed in PBS 
before incubating in an avidin DH/biotinylated enzyme mix for 1 h at RT. Following a final 
PBS wash step, stains were developed utilizing avidin-conjugated horseradish peroxidase 
(HRP) with diaminobenzidine (DAB) as the chromogen (DAKO, Hamburg, Germany). The 
DAB reaction was stopped in ddH2O and sections were counter-stained with Mayer’s 
hemalum solution for 3 mins before redundant hemalum was eliminated in 1.2% HCl for 3 s. 
Sections were then rinsed in lukewarm tap water for 10 min to stabilize the color saturation. 
Dehydration was performed using an ascending alcohol series (50% EtOH, 1 min > 80% 
EtOH, 1 min > 96% EtOH, 1 min > isopropyl, 2 min > Xylene, 5 min) before finally mounting 
sections in entellan. To visualize tumor histology, 2 µm sections were stained with 
hematoxylin and eosin (HE). Rehydrated tumor sections were stained with hematoxylin for 1 
min, before rinsing in ddH2O and quickly exposing to 1.2% HCl. Sections were further rinsed 
with tap water for 10 min, before staining with eosin G (supplier) for 1 min and dehydrating by 
using the ascending alcohol series described earlier, before mounting in entellan. 
Immunofluorescence 
The cellular localization of DKK-1 was assessed and knockout confirmed in both clones 
(clone DKK-1 (I) depicted (Fig. 6). First, circular glass slips, 13 mm in diameter (Menzel-
Gläser, Braunschweig, Germany) were placed in the wells of 24-well culture plates. 
Subsequently MDA-MB-231 were seeded at the density of 20,000 cells per well in normal 
culture medium. 5 h later medium was removed and replaced with serum-deprived culture 
medium for 24 h. Cells were then washed once with PBS and fixed with 4% PFA at RT. 
Permeabilization of the cell and nuclear membranes was achieved by treating with 0.1% 
Triton-X-100 for 20 min. Cells were then was 3 times in PBS and the following incubation 
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steps were performed at RT. 1% BSA/0.05% Tween-20 was used to block unspecific binding 
sides for 1 h before labeling F-actin with 0.06 µM Alexa-Fluor-488 conjugated Phalloidin and 
anti-DKK-1 for 1 h in darkness. The following incubation steps were all completed in 
darkness. Cells were washed 3 times in PBS before adding the secondary antibody to DKK-1 
– Alexa Fluor 594 rabbit-anti-goat for an incubation time of 1 h. Cells were washed 3 times in 
PBS and then cell nuclei were stained with 2.5 µg/ml DAPI for 5 min in darkness. Finally, 
cells were washed 3 times in PBS and glass slips were inverted and embedded in 
fluorescent mounting medium (Dako North America Inc., Carpinteria, CA, USA) on glass 
slides. Cells and stains were analyzed and images captured using the Axioimager M1 
microscope and AxioVision software. 
Microvessel density assessment of xenograft tumors 
Tumor microvessel density was defined as previously described (Wang et al., 2008). 
Endothelial cells were positively stained with a PECAM-1 antibody by IHC in tumor sections. 
Branching structures and single endothelial cells were counted as single vessels. 6 fields-of-
view were counted at x 20 magnification with a field size of 0.6 mm2. 1 field was counted in 
the area of highest vascular density and the remaining 5 fields were randomly allocated, 
avoiding vascularity at the perimeter of the tumor. The total counts of these fields per tumor 
were considered in the analysis.  
TMA and grading 
DKK-1 expression was assessed in a tissue microarray (TMA) of primary breast cancer 
tumor by IHC. The TMA was generously provided by Professor Christian Schem and had 
been generated in the Department of Gynecology at the University Hospital of Schleswig-
Holstein between the years 2000 and 2009. Over 400 breast tumor tissue cores, 
representing patients who underwent surgery to remove the primary tumor were included. 
Tumor specimens were formalin-fixed and paraffin-embedded and from every patient 2 tumor 
tissue cores were mounted in a total of 22 paraffin blocks. Clinical follow-up data with regard 
to time of death were available for all patients. Median time of follow-up was 3.97 ± 2.5 years. 
Median survival time of patients with breast cancer who died within the follow-up period was 
3.52 ± 1.95 years. The expression of DKK-1 in these primary tumor sections was then 
analyzed by IHC. Tumor cores for 396 patients could be successfully graded.  Staining was 
assessed by grading the stain intensity from 0-3 (0 = negative, 1 = faint, 2 = positive and 3 = 
strong positive) (Fig. 7). This grade was then multiplied by a value determining the 
percentage of the cancerous tissue that was stained (0 = 0-24%, 1 = 25-49%, 3 = 50-74% 
and 4 = 75-100%). The final range of the combined grade was from 0-12 and the average 
was calculated for the 2 tissue sections for each patient. Parameters including tumor stage, 
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histological subtype and ER status were correlated to this staining grade of DKK-1. Survival 
curve analysis compared the overall % survival of patients with negative to low DKK-1 
staining (0-2) and positive DKK-1 staining (3-12).  
 
3.2.18 Structural bone analysis 
Micro-computed tomography (µCT; vivaCT 75, SCANCO Medical, Brüttisellen, Switzerland) 
was performed on the excised femurs and L4 vertebrae using X-ray energy of 70 keV, a 
resolution of 10.5 µm, and an integration time of 200 ms. Calibration of the scanner took 
place weekly using hydroxyapatite phantoms. For the 3D visualization of bony tissue, we 
used the SCANCO evaluation software (SCANCO Medical, Brüttisellen, Switzerland). The 
threshold for bone absorption values was set to 285 mg HA/cm3 and 100 slices were 
measured commencing from 10 slices above the growth plate of the femur. Micro-CT 
parameters were reported according to international guidelines.(Bouxsein et al., 2010)  
3.2.19 Statistical analysis 
All in vitro experiments were repeated a minimum of 3 times and for in vivo experiments, 
statisticians from the Institute of Medical Informatics and Biometry determined the sample 
size using the nQuery software, setting the significance level to α = 0.05 and the power to 0.8 
for each experiment. Outliers were determined via Grubb´s test 
A B 
Figure 7: IHC staining of DKK-1 in a human breast cancer TMA. DKK-1 expression was assessed in 
breast cancer tumor sections by IHC. Staining was assessed by grading the stain intensity from 0-3 (0 = 
negative, 1 = faint, 2 = positive and 3 = strong positive) (A). This grade was then multiplied by a value 
determining the percentage of the cancerous tissue that was stained (0 = 0-24%, 1 = 25-49%, 3 = 50-74% and 4 
= 75-100%). The final range of the combined grade was from 0-12. The percentage distribution of combined 
staining grades of the entire patient cohort is depicted in pie chart form for the ranges indicated. Scale bars: x 
2.5 magnification – 200 µm, x 20 magnification – 50 µm. 
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(http://graphpad.com/quickcalcs/Grubbs1.cfm). Data were analyzed using GraphPad Prism 6 
(GraphPad Software, Inc., La Jolla, CA, USA). One-way ANOVA (Analysis of variance) with 
Bonferroni post-test was performed to evaluate the equality of the mean in groups of 3 or 
more and the Student’s t test was used when only 2 groups were compared, unless 
otherwise indicated. To analyze the effects of OVX and everolimus treatment, a two-way 
ANOVA with Tukey post-test was performed. Correlation analysis was calculated by Pearson 
correlation. Kaplan Meier curves were assessed using the Gehan-Breslow-Wilcoxon test. For 
overall survival (OS), death of any cause or time of last follow-up was considered as an 
official endpoint. All results are presented as ± standard deviation of the mean and a p-value 
of < 0.05 was considered statistically significant. 
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4 Results 
4.1 The characterization of the Wnt inhibitor DKK-1 as a tumor 
promoter in breast cancer 
4.1.1 DKK-1 expression correlates with poor prognosis in ER- breast cancer 
To assess the role of DKK-1 as a biomarker of breast cancer and its influence on survival in 
breast cancer patients, a tissue microarray of 396 patients was assessed for DKK-1 
expression by IHC. The expression of DKK-1 correlated with tumor stage, and was 
significantly increased by 2 - 3-fold between stages T1, and T2 compared to carcinoma in 
situ (Tis) (p < 0.05). Although insignificant by one-way ANOVA, stage T3 also demonstrated 
increased expression compared to Tis, whereas DKK-1 expression decreased in the most 
advanced stage of T4 (Fig. 8A).  This suggests that DKK-1 expression increases as the 
primary tumor grows larger with a loss of expression at the latest stages of tumor 
progression. There was no change with increasing grade of tumor differentiation (data not 
shown). Looking at more subtle differences in histopathology, it would also appear that more 
invasive tumors have an increased expression when compared to ductal carcinoma in situ 
(DCIS) (Fig. 8B). Tumors classified as invasive ductal and invasive tubular were also 
significantly increased compared to DCIS (p < 0.05).  
Despite these apparent increases in DKK-1 progressive tumor stages, there was no 
correlation between the level of DKK-1 expression and ER status (Fig. 8C). However, 
Kaplan-Meier estimates of overall survival based on negative and positive DKK-1 expression, 
could demonstrate that patients with negative expression of DKK-1 had a minimal but 
significant survival benefit (p < 0.05) (Fig. 8D). When patients were subsequently subdivided 
into ER+ and ER- groups, it quickly became apparent that for ER- patients only, DKK-1 was 
a decisive predictor of survival with a distinct correlation of positive DKK-1 expression and 
decreased survival (p < 0.05) (Fig. 8E-8F). Selecting for ER- and progesterone receptor-
negative patients increased the significance of this correlation (data not shown), but with 
limited patients available it was not possible to further assess the correlation of DKK-1 and 
triple receptor-negative status with survival outcome. 
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4.1.2 ER status influences the pro-tumor role of DKK-1 in in vivo tumor models 
Based on the previous TMA data it was decided to investigate the role of DKK-1 in ER- and 
ER+ breast cancer cells, by altering DKK-1 expression and assessing subsequent rates of 
tumor growth in vivo. Considering baseline expression of DKK-1 in different breast cancer 
cell lines as reported previously (Rachner et al. 2014b), the ER- MDA-MB-231  (high 
baseline DKK-1 expression) and ER+ MCF-7 cells (low baseline DKK-1 expression) were 
chosen for DKK-1 knockout and overexpression respectively. DKK-1 knockout in MDA-MB-
231 cells was completed using the CRISPR-Cas9 system of gene editing. Two DKK-1 
knockout clones were realized (DKK-1 (I) and DKK-1 (II)). To compare the effects that a 
complete loss of DKK-1 expression in MDA-MB-231 cells may have on tumorigenesis, clone 
(DKK-1 (I)) was selected for in vivo assessment, and in parallel with control-transfected 
Figure 8: The expression of DKK-1 in primary breast cancer tumors is increased in invasive 
tumor stages and correlated with poor survival in ER- patients.  The expression of DKK-1 in primary 
tumor sections of 396 breast cancer patients was analyzed by immunohistochemistry. Staining was assessed by 
grading the stain intensity from 0-3 (0 = negative, 1 = faint, 2 = positive and 3 = strong positive). This grade was 
then multiplied by a value determining the percentage of the cancerous tissue that was stained (0 = 0-24%, 1 = 
25-49%, 3 = 50-74% and 4 = 75-100%). The final range of the combined grade was from 0-12. This combined 
DKK-1 staining grade was then assessed for tumor stages (A), histological subtypes (B) and ER status (C). 
Patients were divided into DKK-1 low/negative (0-2) expression and DKK-1 (3-12) positive groups, and survival 
curves were plotted for the total number of patients (D), and subdivisions of ER-positive (E) and ER-negative 
patients (F). Bar graphs and survival curves were analyzed by one-way ANOVA and Gehan-Breslow-Wilcoxon 
tests respectively (* p < 0.05). 
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MDA-MB-231 cells, inoculated into female NMRI-nu mice. After a growth period of 5 weeks, 
tumor burden was assessed by weighing resected tumors following animal sacrifice. In this 
approach, endogenous knockdown of DKK-1 in the breast cancer cells resulted in reduction 
in tumor growth by 61% (p < 0.05) (Fig. 9).  
 
This result once again supported a pro-tumor role for DKK-1, specifically in ER- breast 
cancer. To confirm the observation that DKK-1 may not have a role in the biology of ER+ 
breast cancer, DKK-1 was overexpressed in the ER+ MCF-7/Neu cell line which is 
transfected with the Neu oncogene allowing the cells to grow independently of estrogen in 
vivo. An increased expression of DKK-1 in this cell line did not alter tumor burden 
significantly when inoculated subcutaneously into female NMRI-nu mice (Fig. 10). This 
strengthened the observations of the TMA, where DKK-1 expression had no apparent role in 
survival outcome of ER+ breast cancer patients.  
 
 
 
Figure 9: Knockout of DKK-1 inhibits subcutaneous breast cancer tumor growth. Female NMRI 
nu mice were injected subcutaneously with 1.5x106 MDA-MB-231/Control or MDA-MB-231/DKK-1(I) cells (2 
sites per mouse) and tumors were allowed to grow for duration of 5 weeks (n = 5 for each group). At sacrifice 
tumor burden was assessed by weighing the resected tumors. DKK-1 knockout was confirmed by IHC. (Tumor 
image scale bar 1 cm, IHC image magnification x 20, scale bar 50 µm) (* p < 0.05). 
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4.1.3 Anti-DKK-1 therapy inhibits breast cancer and melanoma tumor growth 
In order to investigate further the role of DKK-1 in solid tumor growth a translational approach 
was adopted. Here, female NMRI-nu mice were inoculated subcutaneously with the ER- 
breast cancer cell line MDA-MB-231 and the melanoma cell line MDA-MB-435s to assess if 
potential responses were cancer type specific. In the treatment groups, secreted DKK-1 was 
neutralized with intraperitoneal injections of the anti-DKK-1 antibody BHQ, commencing from 
the time point of tumor cell inoculation. At sacrifice, resected tumor weight was used as an 
endpoint to assess differences in tumor growth. Strikingly, BHQ-treated animals displayed a 
50% (p < 0.01) and 43% (p < 0.05) reduction in tumor growth of MDA-MD-231 and MDA-MD-
435s tumors respectively, similar to the reductions in tumor growth of the MDA-MB-231 DKK-
1 knockout clone (I) (Fig. 11A + C). A common factor resulting in reduced tumor growth is 
insufficient tumor vascularization (Hillen and Griffioen, 2007). Therefore, in order to assess 
variations in the microvessel density between BHQ and control-treated tumors, tumor 
sections were histologically prepared for paraffin IHC and stained for PECAM-1, a marker of 
endothelial cells. Vessel staining was quantified and microvessel density, and hence 
intratumoral blood supply, was significantly reduced by 48% (p < 0.05) in the BHQ-treated 
tumors of MDA-MB-231 origin. Strikingly there was no difference in the microvessel density 
in MDA-MB-435s tumors suggesting that inhibited vasculogenesis was not the only anti-
tumor mechanism in operation (Fig. 11B + D). Despite an unknown mechanism at this point, 
these results clearly show that DKK-1 can be therapeutically targeted and has desirable anti-
tumor outcomes in 2 different cancer cell lines. 
Figure 10: Overexpression of DKK-1 in ER+ breast cancer does not promote subcutaneous 
tumor growth. ER+ MCF-7/Neu cells were transfected with a DKK-1 overexpression plasmid and successful 
overexpression was detected by Western Blot (A). GAPDH is shown as the housekeeping gene. 2x106 cells 
were inoculated subcutaneously (x2 tumor sites per mouse) for control (C) and cells with the DKK-1 
overexpression (DKK-1 OE) and tumors were allowed to grow for 5 weeks (n = 5 per group). After sacrifice, 
resected tumors were weighed to assess tumor burden (B).  
A B 
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Figure 11: Anti-DKK-1 therapy inhibits subcutaneous breast cancer and melanoma tumor 
growth. Female NMRI-nu mice were injected subcutaneously with 1.5x106 MDA-MB-231 (A) or MDA-MB-435s 
cells (C). Treatment with intraperitoneal injections of 200 µg BHQ880 (BHQ) in 100 µl H2O, or 100 µl control 
(H2O) commenced on the day of tumor cell inoculation and was continued for a dosing schedule of 3 times per 
week for a period of 5 weeks (MDA-MB-231: control n = 7; BHQ n = 8, MDA-MB-435s: control n = 5; BHQ n = 6). 
At sacrifice, tumor burden was assessed by weighing the resected tumors. PECAM-1 staining by IHC was 
performed to assess variations in tumor microvessel density. The number of positive vessels and cells where 
counted in 6 randomized areas of 0.6 mm² (B + D) (Tumor image scale bar 1 cm, IHC image magnification x 20 
scale bar 50 µm) (* p < 0.05, ** p < 0.01).  
D 
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4.1.4 DKK-1 knockout in MDA-MB-231 cells leads to reduced viability in vitro  
Next, functional assays were completed to assess the cell biology of the DKK-1 knockout 
clones in vitro. In serum-supplemented medium conditions there was no change in cell 
viability observed between control-transfected cells and DKK-1 knockout clones (data not 
shown), however, when the culture conditions were serum-deprived, there were significant 
changes in cell number, viability and activation of caspases 3/7 (signifying apoptosis) after 72 
h. Cell number as assessed by crystal violet staining was significantly reduced in both clones 
by an average of 41.5% (p < 0.001) (Fig. 12A). Assessment of cell viability using the 
CellTiter-Blue® assay also demonstrated a significant reduction of 52% and 33% in the 
clones compared to the control (p < 0.001) (Fig. 12B).  
Figure 12: DKK-1 knockout in MDA-MB-231 cells leads to reduced viability in vitro, in serum-
deprived conditions. After 72 h culture in serum-deprived conditions, MDA-MB-231 DKK-1 knockout clones 
cells were assessed for; cell number by crystal violet staining (A), viability by CellTiter-Blue assay (B), apoptosis 
by Caspase-Glo 3/7 assay (normalized to cell number as determined by crystal violet staining) (C) and cell cycle 
status by flow cytometry analysis of propidium iodide-stained cells (D). Treatment with 500 ng rh DKK-1 did not 
rescue the loss in viability of DKK-1 knockout clones as assessed with the CellTiter-Blue assay ((DKK-1 (I) 
depicted here) (E) (** p < 0.01, *** p < 0.001) 
A B C 
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Caspase 3/7 activation and cell cycle parameters were then analyzed to distinguish if the 
observed loss in cell number and viability were due to apoptotic mechanisms or an inhibition 
of progression through the cell cycle. Results show that caspase 3/7 activity was increased 4 
(p < 0.001) and 2.5-fold (p < 0.01) in DKK-1 clones I and II respectively when compared to 
control-transfected cells (Fig. 12C). Flow cytometry analysis of the cell cycle did not show 
any significant differences between the percentage of control and DKK-1 knockout cells in 
each stage of the cell cycle (Fig. 12D). This was also reflected by a lack of regulation in the 
expression of genes and phosphorylation of proteins involved in cell cycle regulation (data 
not shown). Curiously, the addition of rh DKK-1 to the culture medium did not alter the 
observed reduction in cell viability at 72 h in serum-deprived conditions as depicted for clone 
DKK-1 (I) (Fig. 12E). These results would indicate a role for DKK-1 in conditions of metabolic 
stress and the last example as the first hint of the existence of an unknown, intracellular 
activity role of DKK-1. 
4.1.5 Wnt signaling is independent of DKK-1 expression in MDA-MB-231 cells  
As DKK-1 is an inhibitor of the canonical Wnt pathway which is known to play many roles in 
cancer cell biology, it was important to assess the baseline activity of Wnt signaling in MDA-
MB-231 cells, and in what way Wnt signaling regulates DKK-1 expression and how DKK-1 
regulates Wnt signaling. As shown by TCF-LEF-reporter assay analysis in control MDA-MB-
231 cells, responsiveness to the canonical Wnt ligand Wnt3a, depends on the expression of 
the DKK-1 co-receptor LRP6 to transduce the canonical signal. Wnt3a induces canonical 
Wnt signaling 4-fold from control conditions and this induction is significantly suppressed by 
43% (p < 0.05) when LRP6 expression is decreased by siRNAs. While the solo knockdown 
of LRP5 had no suppressive effect on the induction of canonical Wnt signaling, when LRP5 
and 6 are knocked down simultaneously, the suppression observed by LRP6 knockdown 
was potentiated by another 24% (p < 0.01) (Fig. 13A). This would suggest that Wnt3a has a 
much higher binding affinity for LRP6 than LRP5 in MDA-MB-231 cells. Of interest, ER- 
MDA-MB-231 cells were more responsive to Wnt3a than ER+ MCF-7 cells (data not shown). 
Furthermore, it can be shown that DKK-1 is a canonical Wnt target gene in MDA-MB-231 
cells, as knockdown of both LRP5 and 6 can inhibit the increase of 40% (p < 0.01) in the 
expression of DKK-1 following Wnt3a stimulation in control MDA-MB-231 cells. Combined 
knockdown reduced this increase by 70% (30% below baseline) (p < 0.001) (Fig. 13B). 
However, when assessing the induction of canonical Wnt signaling in the DKK-1 knockout 
clones, there was no change compared to the control-transfected cells, when logically a 
potentiated signaling activity would have been expected (Fig. 13C).  
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The addition of Wnt3a to the culture medium also did not alter the observed reduction in cell 
viability at 72 h in serum-deprived conditions as depicted for clone DKK-1 (I) (Fig. 13D). 
When performing a comparative Wnt signaling gene PCR array between control MDA-MB-
231 cells and the clone DKK-1 (I) cultured to the same time point, 22 Wnt-associated genes 
were ≥ 2-fold downregulated whereas only 3 were ≥ 2-fold upregulated from a total of 84 
genes assayed. Strikingly, another Wnt antagonist, CXXC4 was downregulated by > 300-fold 
and this was confirmed by qRT-PCR (data not shown) (Fig. 13E). These results would 
suggest that Wnt signaling is independent of DKK-1 and that the function of DKK-1 in MDA-
MB-231 cells is independent of Wnt signaling, pointing to another undescribed, Wnt-
independent role for the pro-tumor activity of DKK-1. 
Figure 13: DKK-1 expression does not dictate the response to Wnt3a stimulation in MDA-MB-
231 cells. Canonical Wnt signaling is activated in response to stimulation with L-Cell supernatant containing 
Wnt3a and was assessed by the TCF/LEF reporter assay in control MDA-MB-231 cells (A). Using siRNA to 
transiently knockdown receptors shared by DKK-1 and Wnt3a (LRP5/6), is sufficient to silence activated Wnt 
signaling (siC = control transfected with scrambled siRNA). DKK-1 is a Wnt3a-responsive gene – regulated 
expression as assessed by qRT-PCR (B). DKK-1 knockout clones do not show altered activation of canonical 
Wnt signaling in the TCF/LEF reporter assay (C = Control cell line) (C). Treatment with 200 ng rh Wnt3a does 
not rescue the loss in viability nor promote viability of DKK-1 knockout clones and control cells respectively as 
assessed by CellTiter-Blue® assay - (DKK-1 (I) depicted (D). When analyzing a human Wnt signaling pathway 
PCR array, 22 genes from 84 were more than 2-fold downregulated and only 3 were more than 2-fold 
upregulated. Genes with a fold-regulation of more than 5 are represented (E). (** p < 0.01, *** p < 0.001 with 
respect to L-Cell siC or C conditions; # p < 0.05, ## p < 0.01 and ### p < 0.001 with respect to Wnt3a siC 
conditions. 
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4.1.6 DKK-1 knockout suppresses matrix metalloproteinases in MDA-MB-231 cells  
Prior to the observed apoptosis event, DKK-1 knockout clones displayed an altered, spindle-
like morphology when cultured in serum-deprived medium (data not shown). This could be 
an undesirable display of epithelial-mesenchymal transition (EMT). To address this concern 
a PCR array assessing genes coding extracellular matrix and adhesion molecules was 
assessed. A striking downregulation in the expression in members of the MMP family was 
observed in the DKK-1 knockout clone (I) (Fig. 14A). This result was confirmed by qRT-PCR 
in both clones for the genes MMP1, MMP10 and MMP13, which were all significantly 
downregulated (p < 0.001) (Fig. 14B). Therefore, despite a morphological change indicative 
of EMT in DKK-1 knockout clones in serum-deprived conditions, this small snapshot of 
Figure 14: Matrix metalloproteinases are downregulated in MDA-MB-231 DKK-1 knockout 
clones. A PCR array of 84 genes encoding extracellular matrix and adhesion molecules was analyzed to 
compare the regulation of gene expression between control and MDA-MB-231 DKK-1 (I) cells after 72 h in 
serum-deprived conditions (A). Here the majority of genes were downregulated more than 2-fold. The greatest 
downregulation was apparent in the MMP family of genes. Downregulation of family members MMP-1, 10 and 13 
in both knockout clones were confirmed by qRT-PCR (B). (*** p < 0.001) 
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changes in the gene expression signature would not suggest a more metastatic phenotype, 
but may in fact be a prelude to apoptosis. Further functional assays and analysis of genes 
involved in EMT will be required in the future to clarify these observations. 
Section summary: This work has confirmed that DKK-1 is a tumor promoter in ER- breast 
cancer and has detailed the initial experiments performed as the first steps taken to 
understand the mechanisms of how DKK-1 promotes cancer cell survival in vitro and in vivo. 
It has shown that the role of DKK-1 in ER- breast cancer is independent of canonical Wnt 
signaling and ongoing work will focus on an intracellular role for DKK-1 in the context of 
cancer cell metabolism and the role of DKK-1 in the tumor microenvironment.  
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4.2 The mTOR inhibitor everolimus promotes bone biology and 
inhibits the growth of osteolytic breast cancer metastases 
4.2.1 Everolimus inhibits tumor growth of osteotropic cancer cell lines in vivo 
The focus then turned to role of mTOR inhibition in cancer. Firstly, it was determined if 
mTOR was active in cancer cell lines and if everolimus was effective at inhibiting this 
activation. To this end, human MDA-MB-231 breast cancer cells and murine B16-F10 
melanoma cells were treated with increasing concentrations of everolimus (1, 10 and 100 
nM) for 48 h. Analysis of mTOR activation was assessed by the detection of the 
phosphorylated mTOR protein at Ser2448 by western blot. Increasing concentrations of 
everolimus resulted in decreasing mTOR phosphorylation with concentrations as low as 1 
nM evidencing reduced protein signals, without altering the total protein levels (Fig. 15A + 
B). This reinforces the mTOR inhibitory action of everolimus in the cell lines analyzed. When 
Figure 15: Everolimus inhibits mTOR phosphorylation in vitro and tumor growth of 
aggressive cancer types in vivo. MDA-MB-231 (A) and B16-F10 cells (B) were treated with increasing 
concentrations of everolimus for 48 h and protein expression of mTOR and phosphorylated mTOR (p-mTOR) 
were assessed by Western blot. β-tubulin is shown as the housekeeping control. MDA-MB-231 (C) and B16-
F10 (D) cells were subsequently inoculated subcutaneously into female immunocompetent (C57BL/6) and 
immunocompromised (NMRI nu) mice respectively. Starting on the day of tumor cell inoculation, treatment was 
commenced with a daily dose of 1 mg/kg of everolimus for 2 and 4 weeks in each respective model. At 
sacrifice, excised tumors were weighed to assess tumor growth. (** p < 0.01, *** p < 0.001)  
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these cells were treated with everolimus in a dose and time dependent manner, increasing 
concentrations of everolimus significantly reduced cell viability as assessed by CellTiter-
Blue® at concentrations of 1, 10 and 100 nM at 72 hours for MDA-MB-231 cells (p < 0.001) 
and at 10 and 100 nM at 72 h for B16-F10 cells (p < 0.001) (data not shown). 
Accordingly, the anti-cancer effects of mTOR inhibition in vitro were then verified in vivo, in 
murine models of subcutaneous tumor growth. The MDA-MB-231 and B16-F10 models 
represent immunocompromised xenograft and immunocompetent, syngeneic allograft 
models respectively.  In both models, everolimus at a dose of 1mg/kg/daily was effective in 
inhibiting tumor growth (Fig. 15C + D). Resected tumor weight was potently reduced by 81% 
(p < 0.001) and 71% (p < 0.01), in the MDA-MB-231 and B16-F10 and models respectively. 
B16-F10 tumors are notoriously difficult to treat (Overwijk and Restifo, 2001; Baird et al., 
2013) and MDA-MB-231 cells are an example of triple hormone receptor-negative (ER, PR, 
HER-2) breast cancer which has a reduced overall survival in patients compared to hormone 
receptor-positive breast cancer (Dunnwald et al., 2007). Both of these cell lines are 
representative of aggressive cancers and so the anti-tumor effects observed here carry 
significant weight. 
4.2.2 Everolimus protects ovariectomized mice from bone loss 
AAs discussed, the ideal novel therapy needs to target both tumor biology while exerting pro-
bone effects. A daily dose of 1 mg/kg everolimus was clearly effective in inhibiting tumor 
growth and therefore, the same dose was used to assess the possible bone-protective 
effects of everolimus which were described in the bone analysis of the BOLERO-2 trial 
(Gnant et al., 2013). The patient demographic of postmenopausal women treated with an AI 
was replicated in an OVX model where 9-week-old wild-type C57BL/6 mice underwent OVX 
to induce an environment of high bone turnover and bone loss. Four weeks after the OVX 
procedure, everolimus treatment was commenced at a dose of 1 mg/kg which was continued 
daily for 4 weeks. The OVX was successful, with a difference of 27.49% in the femoral BMDs 
between the OVX and the SHAM control groups (Fig. 16A). The bone loss induced by OVX 
was significantly restored with everolimus treatment, with an increase in BMD of 38.44% (p < 
0.05 (t test). The average BV/TV increased by 37% (p < 0.05 (t test) between the control 
OVX group and the everolimus treated OVX group (Fig. 16B). Increases in trabecular 
number (2.62 ± 0.43 vs. 2.07 ± 0.41 p < 0.01) and decreases in trabecular separation (0.40 ± 
0.07 vs. 0.51 ± 0.11 p < 0.05) in the everolimus-treated OVX group further supported these 
observations (Fig. 16C + D). Results on bone turnover markers (C-terminal telopeptide 
(CTX) and N-terminal propeptide of procollagen type I (PINP)) were inconclusive, with no 
significant changes observed between the groups. However, there was a large standard 
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deviation and no baseline data was available to compare individual changes (data not 
shown). All in all, everolimus was effective at protecting bone loss in conditions of high bone 
turnover, similar to that displayed by postmenopausal breast cancer patients who are treated 
with AIs. 
4.2.3 Everolimus inhibits the increased bone turnover observed in OVX mice 
The clear differences in bone quality of OVX and everolimus treated OVX mice suggested a 
realignment of osteoclast and osteoblast activity. To discern the exact action that everolimus 
has on these bone cells in vivo, bone histomorphometry was analyzed. The OVX and 
everolimus-treated OVX groups were compared and the number of osteoclasts in contact 
with the bone surface was reduced by 25% (ns, p < 0.06) in the everolimus-treated OVX 
group (Fig. 17A). In line with this, a 30% (p < 0.01 (t test)) increase in the bone formation 
rate (BFR/BS) between the control SHAM and OVX groups was reversed by 41.5% (p < 
Figure 16: Everolimus protects ovariectomized mice from bone loss. Female C57BL/6 mice were 
divided into sham (SHAM) and ovariectomy (OVX) groups and subdivided into control or 1 mg/kg daily 
everolimus treatment groups (8-10 mice per group). 4 weeks post OVX, treatment with everolimus commenced 
for 4 weeks. Bone parameters of the femur where assessed by µCT: bone mineral density (BMD) (A), bone 
volume over total volume (BV/TV) (B), trabecular number (Tb.N) (C) and trabecular separation (Tb.Sp) (D). 
Representative µCT images are shown of the trabecular bone of the femur for control OVX and everolimus OVX 
groups (E). Statistical analysis was performed by two-way ANOVA for the effect of Surgery, Treatment and the 
interaction (Surgery*Treatment).  
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0.05) with everolimus treatment (Fig. 17B). In summary, the high bone turnover and bone 
loss that was induced by a hormone-deprived environment in OVX animals was apparently 
prevented with everolimus, by a mechanism of suppressed osteoclast activity. 
4.2.4 Everolimus inhibits osteoclastogenesis in vitro 
Subsequently, mBMDMCs were differentiated to osteoclasts in the presence of everolimus to 
assess the role of mTOR inhibition in the process of osteoclastogenesis. After treatment with 
the osteoclastogenic differentiation factors RANKL and M-SCF and increasing 
concentrations of everolimus for 5 days, the TRAP positive cells were counted and RNA 
analyzed for the expression of osteoclastic marker genes. In murine BMDMCs, the lowest 
concentration of everolimus (1 nM) had no significant effects in dictating the number of TRAP 
positive osteoclasts, however the number of TRAP positive osteoclasts decreased by 83% 
and 86% (p < 0.001) at concentrations of 10 and 100 nM respectively (Fig. 18A). At the level 
of gene expression, Oscar was the only gene for which the expression was significantly 
altered in response to 1 nM everolimus, with a controversial increase of 37% (p > 0.05). This 
is perplexing; however, at increasing concentrations of 10 and 100 nM, the expression of the 
osteoclast marker genes Oscar and Trap were significantly and equally reduced, suggesting 
the existence of an optimal threshold in the pharmokinetics of everolimus in this cell type 
(Fig. 18B). This once more points to mTOR signaling thresholds which vary between cell 
Figure 17: Everolimus inhibits the increased bone turnover observed in OVX mice. In the same 
experiment as Fig. 23, bone parameters of the tibia and femur where also assessed by bone histomorphometry. 
The number of osteoclasts per bone surface (Oc.N/BS) (A) was assessed in the tibia by TRAP staining and 
assessment of double calcein labels was used to determine the bone formation rate (BFR/BS) in the femur (B). 
Representative TRAP staining (red arrows indicating osteoclasts) (x 40 magnification, scale bar 20 µm), and 
calcein labels for these 2 groups is also provided (x 20 magnification, scale bar 100 µm) (C). Statistical analysis 
was performed by two-way ANOVA for the effect of Surgery, Treatment and the interaction 
(Surgery*Treatment).  
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types and origins. Incidentally, the expression of Ctsk also followed a similar trend although 
this was not proven significant. These results demonstrate that everolimus is a potent 
inhibitor of murine osteoclastogenesis, with significant effects starting at a concentration of 
10 nM. In the same experimental set-up using murine RAW 264.7 cells, everolimus resulted 
in significant decreases in all described parameters for all concentrations, including 1 nM 
(data not shown). 
4.2.5 Osteoblasts are less sensitive to the inhibitory effects of everolimus in vitro  
The investigation then turned to the other half of the bone forming unit, the osteoblast. 
MMSCs were differentiated for 7 days in the presence of increasing everolimus 
concentrations to assess the expression of osteoblast marker genes in pre-osteoblasts. Like 
human mesenchymal stem cells (hMSCs) (data not shown), murine osteoblasts were more 
resistant to the inhibitory effects of mTOR inhibition than osteoclast cells. However, while 
there was no significant alteration in the expression of Opg at any concentration, the 
Figure 18: Everolimus inhibits osteoclastogenesis in vitro at higher concentrations. Murine 
bone marrow-derived mononuclear cells were isolated from the bone marrow of female C57BL/6 mice and 
differentiated to osteoclasts in the presence of increasing everolimus concentrations (1, 10 and 100 nM) for 5 
days. Differentiation was assessed by counting TRAP-positive cells in comparison to untreated controls (A). 
Osteoclast marker genes; Oscar, Trap and Ctsk were assessed by qRT-PCR (B) (* p < 0.05; ** p < 0.01, *** p < 
0.001).  
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expression of Alp, Runx2 and Ocn were all significantly reduced (64% (p < 0.001), 33% (p < 
0.01) and 79% (p < 0.001) respectively) at the highest concentration of everolimus (100 nM) 
(Fig. 19A). Despite these negative effects on osteoblastic gene expression when treated with 
100 nM, when the mineralizing ability of these cells was assessed by Alizarin Red S staining, 
a less proportionate reduction of only 21% (p < 0.05) was observed (Fig. 19B). Therefore, 
while it would appear that the differentiation of murine osteoblasts also relies on mTOR 
signaling to a certain degree; they do not rely on mTOR to the same extent as osteoclasts do 
for their differentiation.  
4.2.6 Everolimus inhibits the progression of breast cancer bone metastases 
It was clear that an everolimus dose of 1 mg/kg/daily had anti-tumor and bone-protective 
effects in vivo when each parameter was investigated as a separate outcome under different 
conditions. However, a condition was required in which both dysregulated bone activity and 
tumor biology could be targeted concurrently. With this requisite, the ability of everolimus to 
Figure 19: Osteoblasts are less sensitive to inhibitory effects of everolimus in vitro. Murine 
mesenchymal stem cells were differentiated to osteoblasts in the presence of increasing everolimus 
concentrations (1, 10 and 100 nM). Osteoblast marker genes; Alp, Opg, Runx2 and Ocn, were assessed by 
qRT-PCR at 7 days of differentiation (A). The mineralizing ability of these cells was assessed using Alizarin Red 
S staining, quantified on day 21 (B). (* p < 0.05; ** p < 0.01, *** p < 0.001).  
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inhibit the development of osteolytic breast cancer bone metastases was investigated. 
Intracardiac injection of MDA-MB-231 breast cancer cells expressing the firefly-luciferase 
gene (MDA-MB-231-LucA12) into 6-week-old NMRI-nu mice resulted in the establishment of 
bone destructive metastases after 5 weeks. Animals were divided into 2 groups, one 
receiving control and one receiving an everolimus dose of 1 mg/kg/daily commencing at 
tumor cell inoculation and continuing until the day before sacrifice (day 35).  Prior to sacrifice 
on day 36, the number of lesions with bioluminescent signals over 1 x 107 photons/s/cm²/sr, 
were counted per animal and compared between groups. The average number of overt 
lesions was reduced by 70% in the everolimus-treated group compared with to the control 
group (p < 0.05). Individual metastatic signals were also quantified and could show that 
everolimus treatment reduced the overall tumor burden in the bone by 45.4% (p < 0.01) (Fig. 
20). The results of this experiment could show that everolimus was as effective in targeting 
tumor growth in the bone as it was in subcutaneous tumors, and that the progression in the 
bone could be suppressed. 
 
 
Figure 20: Everolimus inhibits the progression of breast cancer bone metastases. Female 
NMRI nu mice were injected intracardially with MDA-MB-231 cells expressing the firefly luciferase gene. Mice 
received daily treatments of control (9 mice) or 1 mg/kg everolimus (9 mice) and developing metastases were 
monitored weekly, until sacrifice on day 36. 1 mouse in the control group succumbed early to paralysis on day 
34. For this mouse, the measurement on day 28 was included in the final assessment. Bioluminescent signals 
at sites of tumor burden are depicted, with animals arranged according to increasing bioluminescent signals 
from left to right. Individual signals ≥ 1 x 107 photons/s/cm²/sr were counted as established metastases, 
compared between groups and results presented in a boxplot. The average luciferase signal intensity 
(photons/s/sr/cm²) from regions of interest was calculated per metastatic signal focus (everolimus n = 57 and 
control n = 90 detectable lesions) (* p < 0.05; ** p < 0.01).  
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4.2.7 Everolimus inhibits breast cancer metastasis-induced bone destruction 
While it is difficult to assess the relative contribution of the anti-tumor and anti-osteoclast 
mechanisms in models of breast cancer bone metastasis, the assessment of the bone 
parameters additionally supported the use of everolimus to suppress breast cancer 
metastasis-induced bone destruction. Bioluminescent signals could be correlated with 
osteolytic lesions as confirmed by µCT analysis. Bone destruction was assessed 
quantitatively, specifically at the trabecular bone of the femur. The BMD and BV/TV was 
analyzed and in both cases there was an increase of > 50% (p<0.001) in the everolimus 
group (Fig. 21A + B). This preservation in bone quality was also reflected in the analysis of 
trabecular parameters. The control group exhibited 24.25% (p < 0.01) fewer trabeculae and 
separation between these trabeculae was 31.52% (p < 0.01) greater than in the everolimus 
group (Fig. 21C + D). In combination, these results demonstrate that as an individual 
treatment agent, everolimus is effective in suppressing the progression of breast cancer 
metastases in the bone, reducing the tumor burden and associated bone destruction. 
Figure 21: Everolimus inhibits 
metastasis-induced bone destruction. 
Bone parameters of the femur where 
assessed by µCT; bone mineral density 
(BMD) (A), bone volume over total volume 
(BV/TV) (B), trabecular number (Tb.N) (C) 
and trabecular separation (Tb.Sp) (D). The 
sites of bioluminescent signal in the knee 
joint corresponded with osteolysis in 3D 
reconstructions of µCT scans – 
representative images shown (E). (** p < 
0.01, *** p < 0.001)  
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Section summary: This work was based and has elaborated on the observations of the 
BOLERO-2 trial (Gnant et al., 2013) where bone turnover markers and disease progression 
in the bone were decreased by combining the AI exemestane with the mTOR inhibitor 
everolimus in patients with progressive breast cancer. Here, in vivo models and in vitro 
experiments have shown that everolimus preferentially inhibits osteoclast differentiation and 
cancer cell growth, preventing increased bone turnover in an OVX model and concurrently 
inhibiting the progression of breast cancer in the bone and bone destruction in a murine 
model of breast cancer bone metastasis. 
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4.3 P38 MAPK regulates the Wnt inhibitor Dickkopf-1 in 
osteotropic prostate cancer cells 
4.3.1 Prostate cancer-derived DKK-1 inhibits Wnt3a-induced osteoblastogenesis  
This section turns to the role of prostate cancer-derived DKK-1, how it inhibits 
osteoblastogenesis and how p38 MAPK signaling contributes to its regulation. Prostate 
cancer cell lines which demonstrate varied phenotypes when growing in the bone in vivo, 
were first assessed for their DKK-1 expression. MDA-PCa2b and C4-2B cell lines which 
induce osteoblastic and mixed osteoblastic/osteolytic lesions in vivo, had almost 
undetectable levels of mRNA expression and functional secretion of the DKK-1 protein in 
culture media supernatants (Fig. 22A + B). In comparison, the purely osteolytic PC3 cell line 
Figure 22: DKK-1 is highly expressed in osteolytic prostate cancer cells and inhibits Wnt3a 
induced osteoblastogenesis in C2C12 cells. Total mRNA and secreted protein levels of DKK-1 were 
measured by qRT-PCR (A) and ELISA (B) respectively in prostate cancer cell lines. The mRNA levels of the 
osteoblastic marker Alp in C2C12 cells were assessed by qRT-PCR after treating with prostate cancer 
supernatants in presence of Wnt3a (C). C2C12 cells were treated in the presence of Wnt3a with PC3 
supernatant and 1 µg/ml Anti-DKK-1 or 1 µg/ml IgG Goat for 24 hours. Activation of Wnt signaling was detected 
by measuring luciferase activity (D), Alp mRNA expression levels by qRT-PCR (E) and Alp activity (arbitrary 
units) by enzymatic assay (F). (* p < 0.05; ** p < 0.01, *** p < 0.001). Adapted from Browne et al., 2016.  
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revealed intensely elevated levels of DKK-1 expression. To verify the fact that prostate 
cancer-derived DKK-1 can suppress osteoblastogenesis, prostate cancer supernatants were 
collected and used to treat C2C12 cells, which in naive conditions differentiate to osteoblast-
like cells in the presence of Wnt3a.  
When comparing the inhibitory effects of prostate cancer supernatants on Wnt3a-induced 
differentiation of C2C12 cells as assessed by Alp mRNA expression, it was clear that 
supernatants derived from PC3 cultures suppressed Alp expression to a greater degree than 
those derived from the MDA-PCa2b cultures when compared to the control Wnt3a condition 
(23% versus 74% respectively (p < 0.01)) (Fig. 22C). Next, the suppression of Wnt3a-
induced canonical Wnt activity was assessed using a TCF-LEF-reporter assay. Here, Wnt3a 
stimulation increased canonical Wnt activity > 100-fold when compared to the L-Cell 
control/baseline condition (Fig. 22D). This induction could be suppressed by 79% when PC3 
supernatant was introduced to the culture set-up. To prove that this observed suppression 
was a direct effect of PC3-derived DKK-1, DKK-1 was neutralized using a monoclonal DKK-1 
antibody. The outcome was a complete rescue of suppressed canonical Wnt activity back to 
the original level observed in Wnt3a stimulation alone (p < 0.001). This experimental set-up 
was replicated for the assessment of Alp expression and functional Alp activity, which are 
markers of osteoblast differentiation (Fig. 22E + F). The same trend of suppressed Alp 
expression and Alp activity was apparent with the addition of PC3 supernatant. Similarly, a 
complete rescue with anti-DKK-1 treatment was recorded (p < 0.05). These initial 
assessments demonstrate the significance of prostate cancer-derived DKK-1 in the 
suppression of osteoblastogenesis. 
4.3.2 P38 MAPK and DKK-1 are correlated in human prostate cancer 
To determine if there is a connection between p38 MAPK and DKK-1 in prostate cancer, 
similar to that previously described in MM (He et al., 2012), a cDNA array of normal human 
prostate tissue (9 samples) and cancerous prostate tissue (39 samples) was analyzed for the 
expression of DKK-1 and p38 MAPK isoforms. When comparing expression profiles, all the 
analyzed genes were strongly upregulated in samples from patients with progressive tumor 
stages of II to IV (Fig. 23A). In comparison, the same genes were expressed at low levels in 
healthy controls. Of key importance, the levels of expression for each p38 MAPK isoform in 
each patient were positively correlated with those of DKK-1 (p<0.0001) (Fig 23B). While this 
was a relatively small patient cohort, these correlations served as a good foundation to 
proceed with the question as to whether p38 MAPK regulates DKK-1 expression in prostate 
cancer. 
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Figure 23: DKK-1 and p38 MAPK expression are correlated in prostate cancer. A cDNA prostate 
cancer array was used to quantify DKK-1 and MAPK expression in prostate cancer. Expression levels were 
normalized to β-actin. The intersecting red lines and values represent the mean expression in normal and 
progressive tumor stages. Positive correlation of DKK-1 with each p38 MAPK isoform tested in prostate cancer 
cDNA samples. Adapted from Browne et al., 2016. 
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4.3.3 Inhibition and activation of p38 MAPK signaling regulates DKK-1 
To investigate whether p38 MAPK regulates DKK-1 expression in prostate cancer, PC3 cells 
were chosen to assess the impact of p38 MAPK inhibition using small molecule inhibitors on 
DKK-1 expression levels in a concentration and time-dependent manner. Doramapimod, 
LY2228820 (LY) and SB202190 (SB) all significantly suppressed the mRNA expression of 
DKK-1 in a time and dose dependent manner (Fig. 24 A + B). At a concentration of 10 µM 
Figure 24: Inhibition and activation of p38 MAPK signaling regulates DKK-1 in PC3 cells. PC3 
cells were treated for 6 hours with small molecule inhibitors of p38 MAPK signaling; doramapimod, LY2228820 
(LY) and SB202190 (SB) (A). The most effective concentration in suppressing DKK-1 expression (10 µM) was 
used to assess the expression of DKK-1 mRNA in a time dependent manner (B). Time points shown are in 
hours and the control condition was performed for the maximum time period of 6 h. (C) In PC3 cells, total DKK-1 
protein and secreted protein levels was assessed for LY and SB after 6 hours. (D) PC3 cells were treated with 
the p38 MAPK signaling activator anisomycin for increasing time periods and DKK-1 mRNA expression was 
assessed (* p < 0.05; ** p < 0.01, *** p < 0.001). Adapted from Browne et al., 2016. 
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and after 3 h of treatment, all inhibitors suppressed DKK-1 expression by ≥ 50% (p < 0.01). 
Using the 2 most effective 38 MAPK inhibitors (LY and SB), it could be seen that this 
reduction in mRNA expression translated to a reduction in protein expression and secretion 
(Fig. 24C). Consistent with the inhibition of p38 MAPK leading to the suppression of DKK-1 
expression, the activation of p38 MAPK led to an increase in DKK-1 expression. Treatment 
of PC3 cells with anisomycin, an antibiotic which is known to activate p38 MAPK, lead to a 3-
fold increase in DKK-1 mRNA expression at a concentration of 1 µM after 2 h (Fig. 24D).  
Activation and inhibition of p38 MAPK signaling could be verified by western blot analysis of 
target proteins and correlated with DKK-1 mRNA expression (Fig. 25). Here, anisomycin 
Figure 25: Inhibition and activation of p38 MAPK signaling regulates DKK-1 in phenotypically 
different prostate cancer cell lines.  PC3 (A), MDA-PCa-2b (B) and DU 145 cells (C) were treated with 1 
µM anisomycin (2 h post culture medium change for 1 h), anisomycin in combination with either 10 µM LY or 10 
µm SB (anisomycin after 2 h post culture medium change for 1 h and LY and SB for 3 h immediately post culture 
medium change) and each selected inhibitor individually (for 3 h). DKK-1 mRNA expression and both total and 
phosphorylated protein levels of p38 MAPK and HSP27 were assessed after 3 h by Western Blot (*** p < 0.001). 
Adapted from Browne et al., 2016. 
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increased the phosphorylation of p38 MAPK, its downstream target HSP27 and the mRNA 
expression of DKK-1. In all available prostate cancer cell lines, the inhibitors LY and SB were 
effective at preventing both the increase in DKK-1 mRNA expression and phosphorylation of 
HSP27, also reducing the anisomycin-induced phosphorylation of p38 MAPK. Collectively, 
these results present DKK-1 as a target gene of p38 MAPK signaling.  
4.3.4 MAPK11 is the most significant regulator of DKK-1 in PC3 cells 
As described earlier, p38 MAPK exists in different isoforms it was important to investigate 
whether individual isoforms had varied contributions to DKK-1 regulation in prostate cancer 
cells. The expression of isoforms MAPK11, MAPK12 and MAPK14 was targeted in 
triplicates, using siRNAs with different sequences to achieve transient knockdowns in PC3 
cells as attested to by qRT-PCR and western blot analysis. These knockdowns resulted in a 
suppression of DKK-1 in all three siRNA sequences for MAPK11, two sequences for 
MAPK12 and one sequence for MAPK14 (Fig. 26A).  
Figure 26: MAPK11 is the most significant regulator of DKK-1 mRNA expression in the p38 
MAPK family. PC3 cells underwent siRNA transfection targeting individual p38 MAPK isoforms. For each 
MAPK member three individual siRNAs were assessed. 24 hours post transfection DKK-1 mRNA expression 
was analyzed by qRT-PCR (A). Confirmation of MAPK knockdown is shown at the protein expression level as 
assessed by Western Blot. The siRNA most effective at suppressing DKK-1 for each MAPK family member 
(MAPK11; si83, MAPK12; si66 and MAPK14; si86) was selected to assess for any further suppression when 
transfected in combination. Secreted DKK-1 protein levels in PC3 cell supernatant were assessed 48 hours post 
transfection by ELISA (B). Western blots of MAPK family members were also performed to confirm knockdown at 
the level of protein expression (* p < 0.05; ** p < 0.01, *** p < 0.001). Adapted from Browne et al., 2016. 
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The siRNA sequence resulting in the greatest suppression of DKK-1 expression was 
selected for each isoform for individual assessment and in combination. When assessing 
secreted DKK-1 protein levels following knockdown with these selected siRNAs, suppression 
of MAPK11 had the greatest inhibitory effect with a reduction of 33% (p < 0.05). While 
MAPK14 knockdown also showed a trend for DKK-1 suppression (27%), knockdown of 
MAPK12 showed no change (Fig. 26B). Transfecting the three tested isoforms in 
combination did not augment the suppressive effects of MAPK11 or MAPK14 on DKK-1 
expression levels. These results delineate the contributions of each p38 MAPK isoform to 
DKK-1 expression and can inform the development of future inhibitors in the respect as 
discussed later. 
4.3.5 Inhibition of p38 MAPK in PC3 cells rescues suppressed osteoblastogenesis 
Earlier experiments demonstrated different methods for regulating DKK-1 expression in 
prostate cancer cells. Next, it was shown that by directly targeting prostate cancer-derived 
DKK-1 with DKK-1 specific siRNAs, and indirectly by inhibition of p38 MAPK signaling, that 
PC3-suppressed osteoblastogenesis in C2C12 cells could be averted.  
Firstly, DKK-1 expression was transiently knocked down in PC3 cells using 2 different DKK-1 
targeting siRNAs and the resulting supernatants with reduced levels of secreted DKK-1 were 
collected. These, along with control-transfected supernatants containing normal levels of 
DKK-1 were used in the treatment of Wnt3a-stimulated C2C12 cells. Markers of 
osteoblastogenesis; Alp mRNA expression, Alp activity and Oa mRNA expression were all 
significantly suppressed when C2C12 cells were treated with control-transfected PC3 
supernatants (Fig. 27A). Notably, supernatants from DKK-1 siRNA-transfected PC3 cells did 
not result in any significant suppression of these osteoblastic markers.  
Secondly, in a similar set-up, the 3 most effective siRNAs targeting all 3 tested isoforms of 
p38 MAPK, were combined, transfected in PC3 cells and supernatants collected. Once 
again, the supernatants collected from control-transfected cells suppressed the expression 
osteoblastic makers and activity in Wnt3a-treated C2C12 cells (Fig. 27B). As expected, the 
knockdown of p38 MAPK was effective at minimizing this observed suppression.  
Finally, the same experimental set-up was assessed using supernatants where PC3 cells 
had been pre-conditioned with the p38 MAPK inhibitor LY. As described formerly, control-
treated PC3 supernatants suppressed the expression and activity of osteoblastic markers in 
Wnt3a-treated C2C12 cells but treatment with supernatants collected from PC3 cells pre-
conditioned with LY demonstrated a significantly blunted suppression (Fig. 27C). These 
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experiments have underlined the importance of DKK-1 as an inhibitor of osteoblastogenesis 
and show that DKK-1 can be targeted indirectly by inhibiting p38 MAPK expression and 
activity. 
Figure 27: Regulating PC3-derived DKK-1 has reversal effects on suppressed 
osteoblastogenic differentiation of C2C12 cells. C2C12 cells were differentiated in Wnt3a containing 
supernatant and conditioned PC3 supernatants where; DKK-1 had been knocked down using 2 siRNAs (A), 
DKK-1 suppression by knocking down p38 MAPK using siRNAs (combined siRNAs targeting MAPK11, 12 and 
14 (B), and DKK-1 suppression by LY treatment (PC3 cells were treated with 10 µM LY for 6 h before performing 
a fresh medium change and collecting supernatant 18 hours later (LY PTx)) (C). Alp mRNA, Alp activity and Oa 
mRNA expression were assessed for each condition (* p < 0.05; ** p < 0.01, *** p < 0.001). Adapted from 
Browne et al., 2016. 
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Section summary: This section has translated observations from MM to prostate cancer in 
the context of suppressed osteoblastogenesis, a factor which can promote osteolytic activity 
in prostate cancer bone metastases. P38 MAPK was proven to be a regulator of DKK-1 in 
prostate cancer cell lines and could be targeted using small molecule inhibitors to suppress 
DKK-1 expression and secretion in osteolytic PC3 cells, consequentially relieving the 
suppression of osteoblastogenesis in C2C12 cells co-differentiated with PC3 supernatants.  
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5 Discussion 
Solid tumors of the breast and prostate preferentially metastasize to bone in later disease 
stages. Frequently in the case of breast cancer and more uniquely in the case of prostate 
cancer, colonization and expansion of these metastatic cells in the bone microenvironment 
comes at the expense of increased bone resorption and diminished bone quality. The 
resulting skeletal morbidity results in an increased risk of SREs, reducing the quality of life 
and prolonged survival of these patients (Coleman, 1997).  
Current therapies licensed for the treatment of bone metastases do not deliver satisfying 
results and bone metastases remain incurable. Therefore, the identification and development 
of new anti-tumor and bone-targeted therapies is required. The Wnt inhibitor DKK-1 has 
emerged as a realistic target, being preferentially expressed in osteolytic cancers and 
implicated in tumor promotion in many different cancer types. A second therapy of interest 
has proven to be effective in suppressing the progression of aromatase-resistant breast 
cancer. MTOR inhibition using everolimus has been comprehensively studied as an anti-
tumor agent. Despite this, the exact cellular mechanism which is primarily active and 
targeted by everolimus in the metastatic bone microenvironment required further clarification. 
Finally, while there are many antiresorptive targets currently in use and under investigation, 
targeting cancer-inhibited bone anabolism may also directly improve bone quality and 
indirectly suppress osteoclast-mediated bone resorption and metastatic tumor growth. The 
activity of P38 MAPK has been linked with DKK-1 expression and may be of key importance 
for the regulation of osteoblast differentiation in the context of prostate cancer-induced bone 
resorption. The current study aimed to assess regulatory mechanisms, anti-tumor efficacy 
and bone-protective and bone-anabolic actions of strategically targeting DKK-1, mTOR or 
p38 MAPK in osteotropic cancers. 
5.1 Targeting tumor cell biology: DKK-1 as a tumor promoter in 
ER- breast cancer 
From the beginning it was clear that DKK-1 expression in the primary tumors of breast 
cancer patients played an important role as a breast cancer biomarker, with increased levels 
associated with both increased tumor stages and invasive histological subtypes. Strikingly, 
although there was no differences in DKK-1 expression between ER+ and ER- patients, 
when dividing these patients into 2 cohorts based on their ER status, a survival benefit was 
only apparent for ER- patients, where the differences in survival were greatly enhanced. 
These observations correlate with those of others with regards to the correlation of DKK-1 
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expression with ER status and survival rates but not with the similar expression of DKK-1 
between ER+ and ER- patients (Forget et al., 2007; Bu et al., 2008; Xu et al., 2012; Rachner 
et al, 2014b). However, this discrepancy may be explained by the low number of breast 
cancer cell lines and patient cohorts analyzed in these earlier studies, suggesting that the 
observation presented here is more accurate due the increased statistical power, resulting 
from increased numbers of patients. 
To clarify the role for DKK-1 in ER- and ER+ breast cancer, the expression of DKK-1 was 
regulated in breast cancer cell lines in vitro, and in vivo tumor growth was then assessed. A 
DKK-1 knockout in the ER- MDA-MB-231 cells was generated using the CRISPR-Cas9 
system of gene editing and to date, one clone (MDA-MB-231-DKK-1 (I)) has been tested in 
vivo with tumors demonstrating a significantly reduced growth profile when compared to 
control cells. This reflected increased survival rates of ER- patients with low DKK-1 
expression in the primary tumor. Overexpression in ER+ MCF-7/Neu cells also confirmed the 
observation that DKK-1 does not alter tumor growth in ER+ breast cancer. 
This is a curious finding which points to an association between DKK-1 function and estrogen 
signaling. Several Wnt genes are described as mammary oncogenes (Li et al., 2000) and in 
elegant experiments with Drosophila, crosstalk between ectopically expressed human ERα 
and metabolically stable β-catenin/Armadillo mutants reciprocally enhanced similar target 
genes (Kouzmenko et al., 2004). In human MCF-7 breast cancer cells, β-catenin has been 
shown to regulate ERα expression in a positive manner (Gupta et al., 2011). Few studies 
have directly correlated the expression of DKK-1 with estrogen signaling, however in the 
context of neurodegenerative disease, estradiol was shown to inhibit DKK-1 expression and 
promote canonical Wnt/β-catenin signaling (Scott and Brann, 2013). When considering these 
observations together, one could hypothesize that active estrogen signaling inhibits the pro-
oncogenic role of DKK-1, and that in the absence of estrogen signaling DKK-1 is free to fulfil 
its oncogenic potential. 
Next, a translational approach was employed to determine whether targeting DKK-1 could be 
considered as a potential therapy in breast cancer, xenografts arising from ER- MDA-MB-231 
breast cancer cells were treated with anti-DKK-1 antibody BHQ and anti-tumor effects were 
once again observed. These anti-tumor effects of DKK-1 neutralization in vivo, have also 
been observed in the A549 lung cancer cell line (Sato et al., 2010) and in MM (Fulciniti et al., 
2009). Additionally, results are currently pending from two Phase II clinical trials, one which 
focused on the anti-myeloma effects of BHQ in patients with smoldering MM with high risk of 
progression to active MM (NCT01302886) and the other in previously untreated MM patients 
with renal insufficiency (NCT01337752). DKN01, another anti-DKK-1 antibody, is being 
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investigated in a phase 1 trial as a single therapeutic agent, assessing not only patients with 
myeloma but also more interestingly, patients with other advanced solid tumors presenting 
with one or more metastatic sites (NCT01457417).  
Despite this progression of anti-DKK-1 therapy in the clinic, the exact anti-tumor mechanism 
remains unclear. Even within this study, while reduced vascularization was observed in BHQ-
treated MDA-MB-231 tumors, no such trend was apparent in BHQ-treated tumors arising 
from MDA-MB-435s cells, despite displaying a similar degree of growth inhibition as MDA-
MB-231 tumors. The action of DKK-1 has long been associated with angiogenesis albeit 
controversially, with different groups reporting pro and antiangiogenic effects of DKK-1 
expression and treatment (Smadja et al., 2010; Choi et al., 2012; Weng et al., 2012; Park et 
al., 2014). Therefore, these intratumor incongruences in vascularization only serve to 
promote this controversy and they are the first example in this study to highlight the context 
and cell-specific effects of DKK-1. Further research into the in vitro effects of MDA-MB-231-
derived DKK-1 on the endothelial cell line HMEC-1 could not demonstrate any regulation in 
cell behavior by directly altering DKK-1 expression or treatment with breast cancer 
supernatants (data not shown). 
Concentrating on the anti-tumor effects observed when DKK-1 is knocked out in MDA-MB-
231 cells, both DKK-1 knockout clones were assessed in vitro for differences in cellular 
responses. In specific conditions (serum-deprived culture medium at 72 h) they demonstrate 
a sudden loss in viability and an increase in apoptosis as detected by activation of caspases 
3 and 7. Many different studies have suggested a pro-apoptotic role for DKK-1 in a range of 
different cell types and including renal cell carcinoma cells (Hirata et al., 2011), chondrocytes 
in the context of inflammatory arthritis (Weng et al., 2009), medulloblastomas (Vibhakar et 
al., 2007), choriocarcinomas (Cui et al., 2015) and limb development (Grotewold and Rüther, 
2002). Nevertheless, DKK-1 activity has also been reported to have anti-apoptotic roles both 
in cancer and in development (Causeret et al., 2016; Pang et al., 2017). Hence a versatile 
role of DKK-1 depending on context and cancer type appears likely. 
Canonical Wnt signaling is emerging as a major player in the regulation of cell cycle genes 
(Davidson and Niehrs, 2010; Niehrs and Acebron, 2012) and DKK-1 itself has been shown 
as an enabler, allowing hMSCs to reenter the cell cycle following arrest in serum-deprived 
conditions (Gregory et al., 2003). Surprisingly, there were no significant differences in 
progression through the cell cycle stages as assessed by flow cytometry analysis. Therefore, 
the regulation and stimulation of Wnt signaling was investigated in MDA-MB-231 cells to 
assess whether the DKK-1 knockout demonstrated dysregulated Wnt activation. DKK-1 
expression and Wnt signaling responded to and were both upregulated by Wnt3a in MDA-
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MB-231 cells. However, the DKK-1 knockout clones did not demonstrate a potentiated 
induction of Wnt signaling under the same conditions. Moreover, the supplementation of rh 
Wnt3a had no effect on the loss in viability observed at 72 h in the DKK-1 clones (Clone 
DKK-1 (I) shown). When performing a comparative Wnt signaling gene array assay between 
control MDA-MB-231 cells and the clone DKK-1 (I) cultured to the same time point, it would 
have been logically expected that other Wnt inhibitors may be upregulated to compensate for 
the loss in Wnt antagonism. However, this was not the case at the level of gene expression 
and in fact the canonical Wnt inhibitor CXXC4, which has also been reported as a tumor 
suppressor in gastric and renal cell carcinoma (Kojima et al., 2009; Lu et al., 2014), was 
repressed by > 300-fold. Regardless, it can be hypothesized that other Wnt inhibitors, with 
lower binding efficiency than DKK-1 to canonical Wnt receptors, may simply fulfill the role of 
DKK-1 in its absence (e.g. other DKK family members or SOST) (Kahn, 2014; Malinauskas 
and Jones, 2014). 
Despite this unpredictability in the dogmatic function and efficacy of DKK-1 in the inhibition of 
canonical Wnt signaling and in the context of plasma membrane receptor-binding, activities 
of DKK-1 independent of canonical Wnt signaling have also been proposed. Nuclear 
localization of DKK-1 is one example. The localization of nuclear DKK-1 has been reported in 
colorectal cancer and correlated with an increased resistance to chemotherapy (Aguilera et 
al., 2015). This was a novel finding as DKK-1 has been conventionally defined as a secreted 
glycoprotein, mediating signaling by binding to proteins on the cell membrane (Niehrs, 2006). 
Immunofluorescent analysis of DKK-1 could not confirm nuclear compartmentalization in 
either MDA-MB-231 or MCF-7 cell lines (data not shown), however the results of protein 
fractionation detected a signal in the nucleus of MDA-MB-231 and not MCF-7 cells (data not 
shown). Whether this is a perinuclear or intranuclear localization remains to be determined 
(ChIP-seq analysis of DKK-1 could not demonstrate a positive enrichment of DKK-1-bound 
DNA – data not shown), however, what was clear is that DKK-1 was differentially localized 
between the 2 cell lines as well as displaying distinctly different profiles of protein 
glycosylation (data not shown). This could suggest an intracellular role for DKK-1 and offer 
some explanation as to why regulating extracellular levels of DKK-1 have no effect on cell 
biology in vitro. From another perspective, these glycosylation profiles may also explain why 
adding rh DKK-1 had no rescue effect in the DKK-1 knockout clones in vitro. Specialized 
glycosylation profiles are suggestive of protein modification, leaving open the possibility of 
different binding partners and activity (Stowell et al., 2015). It is feasible to hypothesize that 
rh DKK-1 would not have the same glycosylation profile as cancer cell-derived DKK-1 and 
therefore, it may be logical to assume that it would not have the same effect. Further 
investigation of this concept may lead to interesting results.  
5 Discussion 
 
 
87 
Another recent study has shown a tumor promotor function of DKK-1 by signaling through a 
novel plasma membrane receptor, the cytoskeleton-associated protein 4 (CKAP4) in mouse 
tumor models of lung and pancreatic cancer (Kimura et al., 2016). An interesting detail about 
CKAP4 is that it is also localized to cellular organelles, including the microtubules, 
endoplasmic reticulum, Golgi body and the nucleus (Vedrenne et al., 2005; Tuffy and Planey, 
2012; Sandoz and van der Goot, 2015) DKK-1 also shows a strong co-localization to the 
Golgi body by immunofluorescence (data not shown) and the possibility of nuclear 
localization may make it feasible for an intracellular interaction between these 2 proteins of 
interest. This shared localization in the Golgi body region may also be of key interest, as this 
organelle is involved in cellular stress-sensing and the induction of apoptosis (Hicks and 
Machamer, 2005). 
DKK-1 has also been associated as a metastasis promoter, reviewed previously (Menezes et 
al., 2012), and the observed decrease in expression of MMPs may support this view. MMPs 
are frequently implicated in EMT induction in breast cancer and therefore this expression 
profile may provide some evidence to the contrary (Radisky and Radisky, 2010). In 
particular, the expression of MMP-1 was significantly repressed in DKK-1 knockout clones. 
The literature presents MMP-1 as an anti-apoptotic protein in lung epithelial cells (Herrera et 
al., 2013) and as an interrupter of apoptosis induction in the tumor microenvironment 
(Kessenbrock et al., 2010). This profile of MMP-1 would fit to the observation of 
downregulation and increased apoptosis. Encouragingly for future studies of bone 
metastasis, increased expression of MMP-1 has been observed in an aggressive bone-
metastatic clone of MDA-MB-231 (Okuyama et al., 2008) and the MMP inhibitor batimastat 
has been shown to inhibit the development of osteolytic bone metastases when Balb C nu/nu 
mice were inoculated with MDA-MB-231 cells (Lee et al., 2001). 
To summarize, the role of DKK-1 in breast cancer is specific, context-dependent and 
complex. This work presents a clear argument that DKK-1 is a tumor promoter in ER- breast 
cancer and that targeting DKK-1 as a therapy may have potential in the clinic, as attested to 
by the anti-tumor effects reported in in vivo mouse models. However, clarification of the 
mechanism as to how DKK-1 elicits its pro-tumor actions in vitro and in vivo require further 
work and remain to be resolved. 
5.2 Targeting bone metastases: anti-tumor and pro-bone effects 
of the mTOR inhibitor everolimus 
The bones of breast cancer patients are at risk from the therapies that are intended to rescue 
them from premature mortality. Approximately 70% of patients present with ER+ breast 
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cancer for which hormone-ablation therapies are the initial SOC (Lumachi et al., 2013). 
However, the majority of these therapies induce uninhibited bone turnover, increasing 
osteoclastogenesis and bone resorption (Hadji, 2015). Aromatase inhibitors are a prime 
example of how an effective anti-cancer therapy can induce rapid bone loss in patients who 
already may be at risk of osteoporosis due to menopausal status (Hadji, 2009).  
While few clinical studies have investigated mTOR inhibition as a primary therapy in breast 
cancer, the mTOR inhibitor everolimus is currently seen as an effective therapy when 
strategically combined with AIs in hormone receptor-positive breast cancer (Ellard et al., 
2009; Lui et al., 2016). For example, when everolimus was paired with the SERM letrozole 
as a neoadjuvant therapy in patients with operable ER+ breast cancer, the antiproliferative 
tumor response, as assessed by a reduction in Ki67 expression, was enhanced by 27% in 
the everolimus-treated cohort (Baselga et al., 2009). Later, in the BOLERO-2 trial, patients 
with ER+ breast cancer which had progressed despite hormone ablation therapy, were 
afforded a clinical benefit from pairing everolimus with the AI exemestane (Baselga et al., 
2012). In a subanalysis of this trial, it was discovered that the addition of everolimus inhibited 
the increase in bone turnover markers associated with exemestane treatment alone (Gnant 
et al., 2013). Markers of bone turnover ((bone specific alkaline phosphatase (BSAP), PINP 
and CTX) are commonly used as surrogate markers for bone loss, however, these only 
represent one aspect of bone biology and do not automatically reflect changes in bone 
density and risk of fracture (Wheater et al., 2013). In the context of osteolytic bone disease 
arising from breast cancer, an appraisal of mTOR inhibition is lacking and requires 
clarification (Hadji et al., 2013). 
This study assessed the properties of everolimus and its effects on bone and cancer as a 
single treatment agent. Everolimus was confirmed to actively inhibit mTOR activity in 
osteotropic MDA-MB-231 human breast cancer (Wright et al., 2016) and B16-F10 murine 
melanoma cells (Politano et al., 2010), which translated into an effective anti-tumor response 
when used to inhibit subcutaneous tumor growth of these cell lines in vivo.  
In the case of breast cancer, this response was attained using a dose of 1 mg/kg which is 10-
fold lower than what is currently advised for ER+ HER-2- breast cancer in the clinic; however, 
this difference could likely be explained by the route of administration (intraperitoneal 
injection versus oral). These results both confirm and support previous studies. For example, 
when everolimus is used as a sensitizing agent with chemotherapeutics or radiotherapy, anti-
tumor effects were also significant in MDA-MB-231 cells (Albert et al., 2006; Liu et al., 2012; 
Zhang et al., 2012). Nonetheless, when everolimus was used to target established 
subcutaneous MDA-MB-231 tumors as a single therapeutic agent at a dose of 10 mg/kg 3 
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times weekly, only a modest, insignificant tumor response could be demonstrated 
(Yunokawa et al., 2012). Dose, route and frequency of administration would all appear to 
regulate the potency of everolimus as an anti-tumor agent. The exact mechanism of tumor 
inhibition in this context requires further investigation, however a recent study has 
demonstrated that the induction of autophagy could play a key role in the context of AI-
resistant breast cancers which concurrently display a downregulation of the ER (Lui et al., 
2016).  
The B16-F10 model was used as a confirmatory model for the anti-tumor effects of 
everolimus. The use of everolimus as a combined treatment agent with angiogenesis 
inhibitors (Hainsworth et al., 2010; Dronca et al., 2014), has progressed through clinical trials 
in metastatic melanoma. To date these have demonstrated a varied range in clinical activities 
of everolimus; from a disappointing lack of responses to major responses and stabilization. 
As a single agent, the results are less clear. In one instance, a desirable, longer survival was 
reported in patients who were treated with a lower dose than a higher dose of everolimus 
(Rao et al., 2006). Possible explanations have been reviewed previously with improvements 
directed at the pharmacology of everolimus and trial design (Monzon and Dancey, 2012). 
This potent response observed here in B16-F10 cells may be related to mutations in mTOR 
(Kong et al., 2016) and future investigation is required to help clarify dose of everolimus and 
mutation-specific influences in the context of melanoma. 
Hormone ablation therapy was mimicked in an in vivo model by performing OVX in C57BL/6 
mice. Bone loss as a result of OVX could be prevented by treating mice daily with everolimus 
(1mg/kg). This bone-protective effect was due to an inhibition of osteoclast mediated bone 
resorption as assessed by analysis of bone histomorphometry. In the same manner that BPs 
protect bone (Pazianas et al., 2014), everolimus appeared to inhibit osteoclast activity 
without increasing osteoblast activity. BPs are very effective antiresorptive agents; however 
they are also detrimental to osteoblast biology. This may be one advantage everolimus has 
over BPs in this context. In this model, OVX-induced hormone deficiency resulted in an 
increased osteoclastic resorption which was effectively suppressed by everolimus-mediated 
mTOR inhibition. However, in the non-challenged SHAM mice there was no alteration of 
bone quality with everolimus treatment, suggesting that increased mTOR signaling is an 
adaptive response to hormone deprivation. MTOR has been shown to crosstalk with ERα 
under estrogen stimulation in breast cancer (Alayev et al., 2015), therefore it could be 
conceived that in the absence of ER signaling, mTOR can signal independently in a 
potentiated pro-osteoclastic manner. 
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To extrapolate these in vivo observations further, the effect of mTOR inhibition on 
osteoclastogenesis was assessed in vitro. Here, the differentiation of osteoclasts from 
murine bone marrow-derived mononuclear cells demonstrated a potent decrease in all 
osteoclast-specific parameters investigated at 10 and 100 nM concentrations of everolimus. 
In different pathological settings, mTOR signaling has been identified as an integral 
component of successful osteoclastogenesis and osteoclast function (Kneissel et al., 2004; 
Indo et al., 2013). In mTOR deficient mice, not only was retarded osteoclast differentiation 
reported, but when using rapamycin to pharmacologically inhibit mTOR activation in wild-type 
bone marrow-derived macrophages, osteoclast-specific gene expression was repressed, as 
was the differentiation of TRAP positive osteoclasts (Dai et al., 2017). A final supporting 
study, investigated the effects of everolimus on the osteoclastogenesis of peripheral blood 
monocytes in a co-culture model with the TNBC cell line SCP2. In this co-culture model, 
osteoclastogenesis that was activated by SCP2-dervied factors, was effectively inhibited by 
everolimus (Mercatali et al., 2016). 
The role of mTOR activity in osteoblasts is also controversial with the results from this study 
lying somewhere in the middle ground of previous research endeavors. Knocking out key 
components of mTOR signaling have been shown to be detrimental for osteoblast biology, 
particularly the later stages of osteoblast differentiation (Chen and Long, 2015; Huang et al., 
2015; Martin et al., 2015). On the other hand, respective treatments of human embryonic 
stem cells and human mesenchymal stromal cells with rapamycin and another mTOR 
inhibitor BEZ235, resulted in an augmentation of osteoblastogenesis in both accounts (Lee et 
al., 2010; Martin et al., 2010). From the OVX model it was concluded that everolimus was not 
detrimental to osteoblast function, but likewise, everolimus did not potentiate bone 
anabolism. To investigate in more detail the effects of mTOR inhibition on osteoblast biology, 
mMSCs underwent differentiation in the presence of everolimus in vitro and it was concluded 
that osteoblasts were more resistant to the inhibitory effects of everolimus than compared to 
osteoclasts.  
When considering the in vivo and in vitro data as a whole, these results correlate with the 
observations of the BOLERO-2 trial, where patients treated with everolimus displayed a 
reduction in bone turnover markers (Gnant et al., 2013). However, everolimus also 
decreased the progression of bone metastases in these patients. With this in mind, further 
evidence was provided that everolimus at a dose which is effective in preventing bone 
resorption in a hormone deprived environment, and which is effective at suppressing 
subcutaneous tumor growth, can also significantly prevent the progression of ER- breast 
cancer bone metastases. A recent study in support of this result, demonstrated that 
everolimus not only inhibits the expression of pro-osteoclastic factors such as IL-6 in breast 
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cancer cells but that when osteolytic MDA-MB-231 cells pre-treated with everolimus, were 
injected into the tibiae of SCID mice, the area of the resulting osteolytic lesions was 
significantly smaller (Simone et al., 2015). In another study, everolimus was more effective 
than zoledronic acid at reducing the number of lung bone metastases at the first 
measurement point, with 22.2% and 50% of mice having developed detectable lesions 
respectively (Yu et al., 2014). This could indicate that everolimus may demonstrate 
superiority over zoledronic acid as an anti-metastatic agent and supports the findings of this 
study with respect to the efficacy of everolimus in breast cancer bone metastases. 
This work presents everolimus as a potent anti-tumor agent in aggressive tumor types. 
Moreover, at a specific dose everolimus is capable of halting bone resorption in response to 
hormone deprivation by convincingly and specifically targeting dysregulated osteoclast 
activation. A clinical trial (NCT01674140) assessing the development of breast cancer bone 
metastases following combined treatment with everolimus and AIs, is recruiting and may 
yield further interesting data on this topic. Finally, in addition to the important and contextual 
skeletal profile, this study provides further rationale for considering everolimus as an anti-
tumor agent in metastatic, ER- breast cancer, for which it has not yet been licensed.  
5.3 Promoting bone anabolism: restoring osteoblastogenesis by 
targeting p38 MAPK in prostate cancer 
In prostate cancer cell lines, those which have the highest propensity for osteotropism and 
osteolytic behavior in vivo, also have the highest levels of DKK-1 (Hall et al., 2005; Thiele et 
al., 2011; Sanchez-Sweatman et al., n.d.). The role of DKK-1 in regulating the osteolytic 
phenotype has been made clear in a mouse model of bone metastases where the prostate 
cancer cell line C4-2B, which normally produces mixed lesions when injected intratibially, 
resulted in decidedly osteolytic lesions following the overexpression of DKK-1 (Hall et al., 
2005). Similar results were obtained when DKK-1 was overexpressed in the Ace-1 prostate 
cancer cell line which normally induces mixed lesions in vivo (Thudi et al., 2011). Here, the 
osteoblastic phenotype of bone metastases was decreased following intracardiac injection in 
mice. Unexpectedly, the overexpression of DKK-1 not only increased the number of 
metastases but also the overall tumor mass when injected subcutaneously. Furthermore, 
when DKK-1 was knocked down in the primarily osteolytic PC3 cells, the inhibited growth of 
both soft tissue tumors and development of osteolytic lesions was observed (Hall et al., 
2010). Targeting DKK-1 in the clinic is yielding positive results in MM (Iyer et al., 2014) and 
preclinical studies suggest that the same may even have therapeutic potential in the context 
of solid tumor growth and metastasis (Sato et al., 2010; Goldstein et al., 2016; Pang et al., 
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2017). Despite this, little is known about the mechanism behind the regulation of DKK-1 in 
the cancerous cell. 
To assess if DKK-1 was associated with p38 MAPK in prostate cancer, a cDNA array of 
control and cancerous prostate tissues was analyzed. In confirmation of a previous study, the 
expression of DKK-1 was increased in patients with prostate cancer compared to controls 
(Rachner et al., 2014a). In the same trend, the expression of individual p38 MAPK isoforms 
was also increased. Most significantly, within this patient cohort the expression of DKK-1 was 
correlated with the expression of each p38 MAPK isoform. This confirms the findings of this 
investigation and may also not come as a complete surprise. In human development and 
physiology the processes of skeletogenesis and bone turnover rely profoundly on the co-
ordination of Wnt and p38 MAPK signaling pathways (Greenblatt et al., 2010; Zhong et al., 
2014; Thouverey and Caverzasio, 2015). Additionally, in the context of cancer, a crosstalk 
has been shown to exist between both signaling pathways in a mouse model of 
teratocarcinoma (Bikkavilli et al., 2008). 
Next, the regulation of DKK-1 by p38 MAPK was scrutinized in 3 different prostate cancer 
cell lines, each one employing different mechanisms to differentially disrupt bone 
homeostasis in the context of bone metastases. By stimulating the differentiation and 
proliferation of osteoblasts, the MDA-PCa-2b cell line principally forms osteoblastic lesions in 
vivo (Yang et al., 2001). C4-2B cells can directly and indirectly stimulate osteoblastogenesis 
and osteoclastogenesis respectively, leading to a phenotype of mixed osteolytic and 
osteoblastic lesions in vivo (Din-Lii Lin et al., 2001b; Hall et al., 2005). DU145 cells also 
promote the formation of mixed lesions in vivo (Mori et al., 2007). Finally, PC3 cells exhibit 
the most striking osteolytic phenotype in vivo, inhibiting osteoblastogenesis and degrading 
mineralized and non-mineralized bone (Hall et al., 2005; Sanchez-Sweatman et al., n.d.). 
Despite these different credentials, all the prostate cancer cell lines investigated were shown 
to regulate their DKK-1 expression through the activity of p38 MAPK. 
The focus remained on the pro-osteolytic PC3 cell line for which an inherent overexpression 
of DKK-1 was verified in comparison to other prostate cancer cell lines which form 
osteoblastic and mixed lesions in vivo. Functionally, this increased expression of DKK-1 
resulted in an increased inhibition of osteoblastogenesis in Wnt3a-stimulated C2C12 cells, 
which could be rescued by directly targeting DKK-1 with an antibody or by RNA interference. 
The bacterial antibiotic anisomycin is an agent which can potently activate p38 MAPK (Shifrin 
and Anderson, 1999; Croons et al., 2009), increasing both its phosphorylation and the 
phosphorylation of its downstream target HSP27 (Stokoe et al., 1992; Xu et al., 2006). When 
PC3 cells were treated with anisomycin, an increased expression of DKK-1 mRNA and 
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phosphorylation of p38 MAPK and HSP27 was observed. Unmistakeably, small molecule 
inhibitors were able to inhibit this upregulation of DKK-1 and p38 MAPK activation, even 
below baseline levels. This demonstrated the specificity of the p38 MAPK inhibitors, ruling 
out the involvement of JNK/SPAK signaling in the regulation of DKK-1 expression, a pathway 
which can also be activated by anisomycin (Hazzalin et al., 1998). Here, it has also been 
shown that DKK-1 expression can be upregulated by p38 MAPK in normally osteoblastic 
prostate cancer cell lines. Granted, in this context these increases in DKK-1 expression are 
not comparable with the baseline expression of PC3 cells, but nevertheless they indicate a 
shift in the phenotypic signature and analysis of other genes regulating osteoblastogenesis 
may be of interest in the future. 
The small molecule inhibitors LY and SB have demonstrated anti-tumor effects in preclinical 
studies when used to inhibit p38 MAPK activity in solid cancer types (Grossi et al., 2012; 
Campbell et al., 2014), and the assessment of their potential in the clinic is underway in 
clinical trials for advanced cancers – results pending (NCT01393990 and NCT01663857). 
While these inhibitors suppressed the expression of DKK-1 in prostate cancer cells, they are 
known to vary in potency, the p38 MAPK isoforms which they target and can also 
demonstrate off-target effects (Bain et al., 2007). To rule out the possibility of off-target 
effects and delineate the role of individual p38 MAPK isoforms in the suppression of DKK-1, 
PC3 cells were transfected with siRNA targeting the p38 MAPK isoforms MAPK11, MAPK12, 
and MAPK14. All 3 investigated p38 MAPK isoforms inhibited DKK-1 expression to a certain 
degree; however MAPK11 did so most effectively and consistently. There may be benefits to 
selectively inhibiting MAPK11 or MAPK14 based on their known functions in other contexts 
of interest. It has been reported that in breast cancer, MAPK11 increases the secretion of 
monocyte chemotactic protein-1, enhancing osteoclastogenesis and fuelling bone resorption 
in vivo (He et al., 2014). However, MAPK14 is known to maintain the differentiation and 
physiology of osteoblasts (Rodríguez-Carballo et al., 2014). These two examples would 
sanction the inhibition of MAPK11 rather than MAPK14 for future in vivo approaches aiming 
to preserve the bone in the context of osteolytic bone disease, however at present inhibitors 
which exclusively target this isoform are not available.  
The benefits of inhibiting p38 MAPK activity in PC3 cells using small molecule inhibitors or 
RNA interference were also shown in a model of osteoblastogenesis. Control PC3 
supernatants inhibited Wnt3a-induced osteoblastogenesis of C2C12 cells, whereas 
supernatants from p38 MAPK-inhibited PC3 cells did not. This was true for the osteoblast 
markers Alp and Oa, supporting the idea that p38 MAPK inhibitors could have a positive 
effect on bone homeostasis by reducing prostate cancer-derived DKK-1 secretion and 
inhibited osteoblastogenesis. 
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In summary, the expression of DKK-1 in prostate cancer correlates with the activity of p38 
MAPK. Although p38 MAPK is most likely not the sole regulator of DKK-1 expression in 
prostate cancer, the targeting of its activity with small molecule inhibitors can sufficiently 
reduce the secretion of DKK-1 to rescue the suppression of osteoblastogenesis in vitro. 
Specifically, the p38 MAPK isoform MAPK11 should remain in the focus for future research 
selectively targeting DKK-1 in the context of bone metastases in vivo, advancing the limited 
bone-anabolic options available for the treatment of osteolytic, prostate cancer metastases. 
5.4 Limitations of the study 
As with many undertakings in research, there are limitations which influence the 
interpretation of these findings. Such limitations that have not been addressed in the 
introduction or discussion are discussed here. 
A major focus of this work was the role of DKK-1 in osteotropic cancer types. In breast 
cancer it was shown that DKK-1 was a predictor of survival in ER- breast cancer and was 
subsequently shown to be a tumor promoter in the ER- MDA-MB-231 cell line. These cells 
display strong osteotropic and osteolytic behaviour in vivo, however such behaviour may be 
unique to this particular line (Minn et al., 2005). While there are some examples to the 
contrary, the major consensus is that ER- cancers have a lower propensity for bone 
metastasis in the clinic, more commonly metastasising to visceral organs and the brain (Dent 
et al., 2009; Yuan et al., 2014). When playing the devil’s advocate however, ER- breast 
cancers still have the potential to develop bone metastases and those that do have a less 
favourable outcome than their ER+ counterparts (Zhang et al., 1997; Bandyopadhyay et al., 
2007; Lee et al., 2011).  
A general limitation concerns the animal model employed for xenograft tumor models. In 
order for human tumor cells to successfully grow in mice, the mice must be 
immunocompromised. In this study NMRI-nu mice were the host of choice, lacking a 
functional thymus and being subsequently T-cell deficient (Kim et al., 2004). Whether 
positively or negatively, a functioning immune system contributes to the early 
microenvironment of a growing tumor and a compromised system may not account for these 
complex contributions (Vargo-Gogola and Rosen, 2007). “Humanized mice” could be a 
consideration for such tumor models in the future. In this context, immunodeficient mice can 
be engrafted with human hematopoietic stem cells that develop into functional human 
immune systems, solving many of the limitations associated with xenograft tumor models 
(Walsh et al., 2017). 
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In the case of the everolimus metastasis model, many determining features of the metastatic 
cascade are simply not accounted for and true metastatic mechanisms are not reflected 
(Pantel and Brakenhoff, 2004). Future scenarios to improve this investigative approach, 
would be to test the effects of everolimus in genetically modified mice where transgenic 
oncogenes induce tumorigenesis, followed by spontaneous metastasis or to use a murine 
cell line which also metastasizes spontaneously to the bone from an orthotopically inoculated 
tumor (Fantozzi and Christofori, 2006). A concurrent tumor and OVX model in the NMRI-nu 
mice would have been an ideal setting to assess the effects of everolimus on bone and 
tumor biology. However, the bone turnover in this mouse strain does not respond in a 
comparable fashion to human or C57BL/6 mice when deprived of estrogens (Cenci et al., 
2000).  
As alluded to earlier, the reduction of DKK-1 expression and secretion by inhibiting the 
activity of p38 MAPK in PC3 cells, is not suppressed to the ‘baseline’ values evident in the 
non-osteolytic prostate cancer cell lines MDA-PCa2b and C4-2B. Because of this fact, it is 
not possible to attribute these inherent differences in DKK-1 expression, in phenotypically 
different cell lines, to the activation of p38 MAPK exclusively. It is important to remember that 
DKK-1 is known to be responsive to a number of different cellular signaling pathways, 
including JNK and Wnt as described in MM and prostate cancer respectively (Niida et al., 
2004; Colla et al., 2007). Another limitation in this investigation is the sole reliance on C2C12 
cells to demonstrate inhibitory and rescue effects of p38 MAPK and DKK-1-regulated 
osteoblastogenesis. C2C12 cells are extremely sensitive to canonical Wnt stimulation and 
are a commonly used model to assess osteoblastogenesis in the context of Wnt signaling. 
However, not all standard osteoblast markers are increasing upon treatment with Wnt3a. 
This is especially the case for functional assays of mineralization and alizarin red staining. To 
further support these observations, assessments with other osteoblast-line cell lines such as 
the murine MC3T3, or the differentiation of hMSCs to osteoblasts would be beneficial.  
5.5 Future prospects 
While many questions have been answered in this study, many more have arisen and others 
remain to be resolved. In particular, the role of DKK-1 in breast cancer tumor biology is 
specific and yet complex. Confidently stated, DKK-1 is a tumor promoter of ER- breast 
cancer and its expression does not influence the biology of ER+ breast cancer cell lines or 
survival rates in patients. The mechanism of how DKK-1 inhibits cancer cell and tumor 
growth in vitro and in vivo remains to be elucidated.  
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Murine and human DKK-1 share an amino acid sequence identity of 86% and it could be 
shown that BHQ was effective at neutralizing DKK-1 in an ELISA detecting murine DKK-1 
(data not shown) (Niehrs et al., 1998). This makes it difficult to distinguish whether the anti-
tumor effects were direct or indirect. Likewise, the DKK-1 knockout model (coupled with in 
vitro data) supports a direct tumor promoting role for DKK-1, however in the in vivo setting it 
cannot be clearly defined whether DKK-1 inhibition directly inhibits tumor growth or if this 
effect is mediated by cells of the tumor microenvironment in response to reduced tumor-
secreted DKK-1.  
The role of stromal cell-derived DKK-1 could be playing an important role in tumorigenesis 
and many investigations would support this (Fig. 28). As an example, one study in support of 
this hypothesis could show that DKK-1 secretion localized to the bone marrow 
microenvironment, increases in response to subcutaneous lung and melanoma tumor 
growth. This stromal cell-derived DKK-1 mediated pro-tumorigenic effects by increasing the 
recruitment and function of myeloid suppressor cells, suppressing an immune response and 
promoting tumor cell proliferation (D’Amico et al., 2016). Another method to investigate the 
role of stromal cell-derived DKK-1 (in this context murine Dkk-1) on tumorigenesis would be 
to inoculate mice bearing a conditional, cre-mediated, global knockout of DKK-1, with an 
allogenic cancer cell line that express low levels of DKK-1 (such as murine E0771 breast 
cancer cells). To rule out the possible induction of DKK-1 expression in this cell line in vivo, 
knocking out DKK-1 prior to inoculation would also prevent any sources of DKK-1 
‘contamination’ in the model, allowing for further comparisons and highlighting the question 
whether the complete removal of DKK-1 from the host and tumor system results in 
potentiated anti-tumor effects. Treating mice inoculated with DKK-1 knockout cells with BHQ 
could answer the same question if a potentiated anti-tumor effect was observed.  
Because the loss in cell viability in MDA-MB-231 DKK-1 knockout clones in vitro could not be 
rescued by supplementing cells with DKK-1, future work should also address an intracellular 
role for DKK-1. Recently CKAP4 was described as new, novel binding partner for DKK-1, 
mediating pro-tumor effects in lung and pancreatic cancer models (Kimura et al., 2016). This 
protein can also be localized intracellularly and may be a possible signaling candidate in this 
situation. CKAP4 is a receptor for different ligands and hypothetically it could be possible that 
in the absence of DKK-1 binding, ligands such as antiproliferative factor (APF) may mediate 
a tumor suppressive function (Planey et al., 2009). Experiments knocking down the 
expression of CKAP4 in the DKK-1 knockout clones may prove enlightening. Another 
consideration is that DKK-1 has an unknown binding partner. Biochemical, biophysical and 
theoretical methods exist to confirm this fact; however a candidate binding protein is initially 
required! Further clarification of the mechanism of cell death in DKK-1 knockout clones in 
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vitro lies in the investigation of culture medium components. DKK-1 clones only display 
losses of viability and induction of apoptosis in serum-deprived conditions, suggesting that 
specific factors in the serum such as hormones and other growth factors protect against cell 
death. Sequential addition of factors of interest to rescue cell death may provide the key to 
unravelling the striking metabolic profile observed in DKK-1 knockout clones in serum-
deprived conditions.  
Figure 28: The role of tumor versus stromal-derived DKK-1 remains to be clarified in the 
tumor microenvironment. Both neutralizing DKK-1 activity with an antibody and inhibiting expression by 
gene-editing, result in decreased ER- breast cancer tumor growth. The question remains whether this is a direct 
anti-tumor effect (A) or an indirect anti-tumor effect mediated by the tumor microenvironment (B). Different 
stromal cells are recruited to the tumor microenvironment and mediate inhibitory or promoter effects in breast 
cancer tumor growth and invasion (Mao et al., 2013). Adipocytes are an anatomically relevant cell type in the 
breast and have previously been shown to promote the growth of breast tumors (Huang et al., 2017). DKK-1 is 
required for early human adipogenesis and therefore it could be hypothesized that breast cancer derived DKK-1 
could increase the numbers of mature adipocytes to indirectly promote tumor growth. On the other hand, DKK-1 
from infiltrating mesenchymal stem cells has been shown to inhibit breast cancer cell growth in a rat model of 
breast cancer in vivo (Li et al., 2016). Secreted DKK-1 has also been shown to inhibit the accumulation and 
immune suppressive function of myeloid suppressor cells in the tumor microenvironment, promoting tumor 
growth (D’Amico et al., 2016). Whether DKK-1 is derived from tumor cells or is induced in other stromal cell 
types by other tumor-derived factors remains to be clarified in this example. Circulating platelets also contribute 
to secreted DKK-1 levels and in the context of inflammation this has been proven to activate endothelial 
progenitors (Ueland et al., 2009). Endothelial cells facilitate tumor angiogenesis and neovascularization which 
are indispensable for tumor growth. Tumor-derived DKK-1 has been shown to both directly increase angiogenic 
potential of endothelial cells and indirectly by stimulating the expression of angiogenic factors such as VEGF in 
tumor associated fibroblasts (Smadja et al., 2010; Jiang et al., 2015). Finally, tumor associated 
macrophages use different mechanisms to facilitate angiogenesis, tumor growth and metastasis in breast 
cancer (Williams et al., 2016). In a canine breast cancer model, macrophage-secreted DKK-1 was shown to 
simultaneously inhibit tumor growth but promote metastasis (Król et al., 2014). Overall, these examples and the 
results presented herein point to a pro-tumor role of DKK-1. Despite this, the delineation of the exact 
mechanism in vivo will require elegant and complex experiments in the future, as addressing one cell type at a 
time may result in compensatory mechanisms in others.  
A B 
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In the setting of mTOR inhibition, investigating other mechanisms of bone loss and 
osteotropic cancer types is also warranted. For examples, the question “Is it time for 
everolimus-based combination in castration-resistant prostate cancer?” has previously been 
raised (Roviello et al., 2016). It is known that castration (androgen-deprivation) in male mice 
induces bone loss and that this bone loss can also trigger and promote the growth of 
disseminated prostate cancer cells into bone metastases (P. D. Ottewell et al., 2014b). 
Everolimus has been shown to be effective in inhibiting the growth of prostate cancer in the 
bone in pre-clinical models, and increases survival of patients in combination with the anti-
androgen bicalutamide (Morgan et al., 2008; Chow et al., 2016). Furthermore, the initiation 
and progression of prostate cancer bone metastases rely on the activity of osteoclasts 
(Sottnik and Keller, 2013). Therefore, the results from this study could also be translated to 
this setting, investigating the role of mTOR inhibition in osteoclast-mediated bone loss in the 
context of androgen-deprivation. 
Finally, a recent study in this lab also complements the findings presented here with respect 
to p38 MAPK regulation of DKK-1, namely that p38 MAPK activity is correlated with and 
regulates DKK-1 in breast cancer (Rachner et al., 2015). Based on the knowledge that DKK-
1 is a tumor promoter in ER- breast cancer, with literature suggesting the same for AR- 
prostate cancer, the next logical steps would be to assess the effects of p38 MAPK inhibition 
on prostate and breast cancer cell and tumor biology, before progressing to models of 
osteolytic bone metastasis. One in vivo study to support the therapeutic potential of targeting 
p38 MAPK with a small molecule inhibitor, could show that LY reduced tumor growth of a  
xenograft derived from MDA-MB-468 breast cancer cells.(Campbell et al., 2014) Another p38 
MAPK inhibitor, PH797804, also reduced the growth of patient-derived colon cancer 
xenografts (Gupta et al., 2015). Inhibition of angiogenesis resulting from p38 MAPK inhibition 
could be a contributing factor to the observed anti-tumor effects in these examples(Tate et 
al., 2013; Leelahavanichkul et al., 2014), which strikes similarities to the reports of DKK-1 
mediating vasculogenesis (Smadja et al., 2010). However, the response to p38 MAPK 
inhibitors in vivo may be complex and context dependent, differentially regulated by a range 
of other stimuli (Koul et al. 2013). With this in mind, it is important to translate the hypothesis 
based on the in vitro work to an in vivo setting, with a focus on the inhibition of MAPK11.  
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5.6  Concluding remarks 
This thesis has tackled the problem of bone metastases and their treatments from multiple 
angles; including the complexities of tumor cell biology, potentiated osteoclastogenesis and 
inhibited osteoblastogenesis. The Wnt inhibitor DKK-1 has been shown to be a tumor 
promoter in ER- breast cancer and in an osteotropic cell line which is known to induce 
osteolytic lesions in vivo. The bone protective and anti-tumor effects of the mTOR inhibitor 
everolimus, as a single therapeutic agent, have been confirmed in the contexts of bone loss 
induced by hormone depletion and bone-metastatic ER- breast cancer. Finally, DKK-1 has 
been shown to be regulated by p38 MAPK in prostate cancer and targeting p38 MAPK can 
decrease DKK-1 secretion and rescue inhibited osteoblastogenesis, a common factor 
contributing to the development of osteolytic lesions. 
In conclusion, the inhibition of DKK-1 and mTOR may become viable bone-targeted 
therapies, protecting bone and concurrently inhibiting tumor growth in patients at risk of, or 
burdened with, bone metastases arising from osteotropic cancer types. Further investigations 
into the mechanisms involved may also bring other targets into focus and support the 
rationale for future clinical investigations.  
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Summary 
As solid tumor types, breast and prostate cancer are rivalled only by lung cancer in their 
propensity to metastasize to bone in the later stages of disease. At advanced stages of 
disease, approximately 80% of breast and 90% of prostate cancer patients will present with 
bone metastases. Bone metastases are often a painful conclusion to the lives of these 
patients, resulting in bone pain, hypercalcemia, pathological fractures and spinal cord 
compression. The culmination of these comorbidities considerably reduces a patient’s quality 
of life and prolonged survival. Hormone depletion is used as a first line of treatment in the 
majority of cases, negatively regulating bone health due to increased bone resorption by 
osteoclasts and decreased bone formation by osteoblasts. Not only is bone integrity 
undermined, but this action of increased bone turnover is beneficial for the colonization of 
metastasizing cells which co-opt and enhance the same mechanisms to establish and 
maintain their own growth. This is termed ‘the vicious cycle’ of osteolytic bone metastasis.  
Current research approaches aim to identify bone-targeted therapies which not only inhibit 
tumor growth but concurrently protect bone. In this study, Dickkopf-1 (DKK-1), mechanistic 
target of rapamycin (mTOR) and p38 mitogen-activated kinases (p38 MAPK) are presented 
as novel targets. Pro-tumor roles have been described for all and clinical trials are currently 
investigating their efficacy in different cancer types. In normal bone biology DKK-1 is an 
inhibitor of the canonical Wnt signaling pathway which promotes osteoblastogenesis while 
mTOR signaling is a promoter of osteoclastogenesis. P38 MAPK inhibitors have been shown 
to regulate DKK-1 expression and bone destruction in preclinical models of multiple 
myeloma. The aims of this current study were to 1) investigate the role of DKK-1 in the 
biology of osteotropic breast cancer, 2) to assess the potential bone protective effects of 
mTOR inhibition by everolimus in the context of osteotropic cancers and 3) to test the 
hypothesis that p38 MAPK is a regulator of DKK-1 expression in prostate cancer, potentially 
supporting an osteolytic phenotype by impairing osteoblastogenesis.  
In aim 1, analysis of a breast cancer tissue microarray demonstrated that DKK-1 expression 
was elevated in advanced and invasive tumor stages. Strikingly, positive DKK-1 expression 
correlated with a significantly reduced survival rate only in estrogen receptor-negative (ER-) 
breast cancer patients compared to patients with tumors which were negative for DKK-1 
expression. In MDA-MB-231 breast cancer xenograft models, neutralization of secreted 
DKK-1 by treating mice with the monoclonal DKK-1 antibody BHQ880 or knocking out the 
expression of DKK-1 in MDA-MB-231 cells using CRISPR-Cas9 mediated gene editing, 
resulted in reduced tumor growth and burden by ≥ 50% (p < 0.05).  
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In aim 2, the mTOR inhibitor everolimus is presented as an anti-tumor and bone-protective 
agent. The anti-tumor effects of everolimus were confirmed in two subcutaneous tumor 
models and a model of breast cancer bone metastasis, were tumor burden in the bone was 
reduced by 45.4% (p < 0.01). Bone loss induced by a hormone-deprived environment in 
ovariectomized mice was prevented with everolimus treatment as was bone destruction in 
the metastasis model. In more detail, it could be shown that everolimus maintained 
osteoblast function while specifically inhibiting osteoclast function. 
In aim 3, p38 MAPK is presented as a regulator of DKK-1 in prostate cancer. While the 
activation of p38 MAPK upregulated DKK-1, inhibition of p38 MAPK using small molecule 
inhibitors and siRNAs inhibited DKK-1 expression. Furthermore, assessment of different p38 
MAPK isoforms revealed MAPK11 as the most effective regulator of DKK-1 and inhibition of 
DKK-1 by interfering with p38 MAPK signaling was sufficient to prevent the inhibitory effects 
of prostate cancer-derived DKK-1 on osteoblastogenesis in vitro.  
This study has assessed multiple targets and their concurrent roles in cancer and bone cell 
biology. Specifically, DKK-1 has been proven to be a tumor promoter in ER- breast cancer 
and can be targeted therapeutically to inhibit tumor growth. MTOR inhibition by everolimus 
has been shown to be an effective mono-therapy in ER- breast cancer, inhibiting the growth 
of subcutaneous tumor and bone metastases and preventing bone loss induced by estrogen 
ablation. This further supports its use in postmenopausal women with breast cancer who are 
predisposed to developing osteoporosis and bone metastases. It also supports the use of 
everolimus in hormone receptor-negative or triple receptor-negative breast cancer, for which 
it has not yet been approved. A clear link has been made between p38 MAPK signaling and 
DKK-1 expression in prostate cancer and its consequent regulation of osteoblastogenesis.  A 
future focus on the inhibition of a specific MAPK isoform, MAPK11 in particular, may help in 
translating these encouraging in vitro results into promising pre-clinical trials in vivo. 
As a whole, these investigations provide a foundation for further research and could be 
valuable for the design of future clinical trials, leading to improvements in the treatment and 
prognosis of osteolytic bone metastases. 
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Zusammenfassung 
Die Tumore der Brustdrüse und Prostata werden in ihrer Tendenz, in späteren 
Krankheitsstadien Metastasen in Knochen zu bilden, nur vom Lungenkrebs übertroffen. In 
fortgeschrittenen Stadien der Krankheit entwickeln 80% der Brust- und 90% der 
Prostatakrebspatienten Knochenmetastasen. Diese Metastasen führen oft zu schmerzhaften 
Kompressionen des Rückenmarkes, Hyperkalzämie, Knochenschmerzen und 
pathologischen Frakturen. Diese Folgekomplikationen verringern sowohl die Lebensqualität 
als auch die Lebenserwartung der Patienten. Auch endokrine Therapien, welche auf eine 
Reduktion körpereigener Östrogene (Hormonrezeptor-positive Brusttumoren) bzw. 
Androgene (Hormonrezeptor-positive Prostatakarzinome) abzielen, können sich nachteilig 
auf den Knochen auswirken. Der Hormonentzug verändert die Regulation des 
physiologischen Knochenstoffwechsels: die Resorption des Knochengewebes durch 
Osteoklasten erhöht sich, während der Aufbau der Knochenmatrix durch Osteoblasten 
reduziert wird. Nicht nur die Integrität des Knochens verändert sich bei diesen Vorgängen: 
Die höhere Umsatzrate des Knochens erleichtert es sowohl metastasierenden Zellen 
einzudringen als auch deren eigenes Wachstum und ihre Vermehrung sicherzustellen. 
Dieser Prozess wird als „Teufelskreis der Knochenmetastasierung“ bezeichnet. 
Die gegenwärtige Forschung hat daher zum Ziel eine Therapie zu finden, die sowohl das 
Tumorwachstum hemmt, als auch den Knochen schützt. In dieser Doktorarbeit werden 
Dickkopf-1 (DKK-1), mechanistic target of rapamycin (mTOR) und die mitogen-aktivierte 
Proteinkinase p38  (p38 MAPK) als neue Angriffspunkte einer Therapie vorgestellt. Für alle 
diese Faktoren wurden tumorfördernde Rollen beschrieben.  
Im normalen Knochenstoffwechsel agiert DKK-1 als Inhibitor des kanonischen Wnt- 
Signalweges, einem Schlüsselfaktor der Osteoblastogenese, während der mTOR-
Singnalweg die Osteoklastogenese fördert. Darüber hinaus wurde bereits gezeigt, dass die 
mitogen-aktivierte Proteinkinase p38 im Multiplen Myelom die DKK-1 Expression sowie die 
tumorbedingte Knochenzerstörung reguliert.  
Die Ziele der hier vorgelegten Arbeit waren 1) die Rolle von DKK-1 in der Biologie des 
osteotropen Mammakarzinoms zu untersuchen, 2) die Knochen-schützenden Effekte einer 
mTOR-Hemmung durch Everolimus im Kontext osteotroper Tumoren zu bewerten und 3) die 
Hypothese zu überprüfen, dass p38 MAPK auch bei osteotropen Prostatakarzinomzellen ein 
Regulator der DKK-1-Expression ist und den osteolytischen Phänotyp durch Verhinderung 
der Osteoblastogenese unterstützt. 
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Zunächst zeigte die Analyse von primären Brustkrebsgeweben mittels Microarray im ersten 
Teil der Arbeit, dass die DKK-1-Expression in fortgeschrittenen und invasiven Tumorstadien 
erhöht war. Interessanterweise korrelierte eine positive DKK-1-Expression mit einer deutlich 
reduzierten Überlebensrate bei Patientinnen mit Östrogenrezeptor-negativen (ER-) Tumoren. 
In murinen Tumormodellen unter Nutzung Hormonrezeptor-negativer humaner MDA-MB-231 
Brustkrebszellen führte die Hemmung von sezerniertem DKK-1 mit dem monoklonalen DKK-
1 Antikörper BHQ880 oder die Ausschaltung der Expression von DKK-1 mittels CRISPR-
Cas9 Gen-Editing zu einem um ≥ 50% reduzierten Tumorwachstum (p < 0.05). 
Im zweiten Teil der Arbeit wurde gezeigt, dass der mTOR-Inhibitor Everolimus 
knochenschützende Eigenschaften aufweist: Er verhinderte den Knochenverlust in 
ovariektomierten Mäusen. Darüber hinaus wurden unter Nutzung subkutaner Maus-Modelle 
direkte Anti-Tumor-Wirkungen von Everolimus gezeigt. In einem zusätzlichen intrakardialen 
Mausmodell verhinderte Everolimus das Voranschreiten osteolytischer Knochenmetastasen 
um 45.4% (p < 0.01).  Mechanistische Untersuchungen zeigten, dass Everolimus die 
Funktion der Osteoblasten erhält, gleichzeitig aber die Aktivität von Osteoklasten hemmt und 
somit die Knochenresorption stoppt.  
Im dritten Teil der Arbeit wurde nachgewiesen, dass p38 MAPK bei Prostatakrebs ein 
Regulator von DKK-1 ist. Während die Aktivierung von p38 MAPK zu einer Zunahme von 
DKK-1 führte, konnte durch die Hemmung von p38 MAPK mittels „small molecule inhibitors“ 
und siRNAs die DKK-1-Expression blockieren. Zusätzlich zeigte die Analyse verschiedener 
p38 MAPK-Isoformen eine Sonderrolle der MAPK11 in der Regulation von DKK-1 auf. Die 
Hemmung des p38-Signalweges in den Tumorzellen verhinderte hierbei über Blockade von 
freigesetztem DKK-1 die verminderte Differenzierung von Osteoblasten.   
Die vorliegende Arbeit analysierte mehrere neue Zielstrukturen und ihre Rolle in der Tumor- 
und Knochenzellbiologie. Insbesondere DKK-1 ist nachweislich ein Tumor-Promotor bei 
Hormonrezeptor-negativem Brustkrebs und konnte therapeutisch genutzt werden um das 
Wachstum osteotroper Tumorzellen zu hemmen. Die Blockade von mTOR mittels 
Everolimus zeigte sich sowohl effektiv im Schutz vor Knochenverlust in ovariektomierten 
Mäusen als auch in der Hemmung sowohl des Wachstums subkutaner Brustkrebs- und 
Melanomzellen als auch osteolytischer Knochenmetastasen. Diese Erkenntnisse 
unterstützen seine Verwendung bei postmenopausalen Frauen, die an Brustkrebs leiden und 
bei denen die Gefahr besteht, dass sie Osteoporose und Knochenmetastasen entwickeln. 
Die Studie konnte ferner eine Verbindung zwischen dem p38 MAPK-Signalweg und dem 
Wnt-Signalweg-Hemmer DKK-1 in Prostatakarzinomzellen nachweisen. Weitere 
Untersuchungen mit besonderem Fokus auf die Hemmung von MAPK11 sollten in 
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präklinischen in vivo Modellen das therapeutische Potenzial einer p38-Hemmung in 
osteotropen Tumorzellen weiter aufklären.  
Zusammengefasst  können diese Ergebnisse eine stabile Grundlage für zukünftige 
präklinische und klinische Studien bilden und so zu Verbesserungen in der Therapie und der 
Prognose osteolytischer Knochenmetastasen beitragen. 
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